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A new class of lipid lowering agent Proprotein Convertase Subtilisin/Kexin Type 9 
inhibitors (PCSK9) was launched in 2015 for the treatment of heterozygous familial 
hypercholesterolemia (HeFH) in combination with statin therapy. There appeared to 
be a relatively slow uptake of PCSK9 inhibitors. The first aim of the study was to 
examine clinical attributes associated with reduction in low-density lipoproteins 
cholesterol (LDLC) among HeFH patients, while the second aim was to explore the 
factors influencing the use of PCSK9 inhibitors in clinical practice. 
Methods 
The quantitative phase of the study used logistic regression to investigate HeFH 
clinical attributes from the Clinical Practice Research Datalink (CPRD) database 
(n=5134) in relation to a final LDLC level of 5 mmol/l; which is the threshold for 
PCSK9 inhibitor eligibility for HeFH. The qualitative phase of the project involved 17 
in-depth semi-structured interviews to explore stakeholder perceptions of the factors 
influencing the use of PCSK9 inhibitors. 
Results 
LDLC levels featured prominently in the results of both phases of the study. 
Quantitative analysis showed that 18% of HeFH patients did not meet the 5mmol/l 
threshold for PCSK9 inhibitor eligibility even though they did not achieve the 
guideline recommended treatment target of 50% LDLC reduction with statin therapy. 
Lipid consultants perceived the eligibility threshold as an inhibitor of prescription in 
these cases. There was also an issue with LDLC levels not being recorded; 48% of 
HeFH patients in the CPRD dataset did not have a record of LDLC. In the clinical 
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setting, this had the effect of delaying PCSK9 inhibitor prescription when evidence of 
multiple LDLC readings meeting the prescription threshold was required. In primary 
care, GPs suggested that nurses could increase the recording of LDLC records 
because they had first contact with patients while performing health checks. Overall, 
low awareness of HeFH was associated with low rates of referral to secondary care 
for PCSK9 inhibitor consideration. Facilitators of PCSK9 inhibitor use included 
support from pharmaceutical companies who provided educational material for 
PCSK9 inhibitor use. Patients were also perceived to engage with treatment when 
they understood that HeFH could cause cardiac events. 
Conclusions 
This study found that LDLC records were critical to the prescription of PCSK9 
inhibitors. In the quantitative analysis the clinical attributes of maximum LDLC on 
record, age and lipid medication use were statistically associated to LDLC 
achievement. It was however not possible to predict PCSK9 inhibitor eligibility; further 
work would involve the addition of clinical attributes such as lipoprotein (a) to the 
model analysis.  PCSK9 inhibitor prescription was perceived to be hindered by 
inadequate recording of LDLC records. Consultants also reported that the LDLC 
thresholds for eligibility were restrictive in some cases. LDLC is an important 
determiner of PCSK9 inhibitor use; improved LDLC recording and evaluation of 
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Chapter 1 Introduction  
 
Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder that is 
characterised by elevated levels of serum low density lipoprotein cholesterol (LDLC) 
from birth. According to Nordestgaard et al. (2013), less than 1% of heterozygous 
familial hypercholesterolemia (HeFH) patients have been diagnosed in most 
countries, and a majority of identified patients do not meet recommended treatment 
targets.  
A new class of lipid lowering medication, Proprotein Convertase Subtilisin/ Kexin-
Type 9 (PCSK9) inhibitors has been launched for the treatment of HeFH. These 
medicines effectively reduce LDLC levels in HeFH and present a potential 
opportunity to improve the therapeutic management of the disease. 
However, multiple factors have been identified to influence the adoption of new 
medicines (Jones et al. 2001; Garjón et al. 2012; Stevenson et al. 1999; Prosser, 
Almond and Walley, 2003). Prosser, Almond and Walley (2003) categorise these 
factors into; influence from the pharmaceutical industry, colleagues, patient contexts, 
educational written information and biomedical/ pharmacological factors.  The 
existence of these factors could result in potential delays in the adoption of PCSK9 
inhibitors.  
The aim of the present thesis is to explore the potential factors influencing the 
adoption of PCSK9 inhibitors. In order to achieve this, the objectives of the data 




reduction in low-density lipoprotein cholesterol (LDLC) among HeFH patients, and to 
explore the factors influencing the use of PCSK9 inhibitors in clinical practice. 
The current chapter provides a background for this thesis, it discusses;  
 HeFH and identifies potential challenges to its management that could 
influence PCSK9 inhibitor use. 
 The role of PCSK9 inhibitors in the treatment of HeFH. 
 The rationale for studying the barriers and facilitators to the adoption of 
PCSK9 inhibitors. 
1.1 Heterozygous familial hypercholesterolemia 
1.1.1 Definition of familial hypercholesterolemia 
HeFH is an autosomal dominant genetic condition caused by one of several gene 
mutations that affect the metabolism of low density lipoprotein (LDL) cholesterol; the 
resultant clinical effect is a marked increase in serum cholesterol levels (Hopkins et 
al., 2011) (Goldberg et al., 2011).  
1.1.2 Molecular pathology 
The HeFH phenotype is expressed by a mutation(s) on the low density lipoprotein 
receptor (LDLR) alleles causing a loss of function in the clearance of LDL cholesterol 
from the blood stream (Soutar and Naoumova, 2007). Civeira (2004) reported that 
more than 800 mutations had been located on the gene; however, this currently 
stands at more than 1600 (http://www.ucl.ac.uk/fh). These mutations account for 
about 85-90% of FH cases (Goldberg et al., 2011). Defects in specific loci have been 
identified to cause similar variations of FH; these include apolipoprotein b-100 (apoB 
– the ligand for the receptor), PCSK-9 (an enzyme that down regulates LDLR) and a 




al., 2004).The clinical management of these variations of FH does not differ (Civeira, 
2004). 
Due to the autosomal dominant nature of familial hypercholesterolemia, HeFH is 
observed when mutations occur on a single copy of the low density lipoprotein 
receptor (LDLR) allele (Raal and Santos, 2012) (Hopkins et al., 2011). There is 
therefore a 50% chance that HeFH is inherited by a child in the case that one parent 
is affected by the disease (Civeira, 2004). The resultant effect is that 50% of LDL 
receptors are dysfunctional, increasing plasma LDL cholesterol levels to the range of 
5 – 12 mmol/L (Watts et al., 2012). 
1.1.3 Pathophysiology 
Cholesterol is a lipid that forms part of the structural component of cell membranes; it 
is also involved in the synthesis of steroid hormones, vitamin D and bile acids. 
Cholesterol is mainly transported in the circulatory system as low density lipoprotein 
(LDL) secreted by the liver. Watts et al. (2012) described the clearance of the LDL 
from the blood as:  
“Circulating LDL-cholesterol is pre-dominantly cleared via the liver by a tightly 
regulated LDL receptor pathway that involves particle binding and internalisation, 
endosome formation, cholesterol release to the cell and recycling of the receptor 
back to the cell surface.” 
Uncontrolled serum cholesterol leads to increased deposition in tissues causing 
tendinous xanthomata, accelerated atherosclerosis and increased risk of premature 
coronary heart disease (CHD) (Austin et al., 2004). The degree of serum LDLC 
elevation is determined by the extent of the fault on hepatic metabolism of LDLC; 




Cholesterol lowering forms the basis of HeFH management. When the disease is 
untreated, 1 in 2 male and 1 in 6 female patients suffer from CHD by the age of 40 
(Watts et al., 2012), translating to a 24 fold increase in CHD (Robinson, J. and 
Goldberg, 2011) compared to a healthy individual. 
1.1.4 Cardiovascular pathology 
Heart disease is the main cause of death in the UK, approximately 25% of disease 
related mortality is attributed to CVD by the Office for National Statistics (2012). 
Coronary heart disease and stroke cause 75% of these deaths. The contributive 
effect of FH in the causation of irregular serum cholesterol levels that lead to 
premature deaths due to CVD is well documented. The exact cost implication of FH 
to the NHS is however unclear due to a high incidence of undiagnosed cases. 
Coronary heart disease (CHD) is a multifactorial disorder with contributory effects 
from environmental and genetic factors. Age, lifestyle factors including smoking, lack 
of exercise and unhealthy diet form key components of environmental determinants 
of CHD; the mechanism of action of these factors are due in part to the accumulation 
of LDL cholesterol and the depletion of high density lipoprotein (HDL) cholesterol 
(Castelli et al., 1987) (Austin et al., 2004). The association between genetics and 
CHD is drawn from a consistent relationship between CHD patients and their family 
histories (Kardia et al., 2003); this relationship, however, does not account for the 
cumulative effects from the environment. 
The clinical manifestations of CHD are caused by the deposition of excess LDL 
cholesterol in blood vessel walls. LDL cholesterol enters the wall endothelium 
through small damaged segments; the LDL particles are then oxidized and 
monocytes aggregate in these cuts absorbing the LDL cholesterol in the process. In 




stream followed by a healing process, excessive serum LDL cholesterol overwhelms 
the natural healing process causing continuous deposition (Watts et al., 2012) 
(Austin et al., 2004). Healthy vessels are responsible for maintaining blood pressure 
and vascular tone; dysfunctional vasculature, arteries in particular, leads to 
atherosclerosis and an increase in cardiovascular events (Watts et al., 2012).     
1.1.5 Summary of heterozygous familial hypercholesterolemia 
HeFH is a genetic disorder with an autosomal dominant inheritance pattern. This 
means that a child would have a 50% chance of contracting the disease given that 
one parent carries the defective gene. HeFH renders cholesterol clearance pathways 
defective; this causes an accumulation of LDLC in the blood. Elevated serum LDLC 
damages blood vessels and the cardiovascular system in general, resulting in an 
increased rate of CVD morbidity and mortality in HeFH patients. 
1.2 Prevalence and screening of HeFH 
1.2.1 Prevalence of familial hypercholesterolemia 
Patient identification remains an important challenge in the management of HeFH. 
The prevalence rate of the heterozygous form of FH is often quoted as 1/500 (0.2%) 
as documented in Goldstein et al. (1973) in USA. This was confirmed in different 
countries as follows; the UK by Slack (1979) and Patterson and Slack (1972), Japan 
by Mabuchi et al., (1977) among other studies.  
However, more recent studies have reported higher prevalence rates. These include 
Nordestgaard et al. (2013), Marks et al., (2003) and Watts et al., (2012) that report 
prevalence rates of 1/200 (0.5%), consider the prevalence rates reported earlier to be 
underestimates basing their arguments on the actual number of myocardial infarction 
deaths associated with impaired lipid metabolism world-wide, and more recent 
epidemiological studies. Similar results include Neil et al. (2000), which found that 




of Physicians estimated that ~15% of the predicted 120,000 cases in the UK were 
diagnosed (Pedersen et al., 2010). Civeira (2004) estimates that only 10% of 
10,000,000 people with FH world-wide are diagnosed and less than 25% are on lipid 
lowering therapies. 
Screening of HeFH patients and their family members is recommended by the 
National Institute for Health and Care Excellence (NICE ) clinical guidance 71(CG71) 
to improve patient identification. This is discussed in section 1.2.3.5 below. 
1.2.2 Signs and symptoms 
Prior to the advanced stages of the disease, HeFH is largely asymptomatic. This lack 
of symptoms constitutes a potential problem in the diagnosis of the disease. The 
onset of clinical symptoms is associated with a high rate of CVD mortality and 
morbidity and warrants aggressive lipid reduction. This is because the disease 
progresses during the asymptomatic phase as several studies have shown. For 
example, Cabellero et al. (2012), using non-invasive methods (ultrasounds, MRI and 
blood tests), showed the development of aortic (94%) and lipid (33%) plaques in 
asymptomatic FH patients signifying the increase in CHD risk. Although the sample 
size for this study was small, several other researchers have reported similar 
findings; of note is the paper by Neefjes et al. (2011) which found accelerated 
development of subclinical CHD in patients who were receiving intensive lipid 
lowering therapies. The extent of CHD was related on gender and the level of LDLC 
attained during treatment. 
The Cardiac Society of Australia and New Zealand in a review carried out by Sullivan 





Premature coronary heart disease (CHD) 
Premature cardiovascular disease (CVD) 
Aortic stenosis 
Tendon xanthomas (11%) 
Corneal arcus (27%) 
Xanthelasmas (12%) ”. 
Similar to the cardiovascular pathology of the disease (discussed in section 1.1.4), 
the signs and symptoms of HeFH are caused by the deposition of LDL cholesterol in 
bodily tissues (Watts et al., 2012). Xanthomas are caused by the accumulation of 
lipids in the skin, xanthelasmas by the accumulation of lipids around the eyes while 
corneal arcus are formed by the deposition of lipids in the cornea. Xanthomas are not 
associated with any further symptoms; however, corneal arcus have been linked to 
increased intraocular pressure and decreased central corneal thickness (Hovingh et 
al., 2013). 
1.2.3 Diagnosis and screening  
The diagnosis of HeFH is categorized into three criteria that separate the clinical, 
biochemical and genetic aspects of the disease (Marks et al., 2003). A clinical 
diagnosis of HeFH is usually made in primary care and is based on the physical 
symptoms of the disease; this is usually supported by biochemical tests that mainly 
assess LDLC levels. A definite diagnosis of HeFH is based on genetic testing.  
1.2.3.1 Clinical testing 
An understanding of clinical signs and symptoms form an integral part of the initial 
diagnosis of HeFH. Civeira (2004) lists these signs and symptoms as high plasma 




xanthelasmas and arcus cornealis. Some of these symptoms are not specific to 
HeFH; therefore, secondary causes (obesity, diabetes, smoking, hypothyroidism, 
corticosteroids, nephrotic syndrome) have to be excluded before postulating the 
existence of HeFH (Hopkins et al., 2011) (Watts et al., 2012).  
1.2.3.2 Biochemical testing 
Biochemical diagnosis, the measurement of LDLC levels, is necessary for the 
confirmation of HeFH (Marks et al., 2003). However, the range of total serum 
cholesterol levels in HeFH patients overlaps with that of non-genetic 
hypercholesterolemia. This could produce false positive or negative results of 
between 8-18% in suspected HeFH cases (Kwiterovich et al., 1974). Although 
diagnosis based on the clinical and biochemical elements of HeFH ensure that lipid 
lowering agents are initiated in a timely manner; genetic testing remains the best 
method for HeFH diagnosis.  
1.2.3.3 Genetic testing 
NICE UK (CG71) recommends the use of genetic testing to confirm clinical/ 
biochemical test results and to produce a definitive diagnosis of HeFH. A deterrent in 
the use of this method is the cost (Marks et al., 2003) (Pears et al., 2014); from a 
cascade screening perspective however, there is a reduction in the cost once 
causative mutations are identified and family members are tested.  
The multifactorial genetic nature of HeFH means that several causative mutations 
can affect the LDL receptor; additionally, new mutations continue to be discovered for 
this gene as discussed in section 1.1.2 (Molecular pathology). This presents a 
potential limitation in the use of genetic testing for HeFH. In populations with a high 
number of genetic mutations causing FH, this testing process is elongated and may 
be less accurate (Heath et al., 1999). Marks et al. (2003) accredits the limitations of 




diagnosis from clinical and biochemical testing. Genetic testing is nonetheless an 
important method of finding a conclusive diagnosis for HeFH due to inaccuracies in 
biochemical testing, and lack of or insufficient family/ personal histories and lack of 
clinical symptoms (Watts et al. 2012). Furthermore, it has been shown that the 
benefit gained from correctly identifying patients outweighed the procedural 
difficulties experienced (Austin et al., 2004). This is because definitive diagnosis of 
HeFH allows for cascade screening of family members and early identification of the 
condition. 
1.2.3.4 Diagnostic criteria 
Diagnostic criteria are tools that are developed to aid patient identification and 
diagnosis. Austin et al. (2004) discusses diagnostic criteria developed by three 
groups for HeFH. These include the US MedPed (Utah Make Early Diagnosis to 
Prevent Early Deaths) Program, the Simon Broome Register Group in the United 
Kingdom, and the Dutch Lipid Clinic Network (DLCN). These criteria take into 
account key factors that reduce the efficiency of the clinical and biochemical 
diagnostic methods discussed above, and have been statistically and genetically 
validated (Hovingh et al., 2013). The three systems are shown in table 1.1 below. 
The MedPed criteria use only lipid levels, while the Simon Broome Register Group 
criteria and DLCN use physical signs, family and personal history in addition to 





Table 1.1 The most commonly used criteria for the clinical diagnosis of FH, obtained from Fahed and Nemer (2011). 
1.2.3.5 Screening 
Despite the tools available for HeFH case detection, diagnosing an index case of the 
disease remains an opportunistic matter (Neil et al., 2000). Pedersen et al (2010) 
attributed the low rates of diagnosis to the lack of comprehensive national screening 
programs in the UK.  
NICE CG71 recommends that the screening process is initiated when cholesterol 
levels of >7.5 mmol/l are recorded in a patient. This should be followed by the use of 
diagnostic criteria to assess the likelihood of HeFH. In the UK, the Simon Broome 
Criteria are commonly used; these provide HeFH likelihood as a ‘definite’ or 
‘possible’ score. Cascade screening of family members should follow this finding 
using both genetic and biochemical (LDLC) tests. Whenever there is a negative 
Comments
1st Degree relative 2nd Degree relative 3rd Degree relative General population
<18 220 (155) 230 (165) 240 (170)  270 (200)
20 240 (170) 250 (180) 260 (185) 290 (220)
30 270 (190) 280 (200) 290 (210) 340 (240)










8 points LDL-C above 330 mg/dL, 








pediatrics                     AND
Definite FH ( = or > 8 points 
Probable FH (6-7 points) 
Possible FH (3-5 points)
1st degree relative with premature cardiovascular disease or LDL-C >95th 
percentile, or 
Personal history of premature peripheral or cerebrovascular disease, or 
LDL-C between 155 and 189 mg/dL
1st degree relative with tendinous xanthoma or corneal arcus, or 
1st degree relative child (<18 yrs) with LDL-C > 95th percentile, or 
Personal history of coronary artery disease
LDL-C between 190 and 249 mg/dL
Presence of corneal arcus in patient less than 45 yrs old
LDL-C between 250 and 329 mg/dL
Presence of a tendon xanthoma
Total Cholesterol (LDL-C) levels in mg/dL
Simon Broome Criteria (UK)
98% specificity 
87% sensitivity
Dutch Criteria (The Netherlands)
Tendon xanthomas in the patient or in a 1st or 2nd degree relative
Family history of MI at age <50 in 2nd degree relative or at age <60 
in 1st degree relative OR 
Family history of total cholesterol 
>290 mg/dL in 1st or 2nd degree relative




result from the genetic testing of a hypercholesteraemic patient, cascade screening 
of family members is still recommended using LDLC measurements.  
National cascade screening services have been initiated in several countries 
including Netherlands (Umans-Eckenhausen et al., 2001), Norway (Leren et al., 
2004), Spain (Pocovi et al., 2004), Scotland and Wales (Finnie, 2010) and England. 
The service in England is however limited as evaluated by Pedersen et al. (2010); 
Pears et al. (2014) attributed the mixed results of the national FH screening service 
to costs and a general laxity of commissioning groups to adopt the service due to 
current spending commitments, pressure to increase savings and disruption of 
existing models of care.  
Similarities between national screening services include the use of family-based 
methods as opposed to the ‘universal’ approach or population screening. 
Nevertheless, varying rates of effectiveness have been achieved across countries as 
discussed by Fahed and Nemer (2011). This could be explained by the difference 
between the systems in using both patient screening (opportunistic or targeted 
screening) and cascade testing; Iceland, in particular, uses a novel system where the 
ancestors of index cases are traced and the oldest in each lineage screened as 
opposed to testing only first and second degree relations. Netherlands, Spain and 
Wales use a community approach that involves home visits (Hovingh et al., 2013). 
1.2.4 Summary of prevalence and screening of HeFH 
Despite the measures put in place for diagnosis and screening of HeFH patients, the 
identification of patients is limited. Evidence shows that HeFH is managed more 
efficiently in countries that have set up screening, and cascade screening services. 
NHS hospitals continue to implement the screening services; however, more work is 




potential of reducing the number of patients that receive medication. For a new 
medicine, such as PCSK9 inhibitors, inadequate diagnosis could lead to low usage. It 
may therefore be important to assess the patient journey from the perspective of the 
stakeholders involved. This could potentially serve to improve the process, and 
explore the potential effect that the patient identification process could have on 
PCSK9 inhibitor usage. 
1.3 Therapeutic agents for HeFH  
The treatment of HeFH is based on statin therapy. Statins are recommended as first 
line therapy by NICE UK (CG71) in both adults and children of 10 years or older (it is 
however advised that children and young people should be referred for specialist 
treatment); ezetimibe can be used in place of statins due to intolerance or 
contraindications. The treatment objective is to reduce LDL cholesterol levels by 50% 
from baseline using the maximally accepted doses of high intensity treatment if 
required. Bile acid sequestrants (resins), nicotinic acid and fibrates are alternative 
treatment options available from specialists when statins and ezetimibe are not 
appropriate or as additional therapies.  
 
1.3.1 Statins 
HMG-CoA reductase inhibitors or statins antagonise the effect of the enzyme HMG-
CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase); a component of 
the cholesterol synthesis process in the liver. The result is a decrease in serum 
cholesterol levels (Patel, 2014). The safety and efficacy of statins, in lowering blood 
cholesterol and preventing cardiovascular disease, have been demonstrated in 
several placebo controlled clinical trials. Watts et al. (2012) asserts that statins are 
powerful agents in the control of blood lipids, a statement that is reflected in the 




hypercholesterolemia by NICE UK. The effectiveness of statins in reducing mortality 
rates due to heart disease was shown in the Scandinavian simvastatin survival study 
(SCANDINAVIANSIMVASTATINSURVIVAL, 1994). This result was reaffirmed by 
many studies thereafter Sacks et al. (1996), Baigent et al. (2005), Ebrahim et al. 
(1999). As part of the National Health Service (NHS) health technology assessment 
program, Ward et al. (2007) reviewed 49 randomized controlled trials and 5 major 
clinical trials on statins and reported an average reduction of coronary heart disease 
of 27%. In an assessment of lipid management using statin therapy, Waters et al. 
(2009) studied 9955 patients across 9 countries with the primary end point of a 
successful reduction of LDLC levels. The success rate was found to be between 
47%-84% with patients with a higher CVD risk profile having a significantly lower 
possibility of achieving normal cholesterol levels. In a meta-analysis of seven 
randomised controlled trials; Thavendiranathan et al. (2006) estimated that there was 
a 29.2% reduction in relative risk of major coronary events with statins compared to 
placebo.  The reduction effect on overall mortality and coronary heart disease 
mortality was found to be an 8% and 22.6 % respectively. There is general 
agreement on the benefit of statins in the reduction CVD event rates in secondary 
care; however, studies in primary care have produced dissonant results 
(Thavendiranathan et al., 2006) (Ward et al., 2007) (Mills et al., 2008). The effect of 
statins on FH has not been studied; Robinson and Goldberg (2011) attribute this to 
the ethical issues arising from denying patients an effective form of treatment for the 
purposes of research. Statins are effective lipid lowering agents; rosuvastatin is 
presently the only branded statin in the market (NICE UK TA132); it has been shown 
to produce reduction in LDLC of between 40.6-58.1% according to Civeira et al. 





The benefit of statins in children and adolescents with HeFH is recognized although 
the precise age at which the agents are safe for use is currently a matter of clinical 
judgement and consideration of other risk factors in a given situation (Watts et al., 
2012). Statins are contraindicated during pregnancy and breast feeding (Kusters et 
al., 2010). Page et al. (2015) discusses the reduced effectiveness of statins in LDL 
receptor-negative hyperlipidaemia. Intolerance to statins remains a key problem 
under investigation; Williams and Mishra (2015) reported an adverse event rate of 
18.2%.  
1.3.2 Ezetimibe 
Ezetimibe inhibits the absorption of cholesterol by impeding the function of Niemann 
Pick C1-like 1 protein (Hovingh et al., 2013); the effect is a reduction in the amount of 
cholesterol crossing the intestinal wall. As monotherapy, ezetimibe reduces LDLC 
levels by 17.3% while as an adjuvant to statin therapy (at a dose of 10mg) a 
decrease of 14-25% compared to placebo has been recorded (Civeira et al., 2004). 
Although ezetimibe is recommended as an alternative or add-on to statins in specific 
cases for many international guidelines (NICE UK included), there is a general 
agreement that it lacks a robust evidence base of its safety and effectiveness profiles 
(Battaggia et al., 2015) (Califf et al., 2010).  Battaggia et al. (2015), a meta-analysis 
of multiple clinical trials on ezetimibe, documented the disparities in results between 
subgroups of the ENHANCE trial (Kastelein et al., 2008) and concern about 
causation of cancer in the SEAS trials (Rossebø et al., 2008) among several other 
trials with similarly discordant results.      
1.3.3 Alternative therapies; bile acid sequestrants, nicotinic acid and fibrates and novel 
therapies 
Bile acid sequestrants bind to bile in the small intestines inhibiting its reabsorption to 




Firstly, cholesterol is the lone precursor in the formation of bile; a reduction of 
cholesterol causes an incremental function of the hepatic enzyme cholesterol 7-α-
hydroxylase, resulting in the conversion of cholesterol to bile acids. Secondly, there 
is an up-regulation of LDL receptors leading to increased absorption of cholesterol 
from the blood system (Hovingh et al., 2013).  
The action of nicotinic acid, a water soluble vitamin B agent, on LDL cholesterol, 
triglycerides and lipoprotein (a) has led to its use in clinical practice for ~50 years 
(Drexel, 2007). Nicotinic acid is recognized to increase HDL cholesterol levels more 
effectively than other lipid lowering agents; for this reason, it is used in clinical 
practise in combination with statins in low HDLC cases (Sando and Knight, 2015). 
The resultant effect of lipid reduction has been investigated in relation to FH and 
cardiovascular risk reduction (Carlson 1963; 1990). The mode of action of nicotinic 
acid is currently unclear (Hovingh et al., 2013); some research has shown a 
multifactorial system initiated by the inhibition of liver DGAT2 (diacyl-glycerol 
acyltranferase-2) and NADPH (Ganji, Kashyap and Kamanna, 2015). The safety of 
nicotinic acid is established; ‘flushing’ as a side-effect has been the cause of many 
withdrawals from the medication. Multiple research projects have studied better 
methods of managing this side-effect including Guyton and Bays (2007). 
Fibrates are metabolised to fenofibric acid which activates peroxisome proliferator-
activated receptor-alpha (PPAR-α); several genes involved in the management of 
lipid in the body are affected by these receptor (Hovingh et al., 2013). Multiple factors 
have been highlighted to contribute to the function of fibrates. These include; an 
increase in beta oxidation of fatty acids hence reduced LDL and VLDL cholesterol, a 
reduction in the manufacture and increase in the elimination of triglycerides and a 




Fibrates are estimated to reduce serum triglyceride levels by 20-50%, increasing 
HDLC levels by 10-50% and reduces LDLC by 5-20% (Milionis et al., 2010).  
1.3.4 Efficacy of conventional lipid lowering agents in HeFH 
Studies on the long term effects of pharmacotherapy have shown that the CHD risk 
of HeFH patients can be reduced to that of the general population with proper 
identification and management of cases (Watts et al., 2012). However, many HeFH 
patients do not achieve the treatment target recommended by NICE UK using 
conventional lipid lowering therapies (i.e. 50% LDLC reduction from baseline): 
(Morales et al., 2018), (Razek et al., 2018), (Hartgers et al., 2018), (Page et al., 
2015), (Nordestgaard et al., 2013). Pijlman et al. (2010) found that 47% of HeFH 
patients attained NICE therapeutic target, similar to values recorded by Morales et al. 
(2018). If inadequately treated, HeFH patients retain a high risk of CVD.  
Several studies have documented variability in LDLC reduction following statin use. 
The reasons for these variations are reported to either be genetic or phenotypical in 
nature. For example, mutations in apolipoprotein E have been linked to LDLC 
response variability Pedro-Botet et al. (2001). Similarly, differences in the ADME 
process can also affect statin metabolism and vary clinical response Karlson et al. 
(2016).  
Other studies have focused on the effect of decision making and prescribing 
practices in influencing statin efficacy. Morales et al. (2018) attributed this mainly to 
patient non-adherence, the effects of the medication and clinical inertia. Pijlman et al. 
(2010) found that many patients who were not adequately treated were not using the 
maximum lipid lowering treatment stipulated by guidelines. The reasons for this 
included patient-physician satisfaction with achieved results, adverse reactions to 




guidelines 27% of the patients were receiving maximum regimens of conventional 
lipid lowering treatments.  
Nevertheless, studies conducted in more controlled settings have confirmed that on 
average approximately 50% of HeFH patients achieved therapeutic targets following 
the use of statins and conventional lipid lowering agents. For example, Robinson and 
Goldberg (2011) reported the results of a Dutch study involving two academic and 
three regional settings (n=1249); it was found that 53% of patients receiving 
treatment did not reach the therapeutic target in spite of maximal doses being used. 
The implication is that both medication efficacy and stakeholder decision making are 
important in the successful treatment of HeFH. Whereas decision making processes 
can be assessed and changes implemented, the unavailability of effective lipid 
lowering agents for HeFH remained a major problem. Patients who did not achieve 
LDLC targets would receive additive medication while registering minimal changes. 
Furthermore, patients who were intolerant to statins had to take low doses of the 
medication, or use the less effective alternative medication available. The 
introduction of PCSK9 inhibitors, therefore presented an opportunity to potentially fill 
the gaps in the therapeutic management of HeFH. 
1.3.5 PCSK9 inhibitors 
PCSK9 inhibitors prevent the degradation of LDL receptors by exerting an inhibitory 
effect of the PCSK9 component of the LDLR gene (Okere and Serra, 2015). An 
increase in the recycling of LDL receptors produces a corresponding increase in 
LDLC absorption. PCSK9 inhibitors have been shown to reduce serum cholesterol 
levels consistently by up to 50% as monotherapy (Navarese et al., 2015) and up to 
60% in combinative therapy with statins (Hassan, 2015). In a study comprising three 




reactions were injection site reactions, diarrhoea, fatigue and headaches. NICE 
approved two PCSK9 inhibitors with marketing authorisations in the UK; alirocumab 
(case number ID779 with NICE) and evolocumab (case number ID765).  
The guidelines for these lipid lowering agents have also been published and include 
LDLC thresholds for primary and secondary treatment of HeFH (NICE technology 
appraisals 393 and 394). For the management of primary HeFH, NICE UK 
recommends the use of these new medicines when LDLC levels are consistently > 
3.5 mmol/ l despite maximal tolerated lipid lowering therapy for secondary prevention 
treatment; and an LDLC > 5mmol/l in primary prevention treatment. Maximum lipid 
lowering therapy involves the use of statins, ezetimibe and alternative therapies prior 
to consideration of PCSK9 inhibitors.  
1.3.6 Summary of therapeutic agents for HeFH 
Following successful treatment of serum LDLC levels with statins and alternative lipid 
lowering agents, HeFH patients can attain CVD risk equal to that of a healthy 
individual. However, successful treatment is hindered by decision making practices 
among stakeholders and the efficacy of available medication. Currently, the use of 
conventional lipid lowering medication is effective in approximately 50% of HeFH 
patients. There is therefore a potential need for PCSK9 inhibitors in treating HeFH 
patients following statin therapy as guidelines recommend.  
1.4 Rationale for studying barriers and facilitators to the use of PCSK9 
inhibitors 
The rationale for studying the barriers to PCSK9 inhibitor use can be categorised into 
two groups. Firstly, the general challenges in the management of HeFH, such as low 
patient identification and inadequate recording of clinical attributes, could potentially 
affect medication use. Secondly, new medicines are usually costly and their use is 




general effect of stakeholder decision making that could potentially affect PCSK9 
inhibitor usage. 
1.4.1 Stakeholder roles in the management of HeFH 
The knowledge, attitudes and experiences of stakeholders (patients, consultants, 
nurses, GPs etc.) in the care of HeFH has previously been studied in order to explore 
the practice related reasons for inefficiency in the management of disease. Past 
research has shown that various factors influence the decision of stakeholders to 
engage in the HeFH care pathway. These include; feelings of guilt associated with 
the dietary and lifestyle elements of disease management (Frich, Malterud and 
Fugelli, 2007), screening services (Green et al., 2015), and the use of statins (Ågård 
et al., 2005).  
Research projects have focused on individual stakeholders; discussed their roles and 
the potential improvements that can be made to improve provision of care for HeFH. 
Novel approaches of improving the identification of HeFH patients continue to be 
developed and critiqued at various levels Weng et al., (2015), Green et al., (2015), 
Qureshi et al., (2016), Dhiman et al., (2014). Patients’ views and opinions have also 
been studied to assess the reasons behind non-compliance, disease knowledge, 
attendance of HeFH screening and testing (Claassen et al., 2010) (Weiner and 
Durrington, 2008) (Hollman, Olsson and Ek, 2006)(Knowles, 2016)(Green et al., 
2015) (Frich, Malterud and Fugelli, 2007) (Gidding et al., 2015) (Claassen et al., 
2010) (Mortensen et al, 2016). Of interest to this study is the assertion by Watts et al. 
(2016) that patients’ opinions on the controllability of the disease and the efficacy of 
current pharmacological therapies could be a potential influencing factor towards 
their willingness to participate in the health system. This provides an opportunity to 
evaluate the potential of a more effective treatment (PCSK9 inhibitors) in influencing 




Research focusing on healthcare providers include: factors that influence the 
decision to prescribe medications (Proser et al., 2003), bias in using certain 
medications and overprescribing (Green et al., (2007) (Wu et al. 2013) (Mohammed 
et al., 2012), and the level of knowledge that healthcare practitioners possess on 
HeFH. Rangarajan et al. (2016) identified a deficit in the knowledge and awareness 
of GPs based on the HeFH screening, diagnosis and treatment in Tamil Nadu. 
In the management of HeFH in the NHS, patients are generally identified in primary 
care by general practitioners (GPs) and nurses. Patients with severe HeFH or those 
who are inadequately treated are referred to secondary care where they are attended 
to by consultant lipid specialists. The immediate stakeholders in the care for HeFH 
are therefore patients, specialist consultants, GPs and nurses. Specific roles of 
nurses in the care of HeFH are not explicitly outlined (Krass, Walker and Watts, 
2012). Key roles that have been suggested include the monitoring and improvement 
of patient compliance, the provision of education on disease management and the 
facilitation of services that require patient participation. (Marks et al. (2003) (Simoens 
et al., 2005) (Yamada et al., 2005) (Bates,Connaughton and Watts, 2009).  (Allen et 
al., 2014) (Watkins, 2008)(Muir,George and Whitehead, 2012). Research on HeFH 
(Allen et al., 2002) has shown that nurses have the potential to increase patient 
engagement with screening and treatment of patients: while Green et al. (2015) 
utilised an FH audit tool and nurse-led follow up to facilitate the identification of HeFH 
patients in the Medway CCG. Similarly, the potential for healthcare professionals to 
increase patient participation through educational campaigns has been shown by 
Simoens et al. (2005). While Yamada et al. (2005) found that long term interventions 
by healthcare professionals to facilitate adherence and compliance improved the 




hypercholesterolemia management in the UK (Pedersen et al., 2010) suggested the 
development of multidisciplinary teams in an effort to improve care provision for 
HeFH; including the payer’s decision to avail a certain medicine.  
The evidence suggested that a multidisciplinary approach can potentially increase 
patient participation, adherence and compliance. Furthermore, different stakeholders 
have been shown in various projects to be able to positively impact the care for 
HeFH. However, no research has been carried out on the roles of different 
stakeholders in the care of HeFH and how their interactions affect the effective 
delivery of treatment. Research of this nature would also allow for a study of the 
views and opinions of stakeholders on PCSK9 inhibitors; what they perceive their 
potential role to be, and issues that may hinder or facilitate the medication’s use.  
Finally, the prescription of PCSK9 inhibitors are mainly based on the initial use of 
statins and other conventional lipid lowering therapies as outlined by NICE guidelines 
(NICE technology appraisals 393 and 394). Considering the potential influences to 
stakeholder decision making, especially agreement between physician and patients 
in LDLC targets and external influences to prescription practices, it may be useful to 
assess the population of HeFH patients that would require PCSK9 inhibitors following 
statin use in addition to the views and opinions of stakeholders.  
1.5 Conclusion 
 
The current knowledge in the field of HeFH indicates that the disease is currently 
under-diagnosed and under-treated. Most HeFH patients do not achieve the 
treatment target of 50% reduction in LDLC levels as stipulated by NICE guidelines 
following the use of statins, and conventional lipid lowering agents. This presents a 




The use of a medicine is however influenced by factors that revolve around 
stakeholder decision making practices and organisational policies for prescription. In 
the case of PCSK9 inhibitors, it is expected that prescription restrictions will be 
placed on the medication because of their high cost. Additionally, PCSK9 inhibitors 
are indicated following the inadequate control of LDLC levels using conventional lipid 
lowering pharmacological therapies. This may suggest the need to assess patient 
medical records to determine their utility in guiding PCSK9 inhibitor prescription.  
The current literature did not include much research on the potential factors 
influencing the use of PCSK9 inhibitors. The overall implication is that there is scope 
to increase knowledge on these factors with the aim of facilitating the adoption of 







Chapter 2 A review of literature  
The current thesis aims at assessing the potential factors influencing the use of 
proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors in the management 
of for the heterozygous familial hypercholesterolemia (HeFH). As discussed in 
chapter one, the current state of knowledge on heterozygous familial 
hypercholesterolemia (HeFH) includes multiple research studies on the methods 
adopted to improve quality of care. However, PCSK9 inhibitors were not studied to 
the same extent, especially as pertains to their use in clinical practice.  
This chapter consists of a systematic search and narrative synthesis of studies 
specifically focusing on PCSK9 inhibitor use in clinical practice and the associated 
barriers and facilitators to their use. The overall aim of this chapter is to;  
 To identify gaps in literature on the barriers and facilitators to PCSK9 inhibitor 
use. 
 Formulate a research question(s) for the current thesis.   
2.1 Type of review 
The advent of evidence based practices led to a growth of the significance of 
literature reviews in the 1990s (Grant and Booth, 2009). Broadly speaking, a 
literature review is an evaluation of ‘all’, research within a topic area with the intention 
of summarizing the best quality information for various purposes. These include the 
synthesis of knowledge for; the guidance of health policy, the assessment of the 
effectiveness of interventions, or the identification of gaps in literature (Moule et al., 
2017). For these purposes, systematic reviews are considered the gold standard 
(Boland, 2017). A systematic review is a protocol-driven literature search aimed at 
evaluating all the evidence within a narrow research area. The resulting literature is 




difference between a systematic and a traditional review lies in the 
comprehensiveness, transparency and objectivity conveyed in a systematic review 
(Grant and Booth, 2009). 
In some cases however, systematic reviews are either not feasible or unsuitable 
(Popay et al, 2007). The present study found that literature on the factors affecting 
PCSK9 inhibitor use encompassed a variety of research designs. From a review 
perspective, these did not offer sufficient similarity to allow for meta-analysis, and 
from a synthesis perspective different methods were deemed necessary to 
synthesise the data. In such a situation, Snilstveit et al. (2012 proposed the use of 
different types of systematic reviews and methods of synthesis to accommodate the 
information that did not immediately conform to the systematic review formula 
(Petticrew and Rogers, 2006); effectively maintaining the advantages offered by 
systematic methods.  
Current systematic reviews on PCSK9 inhibitors focus on clinical efficacy of 
medication i.e. the low density lipoprotein cholesterol (LDLC) lowering action of the 
medicine and its effect in improving cardiovascular outcomes. On the contrary, 
questions regarding the factors affecting the use of PCSK9 inhibitors have rarely 
been addressed in literature. A systematic search of literature was therefore 
conducted to ensure that all studies assessing barriers to PCSK9 inhibitor use were 
identified. A narrative review and synthesis then followed allowing for an exploratory 
account of the research area. 
The main aim of this literature review was therefore for scoping purposes. The 
intention was to map out all available literature on the barriers to PCSK9 inhibitor 
use, identify potential gaps in the evidence base, and situate the present study. Due 




studies, the quality assessment process was not considered to be necessary. In 
place of the process, the study only included peer reviewed publications. The 
assumption of course, was that the perceived quality established from a peer 
reviewed article was sufficient to meet this review’s aim of identifying literature in the 
topic area. 
The study adopted the framework developed by Kable at al. (2012) to document the 
search strategy in a systematic manner (Table 2.1). Additionally, some elements of 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
protocol were applied to the study. This was in the form of the PRISMA-P obtained 
from http://www.prisma-statement.org/Extensions/Protocols.aspx. Finally, the 
narrative synthesis was guided by a protocol developed by the Economic and Social 
Research Council (ESRC) – Popay et al. (2006).A thematic approach was applied to 
the narrative synthesis as described by Barnett-Page and Thomas (2009) in order to 
categorise the potential barriers to and facilitators of PCSK9 inhibitors. 
Step Process 
1 Purpose statement 
2 Databases and search engines 
3 Search limits 
4 Inclusion and Exclusion criteria  
5 Search terms 
6 Database searches and results 




8 Table reporting of literature in the 
review 
9 Final number of search results 
10 Review 
11 Complete reference list 
Table 2.1 Literature review framework (Adapted from Kable et al., 2012) 
2.2 Methods 
2.2.1 Purpose statement 
This literature review was composed of a systematic review of literature and a 
narrative synthesis (Saks and Allsop, 2013). The main aim of the review was to 
identify the evidence available in the research area, to describe the types of studies 
conducted and to locate the current study in the literature base. This chapter 
therefore aimed to evaluate the body of evidence on the factors influencing the use of 
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors. The key focus 
points of the evaluation were: 
1. What are the potential factors affecting the use of PCSK9 inhibitors? 
2. What are the effects of stakeholder perceptions and opinions on the use of 
PCSK9 inhibitors 
2.2.2 Databases and search engines 
An electronic search was conducted using the EBSCO database. EBSCO provides 
access to academic journals and e-books across a range of databases 
simultaneously; these include AMED (Alternative & Complementary Medicine), 
CINAHLPlus, EconLit, MEDLINE, PsycINFO among others. Further studies/ papers 
were handpicked from reference lists of the papers identified from the search 




2.2.3 Search limits 
Search limits help to maintain relevance in the search process (Kable et al., 2012). It 
was expected that there would be a limited number of studies addressing the use of 
PCSK9 inhibitors because of their relative novelty. Searches were therefore only 
limited to peer-reviewed articles that were written in English.  
2.2.4 Search terms 
Search terms were created using the provisional title of the project ‘barriers and 
incentives to the uptake of PCSK9 inhibitors’. The PICO (Population, Intervention, 
Comparison, and Outcome) tool was used to ensure comprehensiveness of search 
terms as described by Aveyard, Payne and Preston (2016).  
The population of interest was HeFH and associated terms. These terms included 
the two variations in the spelling of hypercholesterolemia (hypercholesterolaemia). 
The term ‘familial hypercholesterolemia’ and associated abbreviations were also 
included. Finally, the heterozygous form of the disease was specified. PCSK9 
inhibitors have currently been approved (NICE UK) for use in HeFH. The 
homozygous form of the disease is treated different and falls outside the scope of the 
current study.  
Similarly, the intervention section was comprised of terms associated with PCSK9 
inhibitors. These included the name of the new class of medication in full, 
abbreviations of the name, and the generic and brand names of the two agents 
currently available in the class. 
The outcome section focused on the terms that were commonly used in studies that 
depicted potential barriers to PCSK9 inhibitor use. A wildcard (represented by the 
asterisk - *) was used to represent different variations that the terms could take. For 




forms as follows; ‘factors that determine PCSK9 inhibitor use’, ‘factors determining 
PCSK9 inhibitor use’ or ‘determinants of PCSK9 inhibitor use’ et cetera. The addition 
of a wildcard would include all these variations of the term ‘determine’ in the search 
results. Similarly, the term ‘detect*’ would identify studies that had PCSK9 inhibitors 
and any variation of the word ‘detect’ in its title or body. The context of such studies 
could be; how HeFH patient detection affects PCSK9 inhibitor use, detecting eligible 
patients for PCSK9 inhibitor use and so on.   
The resulting terms could be roughly grouped as follows;  
 Terms that directly referred to the assessment of potential barriers in PCSK9 
inhibitor use e.g. ‘barriers’, ‘factors’, ‘opinions’, ‘perceptions’. 
 Terms that referred to clinical outcomes in PCSK9 inhibitor use that could act 
as potential barriers e.g. views on LDLC and cardiovascular outcomes 
reduction could potentially influence medication use. 
 Terms that are associated with the management of HeFH that could affect 
PCSK9 inhibitor use as discussed in chapter 1 e.g. guidelines, screening, 
patient identification etc.  
In general, the terms were found to revolve around common issues affecting HeFH 
use with potential impact on PCSK9 inhibitor use; terms that defined stakeholder 
opinions and perceptions on the medication were also included. 
Finally, a preliminary search was conducted on Google Scholar to identify terms/ 
words that were commonly used in the research area. Synonyms of the words were 
added to ensure completeness. The complete list of search terms and the resulting 





Population Intervention Outcome 
familial 
hypercholesterolaemia 









alirocumab opinion* LDL* 









identif* cardiovascular  
 PCSK9' affect* cholesterol 
 praluent influen*  
 repatha factor*  




  barrier*  
  guideline*  
Table 2.2 List of search terms 
 
  
2.2.5 Inclusion and Exclusion criteria  
The PRISMA-P checklist was used to outline eligibility criteria for the selection of 
relevant literature. This checklist adopts the PICO structure which describes the 
population or participants and conditions of interest, the intervention under study, 
comparison/ control groups, expected outcomes, the setting for the studies and the 
study designs expected. Although all these parameters were not relevant in our study 
the template provided a structure that ensured a rigorous set of eligibility criteria was 
adopted. Table 2.3 below presents a summary of the completed checklist.  
Population of interest  Patients with heterozygous familial hypercholesterolemia 
(HeFH) 
Healthcare providers in the management of HeFH 
(consultants, general practitioners, nurses) 
Primary intervention  Proprotein Convertase Subtilisin Kexin/Type 9 (PCSK9) 
inhibitors 
Comparison group  Not relevant to the present review as the study is solely 
focused on PCSK9 inhibitor research. 
Outcomes The opinions and perceptions of stakeholders on the use 




barriers and facilitators. Quantitative analyses that could 
serve to inform the discussion of barriers and facilitators to 
PCSK9 inhibitor use e.g. usage or uptake analyses.  
Table 2.3 PICO formula of inclusion of studies 
Outcomes were considered to be the opinions and perceptions of stakeholders on 
the use of PCSK9 inhibitors. Stakeholder views on barriers and facilitators to PCSK9 
inhibitor use were also assessed.  
The final list of inclusion criteria is shown below: 
 Written in English 
 Peer-reviewed publications 
 Population of interest was HeFH patients and healthcare providers involved in 
the use of PCSK9 inhibitors 
 The primary intervention was PCSK9 inhibitors 
 Outcomes included; qualitative views and opinions of stakeholders on the 
barriers and facilitators to PCSK9 inhibitor use, quantitative analyses that 
could inform the topic of interest 
The final list of exclusion criteria included: 
 Studies on HeFH and related factors (e.g. cascade screening) that did not 
focus on PCSK9 inhibitors 
 Studies that focused on the development process of PCSK9 inhibitors e.g. 
novel genetic research   
 Studies focusing solely on efficacy of PCSK9 inhibitors or cost-effectiveness 
 Studies focusing solely on the description of the initial prescription patterns of 




 The paper was a general review on PCSK9 inhibitors 
 Papers focused on the discussion of clinical guidelines with no assessment of 
their effect on prescription 
2.3 Results 
2.3.1 Database searches and results 
The search terms in for each group were combined in a search using the ‘OR’ 
function and saved. For example, the terms in the population group were searched 
as shown below;  
‘Familial hypercholesterolemia’ OR ‘heterozygous familial hypercholesterolemia’ OR 
‘homozygous familial hypercholesterolemia’ OR ‘heFH’ OR ‘hoFH’  
This combined group was named S1. This ensured that each time a search was 
conducted using ‘S1’, the search engine searched for all included variations of 
‘HeFH’. This process was repeated for all the groups. 
The ensuing groups (S1-S4) were then combined in several searches with each term 
from the comparison and outcome groups using the ‘AND’ function. For example;  
S1 (Population) AND S2 (Intervention) 
S1 (Population) AND S2 (Intervention) AND S3 (Comparison) 
The process was repeated until all the search terms were included.  
The Search was conducted in EBSCOhost, for papers published from 1993 to 2020. 
The date of the search was 24/03/20, and the search covered; all text (TX), author 
(AU), title (TI), subject terms (SU), source (SO), abstract (AB), ISSN (IS) and ISBN 




# Searches Results 
1 familial hypercholesterolaemia or FH or heterozygous familial 
hyperchoelsterolemia or  
heFH or familial hypercholesterolemia 
64,634 
2 PCSK9 inhibitors or proprotein convertase subtilisin kexin or 
alirocumab or evolocumab or  
kexin 9 inhbitors or proprotein convertase subtilisin/kexin or 
'PCSK9' 
5,043 
3 perception* or detect* or opinion* or determin* or screen* or 
identif* or affect* or influen*  
or factor* or policy* or barrier* or guideline* 
19,896,50
1 
4 high cholesterol or low density lipoprotein choelsterol or LDL* or 
high density lipoprotein  
cholesterol or HDL* or cardiovascular or cholesterol 
1,383,282 
5 1 AND 2 1,224 
6 2 AND 3 2,962 
7 2 AND 4 4,330 
8 1 AND 2 AND 3 818 
9 1 AND 2 AND 3 AND 4 810 
10 27 records excluded as they were not in English 783 




12 Exact duplicates of 140 papers removed from the results. 639 
Table 2.4 Search process 
2.3.2 Selection of papers for inclusion in the review 
The completed search generated 810 papers (MEDLINE, n=648; CINAHL Plus 
n=152; SPORTDiscus, n=9; APA PsycInfo, n=1). 27 records were excluded as they 
were not written in English. 4 articles were not published in peer-reviewed journals 
and were therefore removed. 140 duplicates were also excluded leaving 639 papers. 
The inclusion and exclusion criteria described in section 2.2.5 were then applied to 
filter the results. The assessment of study titles led to the exclusion of 513. Excluded 
titles included studies purely on HeFH, cascade screening and the development of 
PCSK9i (n=22), efficacy of medication and novel genetic research (n=35), topics 
unrelated to the research focus (n=108), studies on PCSK9i genetics and 
biochemistry (n=348).The abstracts of the remaining 126 papers were reviewed 
based on the inclusion and exclusion criteria as specified below. 45 articles were 
removed; although these articles covered PCSK9 inhibitors they were mainly 
theoretical articles, commentaries or study protocols. Finally, a full text review of 81 
articles produced 18 papers that were deemed to relevant to the literature review 






Figure 2.1 Flow diagram of selection process 
 
27 records excluded because they 
were not written in English. 
4 records excluded as they were not 
published in journals.  
140 records excluded as a result of 
duplication. 
Total records remaining n= 639 
45 studies were excluded as they did 
not address issues influencing 
PCSK9i usage. The papers consisted 
of reviews and general accounts of 
PCSK9i. 
Excluded titles included studies on 
HeFH, cascade screening and the 
development of PCSK9i (n=22), 
efficacy of medication and novel 
genetic research (n=35), topics 
unrelated to the research focus 
(n=108), studies on PCSK9i genetics 
and biochemistry (n=348). 
513 records excluded based on 
assessment of titles  
Total records remaining n=126 
126 reviewed by inclusion and 
exclusion criteria and review of 
abstracts 
Total records remaining=81 
Excluded texts addressed the 
following topics on PCSK9 inhibitor 
use: prescription patterns (n=22), 
guidelines (n=10), intervention 
efficacy (n=18), cost-effectiveness 
(n=6), general reviews (n=5), future 
challenges of genetic novel therapies 
(n=2). 
81 full-text papers assessed for 
eligibility based on inclusion criteria 
Total records remaining=18 
Results of database search: 
MEDLINE n=648 
CINAHL Plus with Full Text n=152 
SPORTDiscus with Full Text n=9 





2.3.3 Relevance of retrieved literature 
The final evaluation of relevance was conducted by reviewing the full text of 81 
articles on PCSK9 inhibitors based on the inclusion and exclusion criteria. 25 papers 
(31%) addressed stakeholder perceptions and barriers to PCSK9 inhibitor use 
directly. Excluded texts addressed the following topics on PCSK9 inhibitor use: 
prescription patterns (n=22), guidelines (n=10), intervention efficacy (n=18), cost-
effectiveness (n=6), general reviews (n=5), future challenges of genetic novel 
therapies (n=2). A summary of the themes that covered PCSK9 inhibitor use are 
shown in figure 2.2 below. Although these texts were excluded, they were reviewed 
in full because the research topics had the potential of influencing PCSK9 inhibitor 
use. For example, cost of medication is not explicitly identified as a barrier in most 
studies; however, it is a consideration in the development of prescription systems for 
PCSK9 inhibitors. The 18 selected studies directly addressed either the barriers to 
PCSK9 inhibitor use (n=13), or assessed stakeholder views or experiences 
concerning PCSK9 inhibitors (n=5).  
 























2.3.4 Table reporting of literature in the review 
The final list of relevant studies (n=18) span 30 countries (Hong Kong, Australia, 
Bosnia and Herzegovina, Brazil, China, Czech Republic, France, Germany, Greece, 
Hungary, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, New Zealand, Philippines, 
Russia, Saudi Arabia, Serbia, Slovakia, South Africa, Spain, Taiwan, UK, Ukraine, 
US, Uzbekistan, Vietnam). It is worth noting, however, that 8 of these papers were 
based in the US (44%). This was followed by European countries (n=6, 33.3%), 
Asian countries (n=2, 11.1%) and Australia (n=2, 11.1%). Three studies were 
conducted across multiple countries and evaluated HeFH care that involved the use 
of PCSK9 inhibitors – Roth et al. (2015), Pang et al. (2019), Ceska et al. (2019).  
2.3.4.1 Study characteristics 
5 reviews were included in the final selection as they presented expert summaries of 
potential issues affecting PCSK9 inhibitor use. The methodologies adopted in the 10 
primary studies were varied. In total, 6 studies applied quantitative analysis of patient 
or prescription data. However, Cheng, Gaudette & Goldman (2017) determined 
future cost-effectiveness of PCSK9 inhibitors by analysis of data simulations using 
the Future Elderly Model (FEM), while Hess et al. (2017) conducted a retrospective 
descriptive cohort study of HeFH prescription data to address barriers in PCSK9 
inhibitor provision. 3 studies applied observational approaches; Batais et al. (2017) 
adopted a cross-sectional survey, a prospective observational study was chosen in 
Rallidis et al. (2018), and Knickelbine et al. (2019) conducted a practice evaluation 
involved the prescription of PCSK9 inhibitors. Cohen et al. (2017) used online survey 
of healthcare professionals. The remaining three studies adopted a combination of 
qualitative interviews and quantitative methods with Mühlbacher et al., (2018) using a 




89% of the studies involved the assessment of either patients or prescribers of 
PCSK9 inhibitors; 11% involved the assessment of payers or payer approval data. 
Knickelbine et al. (2019) and Pang et al. (2019) assessed the influence of different 
healthcare providers in the management of HeFH and use of PCSK9 inhibitors. The 
stakeholders involved lipid specialists (such as lipidologists, endocrinologists, and 
cardiologists), nurses and nurse practitioners, and a physician assistant.  
The study settings were mainly hospitals and lipid clinics (n= 7, 39%). However, 
Ceska et al. (2019), Roth et al. (2015) and Pang et al. (2019) conducted multinational 
studies. The remaining studies conducted analysis of prescription or patient data, of 
course, with the exception of the 5 included reviews. Sample sizes (across both 
qualitative and quantitative studies) ranged from 133 (Zafrir and Jubran, 2018) to 
51,422 (Hess et al., 2017 – a retrospective cohort study using HeFH patient data in 
the US). 
Data were extracted from the studies to allow for synthesis of the findings. These 
include: 
 Study reference/ year of publication 
 Location 
 Type of research 
 Participant (stakeholders) involved 
 Perceived barriers and facilitators 










This table shows the data extracted from the identified studies. Review papers did not have a study setting and sample size but highlighted 
key issues regarding barriers to PCSK9 inhibitor use.  

















1 Alonso et 
al., (2020) 
Spain Review Physicians, 
patients, 
policymakers 
─ ─ Cost and access for 
medication, long-
term adherence to 
lipid lowering 
therapy and lifestyle 
changes, familiarity 
of FH and 
awareness of clinical 
The use of 
detection strategies 
and models of care 
that address 
barriers in the 
management of 
HeFH can improve 




guidance by general 
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Barriers to PCSK9 
inhibitor use were 
described as cost, 
and the lack of data 




















Hospitals 294 The awareness, 
knowledge, practice, 
and detection of FH 
among physicians 
Training may be 
required for many 
healthcare 
providers in the 
care for HeFH. 
4 Baum et 
al., (2017) 
US Review Patients, payers, 
healthcare 
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─Barriers to PCSK9 
inhibitor use were 
related to formulary 
restriction systems 
set up to reduce the 
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─ Cost Projections showed 
that PCSK9i use 
was cost-effective. 
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was also viable.  
11 Knickelbin















The paper identified 
modified barriers to 













12 Lan et al., 
(2019) 
Australia Review Healthcare 
providers, 
patients 
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modelling for HeFH 
idenitifcation.  
14 Mühlbach
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─ Lack of Government 
funding, deficit in 
patient registries, 
training and research 
─Government 
funding for PCSK9 
inhibitors was only 
provided in the UK 
and Australia. Cost 
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treatment targets. 













400 Perception of 
injections 
The use of pre-filled 
pens or syringes did 
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133 High cost, decision to 
return to statin use, 











The current section used thematic summaries as outlined by Thomas et al. (2012) to 
synthesize the extracted data. Thematic summaries use conceptual similarities 
between studies to group by themes relevant to the review research questions. The 
main limitation of this method is the selection of themes is a subjective process 
(Snilstveit et al., 2012). In order to retain some objectivity, the inclusion and exclusion 
criteria of the review protocol were strictly adhered to ensuring that all studies left in 
the review addressed the research question as part of their outcomes. 
2.3.5.1 Factors influencing PCSK9 inhibitor use 
Direct barriers to the use of PCSK9 inhibitors were identified as cost and 
inaccessibility to medication in 8 (44%) of the total 18 papers selected. With the 
exception of Pang et al. (2019) that identified lack of government funding for PCSK9 
inhibitor usage in some countries, the effect of cost manifests in prescription 
management processes developed to restrict the use of expensive medication. 
Further barriers revolved around inadequate identification of HeFH patients, and low 
levels of knowledge and awareness of HeFH and its associated management (n=6, 
33%). Patient compliance, especially pertaining to perceptions on the use of 
injections and injection site reactions was addressed in four studies (n=4, 22%). Lack 
of government funding and insufficient support for HeFH management initiatives was 
cited in one study (Pang et al., 2019). Similarly, potential gaps in the management of 
certain categories of patients due to guidelines were discussed in another paper 
(Rallidis et al., 2018). 
All but one of the studies concerning barriers to the access of PCSK9 inhibitors were 
conducted in the US, with the exception coming from Spain. The studies conducted 
in the US (Baum et al. 2017, Cheng, Gaudette & Goldman, Cohen et al. 2017, Doshi 




driven by a high number of rejections of PCSK9 inhibitor prescriptions by payers. 
This was mainly because a large proportion of medicines in the US healthcare 
system are payed for by private health insurers, individuals or government programs 
that are independent of the healthcare system. Prescriptions, especially of new 
medication, are therefore often rejected or governed by policies that are designed to 
limit usage of expensive pharmacological therapies (Doshi et al., 2018). Baum et al., 
(2017) presented the findings of two meetings held by the American Society for 
Preventive Cardiology (ASPC) that discussed high PCSK9 inhibitors rejection rates 
of 80% - 90%.It was found that insurance providers applied formulary restrictions 
such as; requirement for prior authorisation (PA), the usage of other lipid lowering 
agents prior to PCSK9 inhibitor consideration and the inclusion of laborious appeals 
processes in the approval system. These processes demanded the provision of 
medical records that were not immediately necessary for the approval process for 
PCSK9 inhibitors. They also introduced bureaucracy that served to lengthen the 
approval process. Cohen et al. (2017) reported the results of an online survey of 434 
healthcare providers on the challenges to the prescription of PCSK9 inhibitors. The 
findings echoed the results discussed by Baum et al. (2017); however Cohen et al. 
(2017) emphasized the availability of patient documentation as an important element 
in the approval process. The conclusions drawn from both papers suggested that the 
processes defined by clinical guidelines were clear, however, organisational 
implementation of the guidelines constituted high thresholds for medication use and 
an unnecessary administrative burden to prescribers (Hess et al. 2017). 
Knowledge and awareness of HeFH among healthcare providers constituted the 
second most reported hindrance to PCSK9 inhibitors use; Arca 2017, Batais et al. 




respectively. Batais et al. (2017) studied the level of knowledge of healthcare 
providers on HeFH reporting substantial deficit in the identification and management 
of the disease. Knowledge was mainly associated with the detection of patients with 
certain studies focussing specifically on the matter. Evidence between the current 
results (Ceska et al. 2019, Mues et al. 2018) and other literature on HeFH 
(Rangarajan et al., 2016) indicated low levels of awareness of the disease that 
contributes to the deficiencies in diagnosis and treatment. Knowledge was evaluated 
by assessing physician actions in the recording of family histories of elevated LDLC 
of HeFH, awareness of diagnostic criteria et cetera as in Rangarajan et al. (2016). A 
direct result of low levels of knowledge was the potential of a lack of recording of 
patient data (Hopkins, 2010). These factors could potentially lead to a low 
identification of HeFH patients who require PCSK9 inhibitors, and difficulties to 
complete the requisite paperwork for prescription.  
Other potential barriers to the use of PCSK9 inhibitors included expected lack of 
adherence due to the use of injections (Cohen et al. 2017, Alonso et al. 2020). 
However, studies directly assessing the perceptions of stakeholders on PCSK9 
inhibitor formulation such as Roth et al., (2015) and Mühlbacher et al., (2018) have 
since found that patients did not view the use of injections negatively. Roth et al., 
(2015) involved 400 participants (200 patients and 200 clinicians) and assessed their 
views on the use of pre-filled pens and syringes. The medication formulation was 
viewed favourably by all groups involved in the study. In a discreet choice experiment 
conducted by Mühlbacher et al. (2018), it was found that patients valued efficacy in 
medication more than the formulation. With regards to PCSK9 inhibitors, patients 
were not deterred by the injection formulation, as their primary goal was to achieve 




formulation is either not tolerated (due to injection site reactions) or simply not 
preferred (Zafrir and Jubran (2018); this potentially suggests that patient perceptions 
remain crucial to effective adoption of PCSK9 inhibitors.  
Finally, as mentioned at the beginning of this section, some studies identified barriers 
that were not immediately relevant to the NHS system. Pang et al., (2019) for 
instance, found that lack of government funding hindered medication provision for 
HeFH. The resultant effect was a deficit in the development of patient registries and 
opportunities for training and research were reduced. The NHS system has improved 
capacity to provide medication, and no studies suggested unavailability to funds to 
supply PCSK9 inhibitors. Nevertheless, studies on the current practices used to limit 
the use of costly medication (in this case, PCSK9 inhibitors) are also lacking.  Rallidis 
et al., (2018) discussed the possibility of guideline related gaps due to the 
management of patients who required different therapeutic outcome. The study 
assessed patients with coronary artery disease (CAD) determining that they 
potentially required further lowering of LDL cholesterol than the current guideline 
recommendations for severe HeFH.  
The overall search results suggested that the factors influencing PCSK9 inhibitor 
adoption were predominantly under researched; at least, from the perspective of 
stakeholders and the barriers and facilitators of usage. Furthermore, a limited 
number of these studies were conducted in the UK. This could possibly be explained 
by the relative novelty of PCSK9 inhibitors and the on-going trials on cardiovascular 
disease prevention. Nevertheless, studies on the potential determinants of PCSK9 





2.3.6 Complete reference list 
As described in section 2.3.2, the review of study titles resulted in the identification of 
81 papers. Following further assessments (abstract review and full text review), 18 
papers were found to be within the current study’s topic area. Only the 18 relevant 
articles have been referenced in this thesis. The full list of 81 papers is however 
included in appendix 12. The complete list of articles obtained from the search 
(n=810) can be provided upon request.  
2.4 Discussion of literature 
The overall findings suggested that the factors influencing the use of PCSK9 
inhibitors were largely under researched. Although 18 articles were included in the 
review, only 6 of the papers were focussed on evaluating barriers to the usage of 
PCSK9 inhibitors (Cohen et al. 2017, Doshi et al. 2018, Hess et al. 2017, Knickelbine 
et al. 2019, Roth et al. 2015, Zafrir and Jubran 2018). The other papers covered 
HeFH in general, but addressed topics that were linked to PCSK9 inhibitor use. For 
example, Batais et al., (2017) assessed the knowledge and awareness of physicians 
on HeFH management. Part of the study addressed medication use, including 
PCSK9 inhibitors, effectively identifying awareness deficits surrounding the 
medication.  
Of the 6 papers that addressed barriers to PCSK9 inhibitor usage, 4 were conducted 
in the US and addressed prescription rejections and methods of improving approval 
rates (section 2.4.1). This did not appear to be a problem in other countries and 
suggests that it was caused by the difference in medication payment structure in the 
US. Nevertheless, the same factors identified in the US could still be of relevance to 
other countries to varying degrees. The 2 remaining papers studied stakeholder 




study of real-world PCSK9 inhibitor usage in a hospital setting (Zafrir and Jubran, 
2018) that identified barriers experienced in the use of the medication. 
In the following segment, the papers that covered topics that were deemed to be 
related to PCSK9 inhibitor use were synthesized; this involved the categorion of 
perceived barriers to PCSK9 inhibitor use into themes as described by Thomas et al. 
(2012). Four themes were identified; two papers were discussed for each theme 
followed by a summary of the results of the other literature. The summary of themes 
and selected papers are shown in table 2.6 below.  






al. (2017)  
PCSK9 inhibitor access barriers-issues and 
recommendations: Improving the access process 
for patients, clinicians and payers. 
 Cohen, J. 
D. et 
al. (2017)  
Barriers to PCSK9 inhibitor prescriptions for 
patients with high cardiovascular risk: Results of a 
healthcare provider survey conducted by the 








Enhancing the value of PCSK9 monoclonal 
antibodies by identifying patients most likely to 
benefit. A consensus statement from the National 
Lipid Association. 
 Hess, G. 
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Proprotein Convertase Subtilisin/Kexin Type 9 
Inhibitor Therapy: Payer Approvals and 











al. (2019)  
A Retrospective Observational Study to 
Determine Baseline Characteristics and Early 
Prescribing Patterns for Patients Receiving 




A systematic approach for successful PCSK9 
inhibitor prescribing in clinical practice. 








O. (2017)  
How to implement clinical guidelines to optimise 
familial hypercholesterolaemia diagnosis and 
treatment. 
 Rallidis, L. 
S. et 
al. (2018)  
Extreme-risk category: High prevalence among 
stable coronary patients and an emerging 
widening treatment gap in achieving LDL-
cholesterol less than 55 mg/dL. 
Table 2.6 Summary of themes and papers 
2.4.1 Access barriers to PCSK9 inhibitors 
The majority of studies that focussed on barriers to the use of PCSK9 inhibitors were 
conducted in the United States of America (US). Overall, 4 papers were found that 
directly addressed access to the use of PCSK9 inhibitors as the main topic; Baum et 
al., (2017), Hess et al. (2017), Cohen et al. (2017) and Doshi et al. (2018). All these 
papers were based on the US healthcare system. As a comparison, studies in the 




inhibitors (Reynolds, T. et al., 2019), cost-utility studies (Crosland, P. et al., 2018), 
and initial experiences and patterns of using PCSK9 inhibitors (Kohli, M. et al., 2017). 
With the National Health Service (NHS) paying for medication, the UK structure 
consists of Area Prescribing Committees and Clinical Commissioning bodies that 
manage the payment and inclusion of medication into policy. It is likely that barriers in 
the provision of medication are therefore not anticipated as teams of healthcare 
specialists are involved in the medication provision pathway. 
2.4.2 Identification of patients eligible for PCSK9 inhibitors 
Several studies have focused on estimating the number of patients who were eligible 
for PCSK9 inhibitors based on clinical guidelines: Gencer et al. (2017), Glueck et al. 
(2016) and Jetty et al. (2017). Glueck et al. (2016) assessed the 734 
hypercholesteraemic patients in order to determine the number that qualified for 
PCSK9 inhibitor treatment based on the Federal Drug Agency (FDA) guidelines and 
insurance eligibility criteria. 220 patients (30%) of the study cohort had HeFH with or 
without CVD and were eligible for PCSK9 inhibitors. The study also found that, 
assuming a 50% reduction in CVD, PCSK9 inhibitors would produce savings of up to 
$250 billion. This was of course, prior to the conclusion of studies that determined 
CVD reduction rates associated with PCSK9 inhibitors. However, the total 
expenditure on the new class of medication would range between $180-342 billion. A 
similar study by Jetty et al. (2017) investigated patient eligibility for both alirocumab 
(ALI) and evolocumab (EVO), and estimated savings achieved based on CVD 
reduction. The study had a population size of 1090 patients, the number of patients 
eligible for both ALI and EVO was found to be 13% (140). The study conducted a 
year later, and with a larger cohort of hypercholesteraemic patients found that a 
smaller number of patients were eligible for the new class for medication. The 




criteria; Glueck et al. (2016) considered patients who had HeFH and/ or CVD and an 
LDLC >100 mg/dl to be eligible for PCSK9 inhibitors, Jetty et al. (2017) included 
patients with definite CVD, HeFH and LDLC>100mg/dl as eligible candidates for the 
disease. Current practice suggests that the latter case is more accurate as a 
diagnosis of HeFH with LDLC>100mg/dl could still be required to demonstrate that 
conventional lipid lowering therapies were insufficient prior to PCSK9 inhibitor 
approval. Jetty et al. (2017) produced revised healthcare savings associated with 
PCSK9 inhibitor use could be estimated as ~$67 billion dollars. However, the 
researchers deemed this finding unclear as more specific CVD reduction results were 
being awaited; they therefore suggested that more study was necessary. The 
reasons for the differences with past literature were not discussed in the paper. 
However, the prevalence of HeFH patients, for instance, in the two cohorts were 
different; with Jetty et al. (2017) having a smaller number of HeFH patients. Statin 
intolerance was also observed less in the larger cohort; 51 in Jetty et al. (2017) 
versus 66 in Glueck et al. (2016). Jetty et al. (2017) also applied more modest 
estimates of 15-20% CVD reduction associated with PCSK9 inhibitors, compared to 
50% used by Glueck et al. (2016). It is worth noting that both studies obtained the 
estimates of CVD reduction from clinical trials. However, initial CVD reduction rates 
for PCSK9 inhibitors were expected to be high, but as longer term studies were 
concluded, these rates were revised to ~20% (Sabatine et al., 2017).  
Other studies on the patient eligibility included Robinson et al. (2019) which 
attempted to identify high risk groups of patients in which PSCK9 inhibitor use would 
be cost-effective. Of relevance to this body of work was the finding that HeFH was 
considered as one of the risk factors for CVD than necessitated PCSK9 inhibitor 




consideration of PCSK9 inhibiting agents, it presented an argument for the direct use 
of PCSK9 inhibitors in high risk populations. Hess et al. (2017) investigated the 
characteristics of patients who were eligible for PCSK9 inhibitors. The results found 
that successful prescription of PCSK9 inhibitors occurred in older patients (>65), 
patients who had experienced a CVD event, and prescriptions by specialist 
consultants. Finally, Groves et al. (2017) conducted an eligibility study for maximally 
treated HeFH patients in the UK. Modest proportions of patients were found to 
require PCSK9 inhibitors at various LDLC thresholds based on NICE technical 
appraisal guidelines. The paper suggested that this could be due to the use of all 
available statin therapy prior to consideration for PCSK9 inhibitors. Furthermore, it 
was suggested that clinical guidelines at the time were based on limited data, and the 
release of secondary prevention data was expected to convey alterations to 
guidelines. 
2.4.3 Prescribing practices in early initiator’s of PCSK9 inhibitors 
The primary research paper for this section is based on a retrospective observational 
study conducted in the UK (n=150) to determine HeFH patient characteristics and 
early prescribing patterns for PCSK9 inhibitors (alirocumab) Reynolds et al. (2019). 
The main results showed that HeFH patients who qualified for PCSK9 inhibitor use 
were older (mean=61.4, SD 10.5), 100 out of 150 (66.7%) patients had HeFH and 
123 had suffered statin intolerance. This results echoes the findings from studies in 
the US (Hess et al. (2017) where patients on PCSK9 inhibitors were found to be 
older (>65) and had experienced an intolerance to statins. Reynolds et al. (2019) 
described patient’s characteristics which included body mass index (BMI mean 29.1 
SD 4.5) and 33 (37.5%) patients having a BMI ≥ 30; it was however found that these 
data were only available for 88 patients (58.7%). The lack of patient data has not 




in the UK. However, the finding is similar to those from American studies that 
perceived lack of patient data as a potential hindrance to PCSK9 inhibitor provision.    
Knickelbine et al. (2019) investigated possible methods of improving PCSK9 inhibitor 
approval in the US based on the prescribing patterns following the approval of the 
medication. As such, the paper mainly dealt with matters identified in the US as 
discussed under section 2.4.1 (Access barriers to PCSK9 inhibitors). The study 
confirmed that modifiable barriers exist that influence the prescription of PCSK9 
inhibitors. The study also revealed that collaboration between stakeholders in the 
provision of care for HeFH was crucial in improving the prescription of this new class 
of medication. The overall study result was an algorithm for improving PCSK9 
inhibitor prescription. However, the model consisted of factors that were unique to the 
US, such as the existence of different payers for medication. It was therefore of little 
relevance to the UK. A further insight from the study was the confirmation of previous 
findings that documentation deficiencies, such as missing data or outdated laboratory 
test results, affected the approval process for medication. This finding may be 
relevant globally, because of the under-identification and under-diagnosis of HeFH. 
This could potentially produce cases where patients are deemed to require 
medication but do not have extensive medical histories due to the opportunistic 
identification of HeFH.     
2.4.4 The impact of guidelines on PCSK9 inhibitors use 
Several studies have focused on the effect of guidelines on the provision of PCSK9 
inhibitors. A noteworthy summary could be produced from Orringer, C. E. (2019) who 
found that updated clinical guidelines and published studies provided a sufficient 
evidence base for the effective management of HeFH. The paper acknowledged the 
existence of therapeutic gaps in guidelines, and suggested the use of literature to 




working group discussion on the implementation of guidelines in order to optimise 
HeFH diagnosis and treatment in France. The paper reported that universal 
screening (including children), screening of high risk patients, better communication 
of elevated LDLC levels and improve of public awareness of HeFH were necessary 
in improving identification of patients. The paper also recommended the use of 
various guidance documentation and therapeutic targets in the management of 
HeFH. An emerging trend that is evident in the literature is that although studies on 
HeFH and PCSK9 inhibitors have been conducted in different countries, the issues 
identified are generally similar. The only differences observed were cases where the 
healthcare system varied greatly from the UK, and therefore significantly different 
prescription influencing factors were identified.   
An interesting observation was the finding that the application of different clinical 
guidelines produced different proportions of HeFH patients that were eligible for 
PCSK9 inhibitors. Gencer et al. (2017) for instance, found that guidelines from the 
American College of Cardiology (ACC) (13.4%) produced 5-fold higher eligibility rates 
for PCSK9 inhibitors compared to the European Society of Cardiology/European 
Atherosclerosis Society consensus (2.7%) statement.  
2.5 Gaps in literature and contribution to the thesis 
The current literature on the barriers to PCSK9 inhibitor use was found to be limited, 
especially in the UK. Studies conducted in the UK on PCSK9 inhibitors mainly 
assessed patterns of use, and cost-effectiveness. The lack of studies on the barriers 
and facilitators to PCSK9 inhibitor use in the UK may be due to the structure of the 
National Health Service (NHS). In the UK, NICE acts as the price watchdog for 
medical interventions and determine usage based on evidence. Contrarily, in the US, 




organisations such as those that care for war veterans among others; the debate 
about cost and accessibility to medication therefore begins as soon as a medication 
enters the market.    
In a discussion about the future of PCSK9 inhibitors, Pandey et al. (2017) postulated 
that widespread adoption of the new class of medication will be determined by their 
effect on CVD reduction. However, the paper also asserted that the study of 
challenges and barriers would form an important part of optimising PCSK9 inhibitor 
usage. As this research is lagging behind in the UK, a gap exists that the current 
study intends to address. 
The contribution of this chapter to the thesis lies in the identification of the gap in 
knowledge and the development of the research question(s). The themes discussed 
in section 2.4 inform chapters three, four and five as discussed below. 
Four themes described the potential influencing factors of PCSK9 inhibitor use; 
access barriers to PCSK9 inhibitors (1), identification of patients eligible for PCSK9 
inhibitors (2), prescribing practices in early initiators of PCSK9 inhibitors (3), the 
impact of guidelines on PCSK9 inhibitors use (4).  
These themes suggested that potential research questions on the use of PCSK9 
inhibitors in the UK would revolve around processes aimed at reducing PCSK9 
inhibitor usage (because of cost) such as the Prior Authorisation system in the US. 
There is also no clear illustration of the typical HeFH patient journey towards the use 
of PCSK9 inhibitors, including the barriers experienced during this process. The 
extent to which guidelines can act as a barrier to medication use as described by 
Rallidis et al. (2018) has also not been assessed. Finally, there is little understanding 




the use of PCSK9 inhibitors in the UK. In other countries, requirements for records of 
LDLC levels and the histories of statin and conventional lipid lowering therapy use 
served to hinder prescription in some cases. 
In the context of the current study, all four themes suggested an exploratory 
qualitative study to assess the views and opinions of stakeholders on the barriers 
and facilitators to the use of PCSK9 inhibitors in the UK (chapter 5). Additionally, 
themes 1, 2 and 4 suggested an assessment of patient health records to determine; 
the number of patients who would not meet LDLC treatment guidelines and those 
who would be eligible for PCSK9 inhibitors, and to assess the overall utility of current 
health databases in identifying HeFH patients who may require PCSK9 inhibitors 
(chapter 4).  
The current study therefore seeks to explore these potential barriers to the use of 
PCSK9 inhibitors in the UK. The aim of the project is twofold; 
1) To study the barriers and facilitators to the usage of PCSK9 inhibitors by 
exploring the views and opinions of key stakeholders (patients, specialist 
consultants/GPs and nurses) in the care of HeFH in the UK.  
2) To assess the feasibility of using the Clinical Practice Research Datalink 
(CPRD) database to develop a predictive model that can identify HeFH 
patients who meet the LDLC eligibility targets for PCSK9 inhibitors.  
2.6 Conclusion 
This chapter reported the conduct of a systematic review and narrative synthesis on 
the potential factors that could influence the use of PCSK9 inhibitors. The potential 





Chapter 3 Methodology  
This chapter presents a discussion of the methodology adopted to address the two 
research questions outlined in chapter two:  
1) To study the barriers and facilitators to the usage of PCSK9 inhibitors by 
exploring the views and opinions of key stakeholders (patients, specialist 
consultants/GPs and nurses) in the care of HeFH in the UK.  
2) To assess the feasibility of using the Clinical Practice Research Datalink 
(CPRD) database to develop a predictive model that can identify HeFH 
patients who meet the LDLC eligibility targets for PCSK9 inhibitors. 
The philosophical stance that underpins the multi-methods approach adopted in this 
study is discussed and the specific research designs employed are outlined. The 
chapter provides; 
 In brief, a background to quantitative and qualitative approaches to research.  
 An overview of the conceptual orientation of pragmatism as the worldview in 
which the current study is situated.  
 The study design of the multi-methods approach employed in the study (Question 
1 – qualitative approach, Question 2 – quantitative approach). 
 The specific steps conducted in the quantitative and qualitative phases of the 
study.  
3.1 Background to research methodologies 
Research methodologies are composed of philosophical assumptions, theoretical or 
conceptual frameworks, and the specific procedures that constitute the conduct of 
the research process (Creswell and Creswell, 2018). The fundamental implication is 




based on a combination of considerations that lead to the development of the 
worldview adopted by the researcher. The worldview consequently guides the type of 
data to be collected; and the methods used (Cohen, 2007). As discussed by Creswell 
and Poth (2017), the worldview is based on the researcher’s philosophical 
assumptions. These relate to how the researcher views their world (ontology), how 
the world is studied or known (epistemology), and the methodology employed to 
gather and analyse information.  
Ontology is generally defined as the nature of existence or the constitution of reality 
(Crotty, 1998). The definition of ontology adopted by the SAGE Dictionary of Social 
Research Methods (Jupp, 2006) provides an illustration of some of the elements that 
establish reality; this is cited below. 
 “A concept concerned with the existence of, and relationship between different 
aspects of society, such as social actors, cultural norms and social structures.” 
Cited from Jupp (2006) 
The existence of these ‘elements of reality’ independent of human beliefs and 
opinions results in an objectivist ontology. However, if the ‘elements of reality’ are 
dependent on human action, beliefs and decisions, a constructivist ontology is 
formed (Bryman, 2008).  
Epistemology concerns the composition of ‘human’ knowledge, or the nature of 
knowledge as we understand it (Crotty, 1998). Epistemology essentially defines what 
is considered to be acceptable knowledge; consequently, this informs how the 
knowledge can be acquired and presented (Cohen, Manion and Morrison, 2007). The 
view that knowledge is objective conforms to a positivist epistemology. The collection 
of objective or hard knowledge can then be gathered using tests or measurements. 
On the contrary, the assumption that knowledge is subjective corresponds to an 




engagement with participants. The components of ontology and epistemology can be 
summarised as shown in table 3.1 below. The content of the table are adapted from 
Al-Saadi (2014). 
 Ontology Epistemology 
Definition Nature of reality Nature of knowledge 
Components of  
assumption 
Objectivist  Constructivist Positivist  Interpretivist 














 Reality can 
be tested or  
measured 
Reality is 
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Together, these assumptions determine the methodological approaches employed by 
the researcher. These philosophical perspectives are applied to research as research 
paradigms; a visual presentation of the relationships is shown in figure 3.1 below. 
Therefore, a research paradigm can be described as a collection of beliefs that 
govern the research process (Guba, 1990).  
 
Figure 3.1 Relationship between philosophical assumptions and the research paradigm 
3.2 Research design 
Traditionally, research was categorized as either quantitative or qualitative. However, 
debate has persisted on the validity of either category as purist advocates argued for 
either side (Lincoln and Guba, 1989; Campbell, Stanley and Gage, 1963). 
Quantitative purists mainly maintain a positivist philosophy while their qualitative 
counterparts adhere to a constructivist or interpretivist philosophy. Advancements in 
the paradigmatic debate have led to the development of mixed methods approaches 
(Johnson and Onwuegbuzie, 2004). Other than the integration of qualitative and 








research (Johnson, Onwuegbuzie and Turner, 2007). Based on the definition of 
mixed methods research provided by Greene, Caracelli and Graham (1989), 
however, this combination of research methods is independent of traditional 
paradigmatic influences. Mixed methods research is therefore mostly situated within 
the pragmatic paradigm (Allmark and Machaczek, 2018). 
3.2.1 Quantitative research 
Quantitative research, broadly speaking, refers to the study of numerical data or 
statistics (Creswell and Creswell, 2018; Bryman 2008). It is however not sufficient to 
differentiate between the quantitative design and qualitative design (for instance) by 
the nature of the data gathered. The discussion of philosophical assumptions 
presented in the preceding sections is evidence of this. In quantitative research, a 
deductive approach underlies the data analysis process while the data collection 
phase is guided by a positivist epistemology. Ontologically, social reality is perceived 
to be objective with scientific tests and measurements being adopted as methods of 
inquiry. Quantitative research is therefore concerned with the testing of hypothesis 
and the study of relationships amongst statistical variables (Creswell and Creswell, 
2018). Further considerations include the generalisability of data and an assessment 
of validity and reliability.   
3.2.2 Qualitative research 
Qualitative research is the study of human processes and ‘lived experiences’ through 
the collection of data from the participant’s natural setting (Ritchie et al., 2013). In 
reality, the definition of qualitative research is continuously evolving; and as asserted 
by Creswell and Poth (2017), as it evolves it becomes increasingly difficult to 
describe. Nevertheless, this definition suggests that qualitative data is comprised of 




matters of importance to them, and influences their decision making process (Miles 
et al., 2014).  
These definitions of qualitative research, however, do not fully highlight the 
philosophical component of the research design. When the ontological 
(constructivist) and epistemological (interpretivist) assumptions are included in the 
discussion of qualitative research, it is clear that a demarcation exists between 
qualitative and quantitative approaches.  
Contrary to quantitative research, qualitative research mainly involves the study of 
‘emerging themes’ from participants’ accounts (Creswell and Creswell, 2018) and 
researcher observations. Data is primarily collected from the participants’ setting and 
the interpretation process is largely inductive in nature.   
3.3 Implications for the current study 
In order to link the research philosophy to the methodology and methods, a 
framework is typically necessary. The implementation of a framework varies between 
disciplines and researchers. For instance, Creswell and Creswell (2018) refer to the 
interconnection of worldviews/ research paradigm, research strategy and research 
methods as the framework to design. An example of this framework could yield the 
following (Table 3.2). 
 
Worldview Research strategy Methods 
Positivism Scientific experiments Close ended-
questionnaires 
Table 3.2 An example of framework to design 
In this example, the worldview (positivism) summarised the philosophical 




researcher’s own beliefs and the research problem. Once an appropriate worldview 
is identified, there exists a choice(s) of research strategies and methods that are 
compatible with the worldview. Methods of data analysis are also linked to either 
worldviews or research strategies. The overall effect is that the worldview determines 
a framework that guides the choice of strategy and methods in a study.  
 
The current study identified two key research problems from the literature review 
(chapter 2) that could be addressed using both qualitative and quantitative methods 
respectively.  
1) To study the barriers and facilitators to the usage of PCSK9 inhibitors by exploring 
the views and opinions of key stakeholders (patients, specialist consultants/GPs and 
nurses) in the care of HeFH in the UK.  
2) To explore the relationship between HeFH patient clinical attributes and LDLC 
reduction following statin use and by extension PCSK9 inhibitor eligibility. 
In order to facilitate the selection process for a suitable research design to address 
these two research problems, the design framework developed by Crotty (1998) was 
employed. This framework is shown in figure 3.2 below. As identified by Crotty 
(1998), the purposes of this framework were twofold. Firstly, it provided a system that 
aided the selection of appropriate methodology and methods for the study. Secondly, 
it enabled the justification of the use of these methods by allowing for the application 
of research philosophy to the research question(s).   
Crotty's framework puts into consideration four elements of the research process. 
This can be applied to the two research questions as shown in table 3.3 below. It is 
worth mentioning that the framework seemingly omits ontology from the discussion. 




of the research topic with the final outcome as the latter. The framework therefore 
only includes epistemology even though ontological decisions have been considered. 
Research question Epistemology Theoretical 
perspective 
Methodology Methods 
What are the perceived 
facilitators of, and 
challenges  
to the use of PCSK9 
inhibitors amongst 
stakeholders in the care 
for HeFH? 
Constructivism Interpretivism Thematic 
analysis 
Interviews 
To what extent do patient 
clinical attributes influence 
the prescription of PCSK9 
inhibitors? 
Objectivism Positivism Data analysis Statistical 
analysis 
Table 3.3 Application of Crotty (1998) research design framework to the current research questions 
 
Evidently, a parallel existed between the methods required to address each of these 
research questions. This suggested the adoption of a multi-methods research (MMR) 
approach which is a form of mixed methods research. Morse (2003) describes multi-
methods research as: 
“qualitative and quantitative projects that are relatively complete but that are used 
together to form essential components of one research program” (Morse, 2003). 
This indicated that the overall research question determined the components that 




addressing sub-questions or objectives relevant to the overall research question but 
that are different.  
As a form of mixed method research, multi-methods research shares the similar 
principles and rationale with mixed methods research. In the current study, the 
strengths of mixed methods research inherent in the integration of data will be 
adopted by conducting partial integration of descriptive quantitative results and 
qualitative results in chapter 6 of the current thesis. For this reason, the rationale and 
the conceptual orientations adopted in this study are briefly discussed from the 
perspective of mixed methods research.    
The reasons for adopting MMR in this case would be for the purposes of 
comprehensiveness, complementarity and corroboration. The qualitative phase of the 
project deals with the core research focus; which is, essentially, an assessment of 
the factors that could potentially influence the use of PCSK9 inhibitors. The 
quantitative phase of the study is concerned with the potential role that the recording 
of HeFH patients' clinical attributes hold in the attainment of LDLC. The quantitative 
phase of the study is therefore smaller in scale compared to the qualitative 






Figure 3.2 Crotty (1998) framework to research design 
3.4 Conceptual orientations in multi-methods research 
The adoption of MMR introduces the debate on appropriateness of methodology. As 
previously mentioned, this matter is generally addressed through the research 
paradigm. It is therefore important to discuss pragmatism, as the worldview in which 
the current body of work is situated. Herein, a brief history of the arguments for and 
against MMR is presented, followed by the links to worldviews and methods.   
For a long period of time quantitative and qualitative purists considered the two 
traditional research methods to be incompatible; and of course, advocated for their 
individual philosophical stances. This period is often referred to as the ‘paradigm 
wars’ (Oakley 1999), or the ‘paradigm debate’ (Creswell and Plano Clark 2007). Most 
arguments against MMR cite epistemological discordance; however, Bazeley (2009) 
suggested that this claim was contradictory to current practice. Bazeley’s (2009) was 
that corroboration between qualitative and quantitative results are often accepted as 
a means of improving research validity, however, the mixing of these two research 
methods continue to face debate. Furthermore, differences in epistemology have 








instance, adopted a concept analysis approach that suggested that qualitative results 
could be effectively presented quantitatively, and quantitative results could be 
justified qualitatively. Given the continued but gradual acceptance of MMR, these 
debates could be said to have delayed the acceptance of the system. However, the 
debates undoubtedly also caused a development of MMR techniques.   
Although the worldview debate is always evolving, many proponents of MMR adhere 
to a pragmatist worldview. A smaller group adopt a realist standpoint. The difference 
between these two viewpoints is that pragmatism focuses on the research topic. 
Consequently, the methods employed are based on the achievement of the research 
goal (Maxwell, 2008). On the other hand, realism is considered to ontologically affirm 
scientific objectivism, while it epistemologically proposes that scientific theory 
provides knowledge on reality independent of human action (Allmark and 
Machaczek, 2018). Such a line of thought is not necessary for this body of work, it 
was therefore suggested that pragmatism was the appropriate research paradigm in 
this context. 
The direct effect of pragmatism’s emphasis on the research question is flexibility in 
methods. This, of course, supports multiple methods approaches (Creswell and Poth, 
2017). However, the research paradigm offers more, and perhaps, deeper 
philosophical advantages to the researcher. From the outset, pragmatism addresses 
the researchers’ beliefs and assumptions as proposed by Morgan (2007). Although it 
is acknowledged that the researcher’s worldview has potential influence on practice, 
this effect is generally not addressed by many research paradigms. Pragmatism also 
offers an opportunity for epistemological interchangeability; an opportunity to 
combine the subjective and objective, the inductive and the deductive (Teddlie & 
Tashakkori, 2003). Finally, pragmatism allows for the study of cases that prove too 




simpler research for the assessment of action and effect, policy research where the 
subjective intertwines with the objective, to cases with conflicting findings between 
stakeholders (Evans, Coon and Ume, 2011). As cited from Schon (1983), 
pragmatism fills the gap for cases where research; 
“…is more a craft than a slavish adherence to methodological rules” 
Cited from Schon, 1983, (p.43) 
The current study does not fall into the category of ‘complex cases’. However, the 
literature in the area, as discussed in chapter 2, showed that the study of stakeholder 
perceptions was a key method of identifying the factors that affected the process of 
medication provision and use. The literature also showed, specifically, that availability 
or non-availability of patient records affected the use of PCSK9 inhibitors. In order to 
account for both of these ontologically different elements of the use of PCSK9 
inhibitors, pragmatism and multi-methods research were deemed to provide a 
creative and effective framework.      
3.5 Study design and methods 
Several MMR typologies have been advanced in the past (Creswell, 1994: Morgan, 
1998, Tashakkori and Teddlie, 1998); consequently, there are a number of 
considerations for the selection of an MMR design. For example, MMR designs can 
be based on the stage of the research process where mixing occurs (Tashakkori and 
Teddlie, 1998). The status of either component (quantitative or quantitative) could 
also influence design choice (Morgan, 1998); for instance, the study components 
may possess equal status, or one could be more dominant than the other. Finally, the 
sequence in which the individual studies are adopted typically leads to sequential or 
concurrent designs (Johnson and Onwuegbuzie, 2004). 
For the purposes of this study, the time ordering and the status of each phase were 




study, while the quantitative phase provided comprehensiveness and corroboration. 
The two phases of the study were independent of each other and were therefore 
conducted concurrently; this is then followed by convergence in the integration stage. 
The resulting design was a concurrent triangulation MMR study that can be 
summarised as shown below: 
QUALITATIVE + quantitative 
A schema of the study processes are shown in figure 3.3 below.  
 
Figure 3.3 The current study’s methods 
 
As previously mentioned, the integration of the qualitative and quantitative elements 
of the study is an important process in MMR (Johnson and Onwuegbuzie, 2004). In 
the current study, integration mainly occurred at the interpretation level (chapter 6 of 
this thesis). Broadly speaking, integration involves the identification of similarities/ 
differences between qualitative and quantitative data; these similarities/ differences 




achieved by transformation of data to allow for comparison, for example, quantitative 
data can be transformed into a narrative account to allow for qualitative interpretation 
(Creswell and Plano Clark, 2007).  
At this juncture, it is important to briefly revert back to the reasons an MMR approach 
was selected, and to focus on justifying the choices made. Based on the five broad 
rationales for MMR proposed by Greene, Caracelli and Graham (1989), this study 
serves to provide corroboration, complementarity and expansion. Over the past three 
decades, several efforts have been made to elaborate on the roles of MMR (Creswell 
and Plano Clark, 2007; Morgan, 1998: Tashakkori and Teddlie, 1998). Whereas 
these expansions add value to the discussion, the Greene et al. (1989) model 
effectively summarises these additions. Using Greene et al.’s model therefore (table 
3.4 below) incorporates the reasons MMR was selected for the current study, and the 
stages in which the researcher anticipated the fulfilment of these reasons.  
Reasons for using 
MMR 
Description Achievement of purpose 
Corroboration Seek convergence or 
disagreement in study results 
Qualitative views of 
stakeholders on the use of 
patient records would be 
compared to the 
quantitative assessment of 
patient records.  
Complementarity Elaborate, illustrate or clarify 
matters identified in  
one phase of the study 
Quantitative analysis would 
illustrate  
prescriptions patterns 





Expansion Increasing the extent of inquiry, 
particularly to include  
an element of the study that was 
absent if only one method was 
used. 
Without the quantitative 
phase of the study,  
the qualitative phase would 
not be able to elaborate on 
the state of patient clinical 
attribute records, or the 
effect it potentially has on 
prescription. 
Table 3.4 Structure for the achievement of MMR purposes 
3.6 Qualitative phase of the study 
As mentioned earlier, the qualitative phase of the current study was based on a 
constructivist/ interpretivist philosophy. This asserts that reality is a construct of 
people’s beliefs, opinions and actions. These views are negotiated during 
interactions with other people; the philosophy is therefore referred to as social 
constructivism. This phase of the study aimed to explore the views and perceptions 
of healthcare stakeholders (i.e. Consultants, nurses, GPs and patients) on a new 
type of medicine: Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) inhibitors. 
3.6.1 Sampling of interview participants 
3.6.1.1 Sample size 
In qualitative research, sample sizes are usually comparatively smaller than 
quantitative research (Ritchie, Lewis and Elam, 2003). Several reasons exist for this; 
firstly, when developing themes in qualitative analysis there can be an element of 
diminishing returns if no new themes are being identified (Mason, 2010). The amount 
of thematic output reduces as the sample increases. Secondly, time and funding 




research, qualitative research involves the logistics of meeting with participants, or 
arranging for telephone interviews, to conduct the study.    
Although there are suggestions that qualitative works, irrespective of method, should 
enrol at least 15 participants Bertaux (1981), some studies have over 50 participants 
(Mason, 2010). In a study on the mean number of participants in qualitative PhD 
projects, Mason (2010) reported an average of 28 participants (standard deviation 
18.7), with a mode of 20 and 30.  
3.6.1.2 Eligibility Criteria 
It was important to select a sample of participants who were knowledgeable about 
PCSK9 inhibitors, and those involved in the care of HeFH patients who may require 
the medication. This required a purposeful approach to sampling. A list of inclusion 
and exclusion criteria was therefore developed to ensure that each participant was 
knowledgeable of, or had experience with PCSK9 inhibitors and/ or HeFH as shown 
in table 3.5 below. Some healthcare practitioners (e.g. nurses and GPs in primary 
care) may not be aware of PCSK9 inhibitors but are involved in the identification or 
signposting of HeFH patients to secondary care where they may be prescribed the 
medication. In some cases, this lack of knowledge could act as a barrier to PCSK9 
inhibitor use. For this reason, it was deemed acceptable to include healthcare 
providers who dealt with HeFH patients but were not aware of PCSK9 inhibitors in 
the study. The participants included in the study were; HeFH patients, lipid clinic 
consultants, GPs and nurses.  
The inclusion of different stakeholders in the care for HeFH was intended to provide 
a comprehensive account of viewpoints relevant to the therapeutic management of 
HeFH with PCSK9 inhibitors. Senior consultants and prescribing nurses are involved 




GPs monitor patients once they are discharged from secondary care; while patients 
can report on the experience with the medication.  
Participant group Inclusion criteria Exclusion Criteria 
Consultants/ GPs  Involvement in the 
prescription of lipid 
management therapies. 
Involvement in the 
prescription of this new 
type of medicine 
 Consultants who are not 
involved in lipid 
management 
Patient groups  Past or current NHS 
patients of high 
cholesterol or 
complicated cases of 
high cholesterol 
  
Who have received or 
are receiving any lipid 
lowering treatment 
 Patients who have 
received this new type of 
medicine 
 Patients who cannot 
tolerate statins 
 Patients who are not 
 Patients with learning 
disabilities, incapable of 
understanding the research, 
under the age of 18, 





responsive to statins 
 
Nurses  Registered nurses who 
routinely care for people  
with high cholesterol and 
HeFH 
 Nurses who have cared 
for patients taking this 
new type of medicine 
 Nurses who work in lipid 
clinics 
 Nurses who have not 
prescribed cholesterol-
reducing medicine before 
Table 3.5 Inclusion and exclusion criteria 
3.6.2 Study setting 
Discussions were held with two cardiology specialists in order to explore potential 
methods of carrying out this study. It was determined that this new type of medicines 
will be used in NHS hospital departments that provide treatment for complicated 
cases of high cholesterol. This is usually NHS lipid clinics; however, some hospitals’ 
biochemistry departments care for these patients. The type of medicine under study 
is relatively new, therefore, only a small number of patients are on the medication per 
research setting. It is therefore necessary to conduct a multicentre study in order to 
obtain a sample size that is adequate for the study. 
 
A list of NHS hospitals that have a lipid clinic was obtained from the heartuk.org.uk 
website. Contact was made with the NHS trust’s research and development 
departments (R&D - http://www.rdforum.nhs.uk/content/contact-details/) and access 




study. Recruitment took place at Fenton GP practice and in lipid clinics at; the 
Manchester University NHS Foundation Trust, the University Hospitals of North 
Midlands. 
3.6.3 Data collection techniques 
Semi structured interviews were used for data collection. The development of topic 
guides was based on literature and the information gathered through the conduct of 
preliminary discussions with two cardiology specialists who were academics at Keele 
University. These discussions described the treatment of HeFH and the stakeholders 
involved in the management of the condition. It was determined that HeFH patients 
were mostly identified in primary care by general practitioners (GPs) and nurses; 
patients were referred to secondary care (lipid clinics) if their LDLC levels were not 
reduced by 50% using conventional lipid lowering therapies. PCSK9 inhibitors could 
then be prescribed to these patients in lipid clinics by consultants. Topic guides were 
developed for each group of stakeholders (Appendix 6-7). They were kept brief, to 
allow for an open exploration of viewer experiences. Open ended questions were 
used to encourage comprehensive accounts of the participants’ views. Probing 
questions were asked for clarification or to elicit further comment on emerging 
themes (Whiting, 2008). The interviews were audio-recorded, audio consent was 
confirmed at the beginning of each interview in addition to the written consent.  
3.6.4 Methodological rigour 
Methodological rigour was assessed using the strategies developed by Lincoln and 
Guba (1986). These criteria include credibility, dependability, confirmability and 
transferability.  
Credibility – This was concerned with methods taken to ensure that the data 
collected by the interviewer, and the responses given by participants were valid. 




 There was prolonged engagement with each study setting. The study was 
conducted across 4 clinical establishments; the study was kept open in all the 
settings for the entire duration of data collection (4 months). This encouraged 
reflections among the participants and they were able to contact the research 
team in case of any additional comments.  
 The interviewer received extensive training on the conduct of qualitative 
interviews and subsequent analysis techniques using NVivo through course 
modules. The interviewer was also in contact with a qualitative specialist 
within the university who advised on the project. Prior to the current research 
project the interviewer had been trained to the Master of Pharmacy (MPharm) 
level on research methods included qualitative work. 
 The interview process and material was testing on two university academics 
involved in the care for patients with cardiovascular diseases – interventional 
cardiologist and general practitioner. This process helped to streamline the 
interview protocol, adjust interview times and better anticipate the conditions 
required for the different stakeholders that participated in the study.   
Dependability – The strategies in this section ensured that the data collected could 
be reproduced if conducted on the same cohort of participants or were analysed by 
different coders. The strategies included: 
 The study protocol was detailed to ensure that different researchers would 
follow the same procedure in the conduct of the study. Its development 
included input from academic researchers, clinicians and research approval 
bodies. The protocol was assessed by the research team for appropriateness 
and correctness, the University research ethics team and it was approved by 




 The data collection processes was detailed in each setting’s site file. There 
was a clear process developed for any changes made to the protocol that 
involved reassessment by the academic research team and research approval 
bodies. 
 The coding process was shared with the supervisory team on a weekly basis. 
The discussions of the findings and the analysis process helped to ensure 
reflexivity on the part of the research and aided in the planning for further 
appropriate action.  
Confirmability – The methods in this strategy provided confidence that the results 
produced could be confirmed by other researchers.  
 The application of multi-methods (quantitative and qualitative approaches) 
provided a method to confirm the data being collected in the study (data 
source triangulation). Quantitative data gave a general indication of the 
management of HeFH while qualitative interviews with stakeholders served to 
elaborate on the issues identified in quantitative analysis, and vice versa.  
 The involvement of different stakeholders also provided a form of triangulation 
on the interview data. Stakeholders commented on the involvement of other 
healthcare professionals confirming or disproving their accounts of the issues 
surrounding PCSK9 inhibitor usage. 
Transferability – This concerned the ability of the results to be transferred or applied 
to other clinical settings. Two techniques were adopted with the aim of achieving this 
transferability: 
 Purposive sampling was used to ensure that participants involved in the study 




All stakeholders involved in the use of the medicine were also included 
ensuring that the same sample would be drawn from any hospital setting.  
 Saturation was achieved ensuring that no new views could be found in the 
accounts of the participants. This increased the likelihood that all the opinions 
and perspectives of stakeholders in the research sites had been assessed. 
 
3.6.5 Data analysis 
Included in Creswell’s (2013) definition of qualitative research is a description of the 
qualitative data analysis process. This is partially quoted below: 
“…data analysis that is both inductive and deductive and establishes patterns or 
themes. The final written report or presentation includes the voices of participants, 
the reflexivity of the researcher, a complex description and interpretation of the 
problem, and its contribution to the literature or call for change. ”  
(Creswell, 2013, p.44) 
Braun and Clarke (2006) hold the view that thematic analysis should be recognised 
as a qualitative data analysis method. This is in contradiction to Boyatzis (1998) and 
other researchers who believe that thematic analysis is a process situated within 
established qualitative analysis methods. Although thematic analysis has previously 
been considered to be located within the realist paradigm (Roulston, 2001); Braun 
and Clarke (2006) argued that the method is free of attachments to theoretical 
frameworks. This argument contends that thematic analysis offers flexibility that 
makes it accordant with different thematic frameworks. Thematic analysis therefore 
provides an analysis method that fits the pragmatic philosophy that governs the 
overall multi-methods approach adopted by this research (Aronson, 1994).   
Some considerations were made in the decision to adopt thematic analysis in this 




determined that the results of the qualitative phase of the study would be composed 
of themes pertinent to the research question, and identified from the data. Other 
analysis methods exist for the assessment of patterns in qualitative data (Holloway 
and Todres, 2003); these include, grounded theory, interpretative phenomenological 
analysis (IPA) et cetera. However, these methods are either tied to philosophical 
stances that do not support this research, or they focus on explaining elements of the 
data that do not inform this study. The method of identifying themes was mostly 
theoretical; it was intentionally driven by the primary research question, and factors 
identified from the literature review (Prosser, 2003). Themes were identified at a 
semantic or surface level (Boyatzis, 1998), and were intended to explain the entire 
data set i.e. the responses from all stakeholders in the study. Having made these 
considerations, it was determined that the choice thematic analysis was justified for 
this study. 
The analysis was conducted using analysis software NVivo. Bazeley and Jackson 
(2019) was used as the main reference material for the use of NVivo. Further 
clarification of the analysis procedure was obtained from Bazeley (2013). The 
thematic analysis process was based on the framework developed by Braun and 
Clarke (2006). Braun and Clarke (2006) proposed a stepwise approach for the 





Figure 3.4 Braun and Clarke (2006) thematic analysis procedure 
A theoretical thematic approach was adopted in the analysis. Open coding was used, 
meaning that the researcher did not include pre-determined codes in the analysis 
process.  
3.6.6 Ethical considerations 
Prior to the commencement of the study, a favourable opinion will be sought from an 
NHS Research Ethics Committee (REC). The Health Research Authority (HRA) 
assesses all research projects carried out within NHS England where the NHS has a 
duty of care to the participants. HRA approval will be required for this study and it will 
not commence until NHS REC/HRA approval is obtained. However, only one 
application has to be submitted to obtain approval from both bodies. All the research 
material (i.e. the research protocol, informed consent forms, study summary, 
invitation letters) will be submitted for review to NHS REC/HRA via the Integrated 
Research Application System (IRAS) website. All correspondence with NHS REC will 
be retained. The researcher will also submit an annual progress report (APR) every 




anniversary. Any changes to the study will not be implemented until an amendment 
of the protocol has been submitted for review and approved. Amendments will be 
categorised as either substantial or non-substantial and be submitted to the HRA, 
with substantial amendment sent to the NHS REC for review. Amendments will be 
recorded in appendix 8 of the research protocol. Finally, the CI will inform the NHS 
REC if the research is terminated prematurely, or when the research is completed. 
Following completion of the study, a report with the findings, publications or abstracts 
will be sent to the REC within a year of the results being obtained. 
3.6.7 Negotiation of access and participant documentation 
Following the receipt of the ethical approval documentation, this information was 
relayed to the research and development (R&D) departments of each participating 
organisation. The NHS trusts issued an NHS passport that allowed the research 
access to the primary coordinator and the research premises.  
The primary researcher then liaised with the primary coordinator (the head of the lipid 
clinic) to present the research documentation to potential participants.  The 
documentation included, invitation letters, research information sheet and consent to 
contact and study consent forms. These are attached in Appendix 1-5.   
3.7 Quantitative phase of the study 
The quantitative phase of the current study was designed to study the potential 
predictive effect of HeFH clinical attributes on LDLC attainment following statin use. 
By extending the LDLC attainment to the thresholds required for PCSK9 inhibitor 
use, a successful model would be able to predict PCSK9 inhibitor eligibility. Data was 
obtained from the Clinical Practice Research Datalink (CPRD) for secondary 
analysis. CPRD is a database that gathers anonymised patient records from general 
practitioner (GP) practices across the UK. The primary care data can be linked to 




(HES APC) data, and other health related datasets in order to produce a 
representative sample for the general UK population. CPRD was established more 
than 30 years ago, it spans across 42 million patient lives and currently contains 13 
million registered patients (CPRD, 2019). 
3.7.1 Sampling strategy 
All patient data with a diagnosis of FH were extracted from the CPRD database. The 
dataset was filtered to include data that was considered acceptable for research 
based on CPRD quality standards (CPRD, 2017). FH was represented by the NHS 
Read Code “C32” and daughter codes (Attached in appendix 13). The diagnosis and 
treatment of FH is based on low density lipoprotein cholesterol (LDLC) 
measurements. The sample was therefore refined to include patients with at least 
two LDLC test records that were more than a year apart of medication usage.  
3.7.2 Quality considerations 
This section discusses the quality considerations extended to the quantitative phase 
of the project. Steyerberg (2009) presents steps that are required for the 
development of a clinical risk prediction model. We discuss the steps relevant to this 
section as follows:  
(I) Determination of the prediction problem 
It is important to select a relevant research problem that is directed by clinical 
guidelines and/or evidence. The aim of the current study was to assess the feasibility 
of predicting HeFH patients that would require PCSK9 inhibitors using the CPRD 
database. The rationale for this aim was based on the systematic review (chapter 2) 
results that identified patient clinical data as a potential barrier to PCSK9 inhibitor 
use.  




The outcome of interest should ideally be guided by clinical guidelines or clinical 
professional opinion/ consensus. This makes the overall model applicable to patients 
or the clinical setting. HeFH management is based on the control LDLC; 
subsequently, the prescription of PCSK9 inhibitors is dependent on the LDLC levels 
remaining above 5mmo/l in primary prevention despite the use of conventional lipid 
lowering therapy. The outcome of interest was therefore an LDLC above 5mmol/l 
despite the use of lipid lowering therapy to determine PCSK9 inhibitor eligibility; as 
stipulated by NICE guidelines (NICE technology appraisals TA 393 and 394). 
(III) Determination of predictors 
The variables tested in the current analysis were obtained from literature; mainly 
Weng et al. (2015) and Mata et al. (2011). As mentioned above, the management of 
HeFH revolves around the control of LDLC. Some clinical attributes associated with 
effective LDLC control have been assessed in longitudinal studies such as the 
SAFEHEART study (Mata et al., 2011), and the successful predictive modelling for 
potential HeFH diagnosis in Weng et al. (2015). No further methods were used for 
feature/ variable selection as these were readily available in literature. 
(IV) Selection of study database 
The current study aimed to develop a predictive model that could be used in the 
primary and secondary care hospital settings. For this reason it was necessary to use 
a clinical database that contained patient data routinely collected in primary care. 
This could potentially serve to inform clinical practice in primary care with regard to 
referral to secondary care for PCSK9 inhibitor consideration; and in secondary care it 
could help to determine the patients who are at a higher risk of not achieving target 




(V) Assessment of CPRD data suitability 
Of the 11 clinical variables considered, only three of them (maximum LDLC record, 
maximum triglyceride record, age at diagnosis) were continuous with the rest being 
categorical data. Normality tests were conducted on the three variables, presenting 
the skew, kurtosis and histograms. Nevertheless, for ease of computation and 
uniformity the three continuous variables were converted into binary variables based 
on clinical guideline specified thresholds. For example, final LDLC achieved following 
treatment was categorised as above or below 5mmol/l, which represents the NICE 
defined threshold for the initiation of PCKS9 inhibitors. Correlation analysis between 
the variables was also conducted to assess covariance and significant associations 
with the dependent variable. 
(VI) Assessment of final and split dataset for derivation and validation  
The derivation and validation cohort data were assessed via a two tailed independent 
sample T-test to assess homogeneity. The result was presented as; the t statistic, p 
value, mean and standard deviation.  
 
(VII) Model evaluation and validation 
The model presented included the following results; beta coefficients, standard error, 
Wald statistic, degrees of freedom, significance value, odds ratio (exponential of the 
B coefficient), upper and lower limits at 95% confidence interval.   
Model discrimination was assessed using sensitivity, specificity and ROC c-statistic. 
Calibration was to be assessed by the Hosmer-Lemeshow goodness-of-fit test 





3.7.3 Study Variables  
The covariates used were based on the variables used by Weng et al. (2015) to 
predict the diagnosis of FH. The nine indicators used in Weng’s model are age, 
triglyceride concentration, lipid lowering drug usage, family history of familial 
hypercholesterolemia, raised cholesterol or myocardial infarction, and the diagnosis 
of either diabetes or kidney disease. Hypothyroidism and drug groups (shown in table 
3.6 below) can affect LDLC levels in the body; these variables were therefore added 
as covariates in this study. The study variables were split into categories prior to 
analysis. The full list of covariates for the study is shown below: 
Study variables Variable categories 
Age at diagnosis 1: 0-40 2: more than 40 
Gender 1: male 2: female  
Maximum low density lipoprotein 
cholesterol (ldlc) measurement 
1: 0-5 mmol/L 2: more than 5 mmol/L 
Maximum triglyceride measurement 1: 0-1.7mmol/L 2: more than 1.7 
mmol/L 
Family history of familial 
hypercholesterolemia  
1: yes 2: no 
Family history of myocardial infarction  1: yes 2: no 
Family history of high cholesterol  1: yes 2: no 
Diagnosis of hypothyroidism 1: yes 2: no 




Diagnosis of diabetes 1: yes 2: no 
Prescribed drug groups following 
diagnosis 
1: statins 2: statins + ezetimibe 3: 
statins + ezetimibe+ fibrates 4: 
medication not recorded 5: 
combinations of lipid therapies  
Table 3.6 Study variables and categories 
3.7.4 Outcome variables  
NICE technology appraisals (393, 394) recommend that PCSK9 inhibitors are 
initiated when LDLC levels are above 3.5mmol/l and 5mmol/l in secondary and 
primary prevention treatment respectively despite lipid lowering treatment. Therefore, 
in order to predict potential PCSK9 inhibitor requirement, the outcome variable for 
this study was based on the LDLC level achieved at the end of the follow up period 
(variable in dataset: final LDLC reading on record). Additionally, NICE guidelines for 
PCSK9 inhibitor use are divided by primary and secondary prevention treatment 
resulting in two outcome criteria (LDLC 3.5 and 5mmol/l). The dataset was therefore 
split into secondary prevention treatment and primary prevention treatment cohorts 
and assessed separately.    
3.7.5 Data analysis 
NICE guidelines for the initiation of PCSK9 inhibitors are divided into primary and 
secondary prevention treatment. The guidelines recommend LDLC levels 
consistently above 5mmo/l and 3.5mmol/l for primary and secondary treatment 
respectively, despite maximal treatment with other lipid lowering therapies. Due to 
this difference in LDLC outcome, the dataset was spilt into two cohorts based on 
primary and secondary treatment requirement and parallel analysis conducted. 
Patients who had a recorded event of ischaemic heart disease (IHD) and myocardial 




patients without these conditions represented the primary prevention cohort. The 
outcome for the primary prevention cohort was calculated as the cases that retained 
an LDLC level of 5mmol/l at the end of the follow up period; whereas, the outcome 
for the secondary prevention cohort was based on a final LDLC reading of 3.5mmol/l. 
Chi square tests and correlation analysis were carried out to assess the correlation 
between the independent variables and the outcome variables for each cohort. 
Binary logistic regression analysis using the forward stepwise method was then 
conducted to produce the predictive model.  
The model was validated by calculating predicted probabilities and group 
membership for the validation cohort. An area under the AUC curve was constructed 
to quantify accuracy of the model (AUC value or Harrell’s c-statistics) and to estimate 
sensitivity and specificity. Calibration was conducted by comparing the predicted and 
observed events stratified by deciles. The functionality of the predictive model 
relative to the predictor parameters was assessed and reported based on the decile 
category. All data analysis was conducted using the IBM Statistical Package for the 
Social Sciences (SPSS) program version 24. 
3.7.6 Power calculation 
Estimates for multiple regression power and sample size calculations were calculated 
using G-Power. G-Power is a calculation tool based on Faul et al (2009); this was 
accessed from the Intellectus Statistics website 
(https://www.intellectusstatistics.com/sample-size-write-up/sample-size-multiple-
regression/). Power analysis was conducted for multiple regression with ten 
predictors using an alpha of 0.05, a power of 0.80 and a small effect size 
(f2=0.02)(Faul et al., 2013). Based on these parameters, the desired sample size 
was determined to be 822. This indicates that this study should have more than 822 




statistical power to detect correct relationships between the variables and to develop 
a stable predictive model. 
3.8 Conclusion 
This chapter outlined the methodology of the present study. The study employed a 
multi-methods approach consisting of one qualitative and one quantitative 
component. The justification for the choice in research design was accomplished by 
describing general philosophical underpinnings of multi-method research followed by 
an assessment of the study’s research questions in the ensuing context. Chapter four 
presents the results of the quantitative phase of the study, while chapter five 
addresses the qualitative component. Finally, the integration and discussion of the 
results are covered in chapter six.  




Chapter 4 Quantitative analysis and results 
This chapter presents the results and analyses of the quantitative phase of the 
current project using both descriptive and inferential statistics. The chapter 
addresses the following research questions as identified in chapter 2: 
- To assess the feasibility of using the Clinical Practice Research Datalink 
(CPRD) database to develop a predictive model that can identify HeFH 
patients who meet the LDLC eligibility targets for PCSK9 inhibitors. 
4.1 Background  
The rationale for this section of the thesis was based on literature that identified the 
inadequate recording of heterozygous familial hypercholesterolemia (HeFH) patients’ 
clinical attributes as a potential barrier to the prescription of proprotein convertase 
subtilisin kexin-type 9 (PCSK9) inhibitors (Cohen et al. 2017, Baum et al. 2017). 
Cohen et al. (2017) described patient clinical attributes that were relevant to PCSK9 
inhibitor prescription as; records of the use of statins/ other lipid modification agents, 
records of low density lipoprotein cholesterol (LDLC) measurements, and history of 
cardiovascular disease (CVD).  
Current United Kingdom (UK) clinical guidelines recommend initiation of PCSK9 
inhibitors following the failure of statin therapy and associated adjuvant medication to 
regulate LDLC levels. Records of patient clinical attributes are used to ascertain 
these requirements as follows. A record of statin therapy confirms that the step 
therapy system stipulated by the National Institute for Health and Clinical Excellence 
(NICE) guidelines is followed prior to consideration of PCSK9 inhibitors. Similarly, 
records of low density lipoprotein cholesterol (LDLC) measurements are used to 
determine whether the guideline recommended LDLC thresholds for PCSK9 inhibitor 




of HeFH; guidelines recommend lower LDLC thresholds for PCSK9 inhibitor initiation 
in these cases. The unavailability of these records was associated with high rates of 
rejection of PCSK9 inhibitor prescriptions.  
Given the parallel between inadequate recording of HeFH data and the reliance on 
said data to determine PCSK9 inhibitor prescription; the present chapter investigated 
the relationship between recorded patient clinical attributes and LDLC reduction 
required for PCSK9 inhibitor initiation. Under the current NICE guidelines PCSK9 
inhibitor prescription is dependent on the failure of statins to reduce LDLC levels 
below 5mmol/l, PCSK9 inhibitor prescription was therefore based on this therapeutic 
target. 
4.2 Database access 
The Clinical Practice Research Datalink (CPRD) is a database that gathers 
anonymised patient records from general practitioner (GP) practices across the UK 
(CPRD, 2019). CPRD data consists of primary care consultation records that 
document basic patient demographic details, medical history events (including 
symptoms, signs and diagnoses), clinical tests conducted and their results, records 
of prescriptions and reasons for referral to secondary care among other patient 
related clinical attributes. CPRD data is composed of 1,800 primary care practices 
and includes 50 million patients, of which 14 million are actively registered. The data 
is also aligned with UK demographics with respect to age and sex (CPRD, 2019). 
CPRD therefore provides longitudinal data that allows for both retrospective and 
prospective analyses. CPRD data allowed for longitudinal follow up of HeFH patients 
while accounting for the use of lipid lowering agents and the monitoring of LDLC 




4.3 Summary of data definitions 
The rationale for the quantitative phase of the thesis was based on the results from 
the systematic review (chapter 2) as described in section 4.1 above. However, other 
variables associated with LDLC management have been identified and exist in other 
literature. It is therefore important to note that variable selection for the study was 
based on published literature as discussed below; and not on the systematic review 
that solely focused on the influencing factors of PCSK9 inhibitor use. 
Two publications were used to inform the selection of variables; Weng et al. (2015) 
and Mata et al. (2011).  Weng et al. developed a successful diagnostic predictive 
model using HeFH clinical attributes while Mata et al. presented the association of 
some clinical characteristics with LDLC.  Predictive modelling with regards to PCSK9 
inhibitors is understudied, hence the current project sought to assess the feasibility of 
such a model by assessing several potential clinical attributes. HeFH treatment is 
associated with the management of LDLC and clinical attributes that can influence 
LDLC levels; these attributes were selected from the studies as potential predictors in 
the current study.  
The outcome of the study was based on NICE guidelines for the prescription of 
PCSK9 inhibitors i.e. an LDLC value consistently above 5mmo/l despite statin 
treatment. 
4.4 Data extraction procedures 
HeFH was represented by the NHS Read Code “C32” and daughter codes (Attached 
in appendix 13). The start and end of follow up was based on the first and last LDLC 
measurements during the one year period of medication usage. The data covered 
the period of 1 January 1999 until December 2017 or the latest time which CPRD 




medication for a period or one year or more to ensure enough time for step therapy 
with statins and other conventional medicines. 
The complete CPRD dataset consisted of 5656 patients with familial 
hypercholesterolemia and other related diseases. CPRD medical codes were used to 
obtain patients with a diagnosis of pure HeFH; this resulted in a total of 5134 
individuals.  3761 patients were found to have at least one LDLC measurement in 
their record. However, in order to ensure that the reduction in LDLC levels could be 
determined, at least two readings were required per case (n=3297). The dataset was 
further filtered to exclude cases that had not received lipid lowering medication for a 
period of one year or more (n=2949). The final study cohort therefore consisted of 
2949 cases that could be analysed for the purposes of this research study. A 
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NICE technology appraisals (TA) 393 and 394 (for alirocumab and evolocumab 
respectively) recommend that PCSK9 inhibitors are initiated when LDLC levels are 
persistently above 5mmo/l and above 3.5mmo/l for primary prevention and 
secondary prevention treatment respectively. This is following the use of the 
maximum tolerated doses of other lipid lowering agents possible. These two targets 
determine when PCSK9 inhibitors can be used and would therefore form the primary 
outcome of these analyses. 
The dataset was therefore split into primary and secondary treatment cohorts; the 
secondary prevention treatment cohort was composed of patients who had suffered a 
CVD event (such as acute coronary syndrome, coronary heart disease; ischaemic 
stroke; peripheral arterial disease.), while the patients in the primary prevention 
treatment group had not recorded a CVD event.  
All the patients in the secondary treatment cohort met the outcome target of 
3.5mmol/l, and were therefore eligible for PCSK9 inhibitors based on NICE 
guidelines. This could be possibly be explained by the fact that patients who have 
experienced a CVD event are deemed to be at a high risk of suffering a recurrent 
event. For this reason, a lower LDLC threshold for PCSK9 inhibitor requirement is set 
for this group of patients, i.e. 3.5mmo/l. No further analysis was therefore conducted 









Figure 4.2 Overview of the research methods 
 
The primary cohort (n=2899) was split into a derivation cohort for the development of 
the predictive model, and a validation cohort to test model performance. There is no 
concise recommendation on which method to use when dividing a study cohort for 
validation purposes. However, the derivation cohort needs to be as large as possible 
in order to more closely reflect the characteristics of the general population. For 
example, a study on predictive modelling for HeFH (Weng et al., 2015) split their 
modelling cohorts by 75/25. Therefore, to ensure that we achieved appropriate power 
(discussed in section 4.7) whilst maintaining a large derivation cohort, the study 
cohort was split by 65/35. The derivation cohort therefore consisted of 1907 cases 




4.6 Quantitative analyses 
Correlation analysis was conducted using Chi square tests. The analysis assessed 
the relationship between the outcome variable (final LDLC record attained) and each 
predictor variable. The significance level (p value) for each variable was calculated to 
determine whether the relationships were statistically significant.  
Regression analysis describes how a predictor variable is numerically related to the 
outcome variable. Univariate regression analysis therefore assessed the 
relationships between each individual predictor variable and the outcome variable 
without controlling for the other variables. 
Stepwise logistic regression was used to develop the predictive model. The process 
evaluates the cumulative predictive effect of the predictor variables on the outcome 
variable. Using the stepwise approach, the effect of each variable on the model was 
assessed and the variable was subsequently added or removed from the model 
(Field, 2005). 
The area under receiver operating curve (AUC) was used to determine the best cut 
off value for predicting an observation categorised as (0) or (1). In the case of the 
current study, the outcome variable shows whether the LDLC value of a HeFH 
patient is above or below 5mmol/l following statin treatment; thereby predicting 
PCSK9 inhibitor eligibility. 
The AUC is calculated using the sensitivity and specificity values of the model. 
Specificity refers to the ability of the model to correctly identify patients who have a 





The model was validated by calculating predicted probabilities and group 
membership for the validation cohort. An area under the AUC curve was constructed 
to quantify accuracy of the model (AUC value or Harrell’s c-statistics) and to estimate 
sensitivity and specificity. Calibration was to be assessed by the Hosmer-Lemeshow 
goodness-of-fit test statistic following effective discrimination. The functionality of the 
predictive model relative to the predictor parameters was assessed and reported 
based on the decile category. All data analysis was conducted using the IBM 
Statistical Package for the Social Sciences (SPSS) program version 24. 
4.7 Power calculation 
Estimates for regression analysis power and sample size were calculated using G-
Power. G-Power is a calculation tool based on Faul et al (2009); this was accessed 
from the Intellectus Statistics website (https://www.intellectusstatistics.com/sample-
size-write-up/sample-size-multiple-regression/). Power analysis was conducted for 
multiple regression with eleven predictors using an alpha of 0.05, a power of 0.80 
and a small effect size (f2=0.02) (Faul et al., 2013). Based on these parameters, the 
desired sample size was determined to be 900.    
4.8 Results 
4.8.1 Descriptive analysis  
The study contained a total of 11 independent variables (covariates) obtained from 
past research studies (Mata et al., 2011; Weng et al., 2015). Nine of these covariates 
were based on Weng’s model; these were age, triglyceride concentration, lipid 
lowering drug usage, family history of familial hypercholesterolemia, raised 
cholesterol or myocardial infarction, and the diagnosis of either diabetes or kidney 
disease. Mata et al. (2011) also found significant statistical associations between 
hypothyroidism and drug groups and LDLC levels in the body; these were therefore 




variables were transformed into dichotomous values for each case represented in the 
study. The full list of covariates is shown in table 4.1 below: 
Study variables Variable categories 
Age at diagnosis 1: 0-40 2: more than 40 
Gender 1: male 2: female  
Maximum low density lipoprotein 
cholesterol (ldlc) measurement 
1: 0-5 mmol/L 2: more than 5 mmol/L 
Maximum triglyceride measurement 1: 0-1.7mmol/L 2: more than 1.7 mmol/L 
Family history of familial 
hypercholesterolemia  
1: yes 2: no 
Family history of myocardial 
infarction  
1: yes 2: no 
Family history of high cholesterol  1: yes 2: no 
Diagnosis of hypothyroidism 1: yes 2: no 
Diagnosis of kidney disease 1: yes 2: no 
Diagnosis of diabetes 1: yes 2: no 
Prescribed drug groups following 
diagnosis 
1: statins 2: statins + ezetimibe 3: statins 
+ ezetimibe+ fibrates 4: medication not 
recorded 5: combinations of lipid 
therapies  
Table 4.1 Study variables and categories 
Other than the ‘yes’ ‘no’ categories, gender and the medicines covariates, the 
creation of the remaining covariate dichotomous groups were based on literature. 
The mean age of onset of cardiovascular disease (CVD) is 40 (Robinson and 




1.7mmo/l and LDLC levels above 5mmo/l are considered to be high (Watts et al., 
2012). The clinical attributes of the final study cohort (n=2949) are presented in the 
table 4.2 below.  
 
Clinical attributes Count(n) Percentage 
(%) 
Age at diagnosis    
1:0-40 542 18.4 
2:more than 40 2405 81.6 
Gender   
1:male 1193 40.5 
2:female 1756 59.5 
Maximum LDLC measurement   
1:0-5mmol/L 1068 36.2 
2:more than 5mmol/L 1881 63.8 
Maximum triglyceride measurement   
1: 0-1.7mmol/L 884 30.0 
2: more than 1.7 mmol/L 2064 70.0 
Family history of familial 
hypercholesterolemia 
  
1:yes 305 10.3 
2:no 2644 89.7 
Family history of myocardial infarction   
1:yes 152 5.2 




Family history of high cholesterol   
1:yes 154 5.2 
2:no 2795 94.8 
Diagnosis of hypothyroidism   
1:yes 179 6.1 
2:no 2770 93.9 
Diagnosis of kidney disease   
1:yes 1 0.03 
2:no 2948 99.97 
Diagnosis of diabetes   
1:yes 48 1.6 
2:no 2901 98.4 
Prescribed drug groups    
1: statins 1762 59.7 
2: statins + ezetimibe 423 14.3 
3: statins + ezetimibe+ fibrates 122 4.1 
4: medication not recorded 381 12.9 
5: combinations of lipid therapies 261 8.9 
Table 4.2 Frequency values for main study cohort 
Outcome variable 
NICE technology appraisals (TA 393, 394) recommend that PCSK9 inhibitors are 
initiated when LDLC levels are above 5mmol/l in primary prevention in patients with 
primary HeFH. Therefore, in order to predict potential PCSK9 inhibitor requirement, 
the outcome variable for this study was based on the LDLC level achieved at the end 
of the follow up period (variable in dataset: final LDLC reading on record). For 




would therefore form the category of interest, and represents the HeFH patients that 
were eligible for PCSK9 inhibitors. 
 
4.8.2 Quality considerations 
 There were three continuous variables in the final dataset; LDLC, triglyceride 
measurements and age at diagnosis. Tests for normality were conducted for 
these variables at a 95% confidence interval for mean and the results are 
presented in full in appendix 15; these included tests for skewness, kurtosis 
and associated histograms. It is important to note that all other variables under 
study were categorical, and these three variables were converted into 
categorical variables using clinically defined thresholds for ease of analyses. 
Secondly, due to the fact that this was a feasibility study, the effect of all 
related clinical attributes within CPRD were included. These have been shown 
to produce a successful diagnostic model for HeFH in Weng et al. (2015). 
In total, four variables were tested - the LDLC variable was divided into 
maximum LDLC on record and final LDLC measured as these are relevant to 
PCSK9 inhibitor indication. Age at diagnosis (skewness 0.364080863, kurtosis 
0.054316286) and maximum LDLC on record (skewness 0.1190817 
, kurtosis 0.2061561) were normally distributed.   
Final LDLC on record had a kurtosis value of 28.0509855 and a skewness 
value of 2.7314077 indicated that the distribution was not normal. From a 
clinical perspective however, the data reflected the current management of 
LDLC levels in HeFH treatment. Final LDLC measurements were 
concentrated on between the 3.5 and 6mmol/l, at this point the LDLC level 




with regard to PCSK9 inhibitor prescription which requires a final LDLC value 
of 5mmol/l. Similarly, irregular triglycerides levels are typically associated with 
irregular LDLC levels and the distribution was understandable from a clinical 
point of view (skewness 3.90079023, kurtosis 1.79035318). 
 The derivation and validation cohorts were also assessed to ensure 
homogeneity. The full details of the analyses are included in appendix 18 and 
include; the number of cases in each cohort, frequencies and percentages 
between the cohorts and T-tests for the cohorts. Provided in table 4.3 below is 
a summary of the F-test for variance. At an Alpha value of 0.05, F value was 
smaller than critical so the samples are the same. 
  
F-Test Two-Sample for 
Variances 
 
     Variable 1 Variable 2 
Mean 448 862.5555556 
Variance 139830.231 523750.4872 
Observations 27 27 
df 26 26 
F 0.26697871 
 P(F<=f) one-tail 0.00062949 
 F Critical one-
tail 0.51834617   
Table 4.3 F test for the derivation and validation cohorts 
 
4.8.3 Correlation analysis 
The correlation analysis and cross tabulation tools were used to assess the 
relationships between the 11 independent variables and the outcome variable 
(outcome=5mmol/l). The aim of the process was to identify the independent variables 
that were statistically significant (p value) to the outcome variable. The Chi square 




level attained. These were family history of HeFH (p=0.008), age at diagnosis 
(p=0.000) and maximum LDLC on record (p=0.000).  
These results can be interpreted as; patients who were diagnosed past 40 years of 
age were less likely to attain the LDLC treatment target of less than 5mmol/l. 
Similarly, patients with a family history of HeFH and a high maximum LDLC on record 
were also not likely to achieve the treatment target. Statistical significance between 
the variables ensured that there was a possibility for regression analysis and 
informed the logistic regression analysis phase.  
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 -.015 -.008 
Sig. (2-tailed) .001 .891 .620 .707 .013 .900  .183 .021 .000 .507 .720 
N 1941 1941 1941 1941 1941 1941 1941 1941 1941 1941 1941 1941 
fammi1 Family 
history of MI 
Pearson 
Correlation 
.025 -.026 .003 .006 .015 -.005 -.030 1 -.025 .009 -.003 -.010 
Sig. (2-tailed) .265 .259 .906 .801 .501 .809 .183  .280 .693 .895 .652 
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 .004 -.006 .005 .081
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Sig. (2-tailed) .033 .862 .793 .843 .000 .882 .507 .895 .817 .043  .857 
N 1941 1941 1941 1941 1941 1941 1941 1941 1941 1941 1941 1941 






 .001 .016 .053
*
 -.002 -.008 -.010 .005 -.034 -.004 1 
Sig. (2-tailed) .676 .009 .949 .475 .019 .932 .720 .652 .838 .135 .857  
N 1941 1941 1941 1941 1941 1941 1941 1941 1941 1941 1941 1941 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 






4.8.4 Logistic regression analysis 
The three variables that had a significant relationship to the outcome variable were; 
medication use (p= 0.001), the maximum value of LDLC measurement (p= 0.000) 
and age at diagnosis was found to have a significant association to treatment 
outcome (p=0.002).  All these clinical attributes are categorical as described in 
sections 4.8.1 and 4.82. 
Stepwise logistic regression was conducted to derive the predictive model based on 
all study variables. The optimal multivariate model was composed of 3 predictor 
variables; maximum low density lipoprotein cholesterol (LDLC) measurement, 
medication use and the age at diagnosis (table 4.5). The Nagelkerke r2 value (NV) 
shows the variance explained by a model with 1 representing a perfect score. The 
NV value for this model was (0.285); this indicates that the best model explained 
28.5% of the outcome variance.  
Variables in the Equation 






 1=0-5(1) -3.966 .415 91.372 1 .000 .019 .008 .043 
Constant -.853 .064 176.557 1 .000 .426   
Step 2
b
 1=0-5(1) -4.222 .424 99.040 1 .000 .015 .006 .034 
Whether the patient 
took medication or 
not(1) 
-.967 .234 17.117 1 .000 .380 .241 .601 
Constant .044 .225 .039 1 .844 1.045   
Step 3
c
 AgeAtDiagnosis(1) .467 .152 9.431 1 .002 1.595 1.184 2.148 
1=0-5(1) -4.208 .425 98.276 1 .000 .015 .006 .034 
Whether the patient 
took medication or 
not(1) 
-.995 .235 17.977 1 .000 .370 .233 .586 
Constant -.032 .227 .020 1 .889 .969   
a. Variable(s) entered on step 1: 1=0-5. 
b. Variable(s) entered on step 2: Whether the patient took medication or not. 
c. Variable(s) entered on step 3: AgeAtDiagnosis. 




The odds ratios of the three variables that were significantly correlated to LDLC 
reduction can be interpreted as follows. Patients who were diagnosed with HeFH at 
an age <40 were less likely to attain an LDLC level lower than 5mmol/l and would 
therefore require PCSK9 inhibitors. Patients who were taking lipid lowering 
medications and those that had a maximum value of LDLC less than 5mmol/l were 
more likely to attain an LDLC reduction that was less than 5mmol/l and would 
therefore not require PCSK9 inhibitors.   
The complete sets of analyses conducted as part of the logistic regression are 
attached in appendix 16. 
4.8.5 Model validation 
The model developed through logistic regression analysis produces a log scale that 
group membership predictions (predicted logit) are based upon (A visual 
representation of this distribution is shown in figure 4.4 below). The validation 
process involves the calculation of predicted logit values for the study’s validation 
cohort. This computation utilises the beta coefficients (B) and constant value from the 
regression model. As previously discussed, the conversion to log enables the 
simulation of a linear relationship; the linear equation model of y=mx+c (m=gradient, 
c=constant) can be applied in this case. The resulting equation as seen in SPSS 
syntax is: 
COMPUTE predicted_logit = (-0.032) + (0.467*AgeAtDiagnosis) + (-
4.208*LDLCmaximumvalue) + (-0.995*MedicineUse). 
EXECUTE. 
 
Further computation was conducted to convert the predicted logit into predicted 




COMPUTE PredictedProbabilities = (2.718281828**predicted_logit)/ 
(1+2.718281828**predicted_logit). 
EXECUTE. 
Following these calculations, the predicted logit and probabilities for group 
membership were compared with the observed cases in the validation cohort. For 
this purpose, the area under receiver operating curve (ROC – we refer to this as area 
under the curve (AUC) herein) command was used. The resulting curve presents a 
platform to decide the optimal model cut-off point and presents the sensitivity and 
specificity values for model predictions. This forms the model calibration process and 
determines model accuracy and discrimination.  
4.8.5.1 Sensitivity and specificity analysis 
Shown below (Figure 4.3) is the result of the AUC calculation.  The diagonal 
reference line represents a 50/50 prediction, therefore the area between the line and 
the curve formed by the model prediction represents the extent to which model 
performance is better than chance. A perfect prediction would meet the top left 





Figure 4.3 Area under receiver operating curve for the model 
A sensitivity of 0.967 and a specificity of 0.447 were attained for the ideal cut off 
point. The highest point of the curve corresponding to these cut-off points was 
0.001667. The sensitivity value obtained suggests that there is a 96.7% chance that 
a prediction of a patient requiring PCSK9 inhibitors is indeed correct. The specificity 
value indicates that a prediction that a patient does not require PCSK9 inhibitors will 
be true 44.7% of the time. An AUC value of 0.774 was achieved indicating 
substantial discrimination between the outcome cases; this suggests that any model 
prediction will be 27% better than a prediction by chance (50%). 
The complete set of analyses conducted using AUC-ROC is attached in appendix 17. 






Figure 4.4 The predicted distribution for the requirement of PCSK9 inhibitors 
Figure 4.4 shows the distribution of each patient in the validation cohort on a scale of 
predicted probabilities.  (+ represents patients who require PCSK9 inhibitors, O 
represents patients who would not require PCSK9 inhibitors). Assuming a cut-off 
point of -7.0 on the diagram, the right side of the cut-off point would represent cases 
that require PCSK9 inhibitors and the left side would represent cases that do not 
require the medication. A prediction for PCSK9 inhibitor requirement would be correct 
96% because of the partitioning achieved by the model. However, a prediction on the 
left side of the plot (patients who do not require PCSK9 inhibitors) would be prone to 




medication. Whereas, the model can partition between the cohorts to some degree, 
the discrimination between the cases is sub-optimal. 
 
4.8.6 Interpretation of modelling results 
The sensitivity and specificity values for the model can be interpreted as follows. 
When it predicts that a patient would require PCSK9 inhibitors (positive prediction), 
the prediction would be correct 96.7%. However, when the model makes a negative 
prediction, it is only right 44.7% of the time. This reduced the discriminatory accuracy 
of the model as shown in fig. 5 above. Although positive predictions will be correct 
most of the time, many true positive cases will not be recognised by the model and 
will be classified as a negative prediction. Negative predictions would therefore 
contain many false negatives. These results can be further summarised by the AUC 
value of 0.774; this translates to a 27% chance that the model prediction is better 
than chance. Overall, this predictive model showed that three clinical attributes of 
HeFH patients can be explain some part of final LDLC as a study outcome. This is 
quantified by the Nagelkerke r2 value (NV) score of 28.5%. However, this was not 
sufficient to produce significant discriminatory accuracy.   
4.9 Discussion of quantitative analysis results 
The analyses in this chapter studied the HeFH patient clinical attributes that were 
related to LDLC attainment following statin use, and could potentially predict PCSK9 
inhibitor eligibility. This section presents a discussion of the findings from these 
analyses and their potential implications.  
4.9.1 Patient clinical attributes that could potentially influence LDLC attainment 
A survey by Cohen et al. (2017) found that a lack of or insufficient recording of 
patient clinical attributes for HeFH patients was a major barrier to PCSK9 inhibitor 




information, genetic records (for confirmation of HeFH diagnosis), complete set of 
laboratory values (including LDLC), history of statin use and requirement for 
maximum doses to be used (or reasons for their omission).This information was not 
always available at the point of prescribing. These clinical attributes are similar to 
CPRD records on HeFH patients; with the exception that genetic information is not 
included.  
The first observation was made during the implementation of the inclusion criteria. 
The main inclusion requirements were that patients had at least two LDLC values 
and medical records for a period of 1 year. This filter reduced the complete dataset of 
HeFH patients (n=5656) by 48% to obtain the final study cohort (n=2949). 
3761patients were found to have at least 1 record of LDLC whilst 3297 had at least 
two values on record. These findings are in agreement with past studies that have 
reported low levels of recording of HeFH patient data (Cohen et al., 2017). From a 
statistical perspective, this study lost 2707 potential cases due to non-availability of 
records. It is not possible to ascertain the effect this could have had on the 
regression analysis, however, larger sample sizes often serve to improve the 
performance of statistical analyses (Field, 2005).   
A comparison between the clinical characteristics of HeFH patients in the CPRD 
dataset and longitudinal study (Mata et al., 2011) revealed higher prevalence rates in 
the research setting. Possible reasons for this could potentially revolve around known 
differences between study and real-world data (Razek et al., 2018). It is expected 
that more comprehensive patient data are collected within a research setting, such 
as a longitudinal study.  
In HeFH in particular, barriers to treatment related to low patient identification and 




recording of patient information (Hardcastle et al., 2015; Alonso et al., 2020) For 
example, due to the asymptomatic nature of HeFH, patients with no secondary 
illnesses may not fully commit to treatment until a cardiac event occurs and they 
understand the severity of the disease. This could potentially translate into irregular 
hospital attendance and non-compliance with medication prior to a cardiac event. 
The clinical records of these patients could therefore contain gaps. Furthermore, until 
2016 HeFH (and familial hypercholesterolemia in general) did not have a unique 
International Classification of Diseases (ICD-10) code. This meant that HeFH was 
classified and treated as a typical form of hypercholesterolemia. As such, clinical 
attributes which are important in the management of the condition may not have 
been documented appropriately.  
4.9.2 Is the available data sufficient to develop and validate a predictive model for 
PCSK9 inhibitor requirement? 
The present study used 11 clinical attributes of HeFH patients that were recognised 
to be associated with LDLC modification in past literature (Mata et al., 2011; Weng et 
al., 2015; Masson et al., 2014; Perez De Isla et al., 2016). These clinical attributes 
were used to develop and test a mathematical model for the prediction of patients 
who were likely to require PCSK9 inhibitors.  
Firstly, an assessment of normality for the three continuous variables showed that 
LDLC and age at diagnosis were normally distributed while triglyceride and final 
LDLC on record were not normally distributed. However, from a clinical perspective, 
the distribution of these data was understandable. In the case of final LDLC reading 
following the use of conventional lipid lowering therapy; LDLC levels were generally 
be reduced achieving lower mean. Relatively smaller numbers of patients who did 
not register much LDLC reduction were then distributed towards the higher end of the 




assessment by parametric means. Covariance was also weak (less than 5 in all 
cases) between the four continuous clinical variables. In general, the data quality was 
sufficient for analyses. 
Secondly, three clinical attributes of HeFH patients had a significant correlation to the 
final LDLC achieved following treatment with currently available medication. These 
were; age at diagnosis, maximum LDLC on record and the use of lipid lowering 
medication. The relationship between these variables and final LDLC achieved gave 
a prediction 27% better than a prediction due to chance. Nevertheless, the model 
could not discriminate between patients who required PCSK9 inhibitors and those 
who did not with sufficient accuracy.  
These results suggested that there was potential for predictive modelling for PCSK9 
inhibitor requirement based on the ROC value of 77.4%. A potential resolution could 
be found in the inclusion of more clinical variables related to LDLC attainment. For 
example, past studies have identified associations between Lipoprotein a (Lp (a)) 
and LDL-cholesterol (Donnelly et al., 2013). These have led to the inclusion of Lp (a) 
in modelling analysis for HeFH identification (Sun et al., 2019) improving past results. 
Similarly, studies on LDLC attainment in HEFH such as Perez De Isla et al. (2016), 
found that defective allele mutations was an additional determiner for LDLC target 
attainment. The introduction of novel and more accessible genetic testing methods 
(Jiang et al., 2018) increases the chances of using genetic data for modelling studies 
in the future. However, as mentioned above, the recording of HeFH patient clinical 
attributes in practice remains poor in most cases (Cohen et al., 2017). This increases 
the number of challenges to the modelling for HeFH and PCSK9 inhibitor use in 
general. With more complete data and an increase in the number of predictor 




databases based on clinical practice such as CPRD. Currently, CPRD data does not 
appear to be sufficient for the development of predictive models for PCSK9 inhibitor 
eligibility in HeFH patients.  
4.9.3 Implications for predictive modelling for HeFH lipid lowering therapy  
The current study supported results by Mata et al., (2011) and Perez de Isla et al., 
(2016) that reported significant relationships between LDLC reduction and the clinical 
variables; age, history of CVD, type 2 diabetes mellitus and the use of lipid lowering 
medication. This suggested that further study on predictive modelling for PCSK9 
inhibitor eligibility may be possible; but this may require an improved database of 
HeFH records and additional predictor values for LDLC attainment. 
The prevalence rate of some of the clinical attributes in HeFH was less than 10% in 
the current study sample. A literature search revealed similarly low prevalence rates 
in the HeFH population (Mata et al., 2011; Besseling et al., 2015; Perez De Isla et al., 
2016); however, values in the CPRD dataset were lower. These observations 
suggested that data from CPRD may currently not be suitable in statistical modelling 
for LDLC goal attainment. Data from longitudinal studies on HeFH, such as the 
Spanish Familial Hypercholesterolemia Cohort Study (SAFEHEART – 
clinicaltrials.gov ID: NCT02693548) with higher levels of recording of HeFH patient 
clinical attributes than CPRD may provide more utility in the development of 
predictive modelling. Furthermore, the assessment of the genetic component of 
HeFH in these studies could potentially add useful variables to improve statistical 
modelling. 
However, tests for normality of data in the current study suggested that ongoing 
feasibility studies were possible. Following the adoption of an independent ICD code 




on HeFH patient management would develop at a faster rate than previously 
recorded. It may be possible to continue testing the feasibility of developing a 
predictive model for PCSK9 inhibitor use as databases such as CPRD continue to 
collect data on HeFH. 
4.10 Conclusion 
The current study found that there is potential to predict HeFH patients who could 
potentially benefit from PCSK9 inhibitors using CPRD patient data; however, the 
current data was not sufficient to sustain the development of a clinically significant 
predictive model.  The use of other health databases or improved CPRD records for 
HeFH patients could potentially serve to improve the functionality of the current 
model. 
In summary, the predictive model developed retained three patient clinical attributes 
(age at diagnosis, maximum LDLC on record and the use of lipid lowering 
medication) and produced a predictive ability that was greater than chance. However, 
the model could not distinguish between positive and negative cases sufficiently and 
therefore the predictive result was not clinically significant.  
With regard to the overall aim of the study of assessing potential barriers and 
facilitators to the prescription of PCSK9 inhibitors; descriptive analysis of the data 
found that a large proportion of HeFH patients did not have clinical attributes relevant 
to PCSK9 inhibitor prescription on record. This supported results from other studies 
that suggested low levels of recording of HeFH patient clinical attributes (Cohen et 
al., 2017). Compared to HeFH patient data from longitudinal studies (Mata et al., 
2011; Perez De Isla et al., 2016), CPRD data was found to have a lower recording of 




guideline recommended LDLC treatment targets; and 63.9% of these patients did not 





Chapter 5 Qualitative data analysis and results 
5.1 Introduction 
This chapter presents the results and analyses of the qualitative phase of this project. 
The chapter addresses the following research questions as identified in chapter 2: 
- To study the barriers and facilitators to the usage of PCSK9 inhibitors by 
exploring the views and opinions of key stakeholders (patients, specialist 
consultants/GPs and nurses) in the care of heterozygous familial 
hypercholesterolemia (HeFH) in the UK.  
The rationale for this section of the thesis was based on the finding that the 
knowledge, attitudes and experiences of stakeholders (patients, consultants, nurses, 
GPs etc.) influenced the care for HeFH and provision of HeFH. The literature review 
conducted in chapter 2 found that the prescription of PCSK9 inhibitors was 
influenced by bureaucratic processes and clinical guidelines in the US and other 
countries. This research was lacking in the UK. The current chapter focussed on 
exploring the opinions of stakeholders in the care of HeFH to determine the potential 
barriers and facilitators to PCSK9 inhibitor use in the UK. 
The section begins with a brief description of the data collection and analysis 
methods. This is followed by an account of the participant demographic information 
and a summary of the characteristics of participants. The results are then presented 
in five themes identified via thematic analysis as described by Braun and Clarke 
(2006). The chapter concludes with a discussion of the themes and sub-themes 
emerging from the analysis.  
5.2 Sampling of interview participants 
A total of 17 people participated in the study. Saturation was monitored through the 
data collection and analysis processes. No new themes emerged after 13 interviews; 
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however, 4 more interviews were completed. Saturation was determined by an 
‘inductive thematic’ approach as discussed by Saunders et al., (2018). This meant 
that further data collection only contributed to the themes that had already been 
identified as opposed to producing new themes. Additionally, there appeared to be 
consensus across participants on specific themes and the overall patient journey to 
the use of PCSK9 inhibitors. For example, lipidology consultants (prescribers of 
PCSK9 inhibitors) expressed the existence of restrictive LDLC thresholds for PCSK9 
inhibitor usage that were not achieved in some HeFH patients.    
 
“…less than 50% reduction but the LDL, they’ve not got cardiovascular disease and the LDL 
is less than five, then we’ve got no other option…” (A5, consultant) 
 
“There is no way round this but the big issue is that certain patients try very hard and their 
LDL may come down to 3.8 and they’re not eligible for PCSK9s.” (A3, consultant) 
Differences did exist in participant experiences, but these experiences expressed 
similar themes. In the case of patient participants, for example, some patients 
described having high LDLC levels but HeFH was not suspected for prolonged 
periods of time in primary care. Whereas some diagnosed HeFH patients felt that 
they were treated insufficiently for long periods of time before they were referred to 
secondary care to be considered for PCSK9 inhibitor use. These experiences both 
suggested concerns with the level of awareness of HeFH and PCSK9 inhibitors in 
primary care. 
 
For these reasons, the study was able to capture the complexity of the HeFH patient 
journey towards the use of PCSK9 inhibitors and associated barriers. The results 
allowed for the illustration of a patient journey between primary care and secondary 
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care that retained relevance across the stakeholder groups. The sample size was 
also in line with past studies on the factors that affected prescription.  
5.3 Data analysis 
The process was driven by the primary research question and involved the 
identification of relevant excerpts of text called codes that depicted a barrier to 
PCSK9 inhibitor use. Codes were therefore identified as participant statements that 
constituted potential factors that could affect the use and provision of PCSK9 
inhibitors. For example, figure 5.1 below shows a portion of an interview conducted 
with a consultant. When asked about the accessibility of PCSK9 inhibitors, the 
participant describes the Blueteq process that outlines the requirement of LDLC 
records prior to approval. As this was perceived as a barrier, the highlighted portion 
of the excerpt was coded. 147 codes were deemed to be relevant to the research 
question (Appendix 11). 
The identification and categorisation of codes involved an iterative process 
composed of line by line code selection and the development of themes. Associated 
codes were grouped together in an initial categorisation process. Themes were 
considered to be patterned responses in the identified codes. The surface level 
descriptions of the initial categories were therefore used to name the themes 





Figure 5.1 Example of coding excerpt 
There was no explicitly stated number of references required to make a theme, each 
resulting theme had at least 35 references within each stakeholder group as shown 




Figure 5.2 Summary of code references 
 
5.4 Participant demographics 
In total, 17 participants were recruited from 3 NHS lipid clinics and a local GP 
practice. 64.7% of the total participants were male, 35.3% were female. Of the total 
number of participants, 7 were consultants, 2 were nurses, 3 were GPs, and 5 were 
patients. All patients had a diagnosis of HeFH and had been referred to one of the 
lipid clinics. All health care providers (HCPs) were involved in the management of 
HeFH patients at different capacities. All HCPs had been working in lipid 
management for more than 5 years (participant A17 had started a new role in 
preventive cardiology, but had more than 5 years’ experience in lipid management). 
A summary of participant characteristics are shown in table 5.1 below.    


























Summary of code references 
 
1 : Experiences and
opinions on medication
2 : Knowledge of
stakeholders
3 : Organisational factors
4 : The effect of clinical
guidelines




A1 Consultant M 13 
A2 Consultant M 12 




A5 Consultant F 16 
A6 Patient M - 
A7 Patient F - 
A8 Consultant M 14 
A9 Patient F - 
A10 Patient M - 
A11 GP F 10 




A14 GP M 10 
A15 GP M 18 
A16 Consultant M 13 
A17 Consultant M 1.75 
Table 5.1 Summary of patient characteristics 
All participants in lipid clinics were recruited through the lead consultants in the lipid 
clinics. Letters of invitation were sent to the clinics and the investigator only pursued 
potential participants that responded to the invitation. There was no variation in the 
recruitment process. Similarly, invitation letters were sent to the local GP practice 
through a lead collaborator, the investigator only pursued the respondents. For 




A total of 17 interviews were conducted (telephone n=12, 70.6%, face to face n=5, 
29.4%). The average length of the interviews was 19.7 minutes (SD=7.11).  
5.5.1 Coding and initial categorisation 
In total, five initial themes were identified; these were  
 Experiences and opinions on HeFH treatment  
 The effect of clinical guidelines  
 The knowledge of stakeholders  
 Organisational factors  
 Facilitators of PCSK9 inhibitor adoption 
 ‘Experiences and opinions on HeFH treatment’ explored the views and perceptions 
held by stakeholders, and how these could potentially impact the use of lipid lowering 
agents. ‘The effect of clinical guidelines’ explored the potential impact of clinical 
guidelines in relation to the decision making processes of HCPs. ‘The knowledge of 
stakeholders’ focussed on the awareness levels of clinicians and patients on HeFH 
and the treatment pathway for the disease. ‘Organisational factors’ focused on 
factors revolving around NHS trust prescription policies and the collaboration 
between HCPs in delivering care to HeFH patients. The theme of facilitators of 
PCSK9 inhibitor use consisted of three sub-themes. ‘Influence from pharmaceutical 
companies’ identified the methods used by pharmaceutical companies in order to 
facilitate medication adoption. ‘Patient awareness of HeFH severity’ was found to be 
a motivational factor for patients to learn and engage with the treatment process. 
‘Views on medication use’ focussed on the opinions on medication that increased the 
participant’s likelihood to seek or prescribe PCSK9 inhibitors.  
5.5.2 Reassessment of themes  
The initial set of themes was refined following further analytical assessment of the 
categories as discussed by Thomas and Harden (2008). The categories were 
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renamed in order to align with the overarching research question and to reflect the 
barriers to PCSK9 inhibitor use demonstrated by the excerpts. The table (table 5.2) 
below shows the final list of themes and subthemes identified from the data. 
Broad 
Categorisation 
Themes  Sub-themes 
Barriers to PCSK9 
inhibitor adoption 
Low referral rates to 
secondary care 
 
 Therapeutic gaps in 
clinical guidelines 
The use of clinical guidelines 
for lipid management in HeFH 
  Strict clinical guidelines on 
PCSK9 inhibitor provision 
 Low levels of knowledge 
and awareness of HeFH  
Low awareness of HeFH 
amongst clinicians 
  Inadequate understanding of 
HeFH in patients 
 Inhibitory organisational 
prescribing policies 
Inhibitory prescription policies 
for PCSK9 inhibitors 
  Lack of consensus on 















 Negative views on the 
use of statins 
 
Table 5.2 Final list of themes and sub-themes 
5.5.3 Barriers to PCSK9 inhibitor adoption 
An illustration of the HeFH patient journey towards the use of PCSK9 inhibitors with 
the potential barriers highlighted at the typical points of occurrence in the treatment 
process is shown in figure 5.3 below. Barriers in primary care resulted in delays and 
low referral rates of HeFH patients for consideration of PCSK9 inhibitor use in 
secondary care. In secondary care barriers were mainly associated with strict clinical 
guidelines for the initiation of PCSK9 inhibitors and inhibitory policies targeted at 
reducing the use of costly medication such as PCSK9 inhibitors. The following 
sections present the views and opinions of stakeholders as pertains to the identified 
themes. 
 




5.5.3.1 Low referral rates to secondary care 
5.5.3.1.1 The HeFH patient journey  
The primary care clinician mainly identified markedly elevated LDLC levels, referrals 
were then made to secondary care based either on LDLC values or a combination of 
LDLC values and family history of cardiovascular disease (CVD).    
“…we see patients for NHS health checks who are not on a register, so they have erm, they 
come and a have a cholesterol and a glucose check… so they’ll have bloods done. Often 
those bloods come back to me so I sort of action the blood results based on the sort QRISK 
score… and if that becomes over 10% for patients, irrespective of where the cholesterol sits 
then I ask to see them erm, with obviously sort of the guidelines or if we’re over 10% with 
some of these patients dependent on obviously history and lifestyle, you know, recommend 
that they have statins.” (A13, prescribing nurse) 
“Right, so a good scenario would be we’d do a routine screening for a patient that comes in 
and says yeah they want an NHS health check or maybe you’re just suspecting that I should 
check the lipid profile in this particular patient. And within a week the results come back and 
yes, if the total cholesterol is raised the patient will then come to us, we’ll make them aware 
of the condition and then we’ll do an immediate referral to the lipid clinic at the UHNM. That 
tends to be an urgent referral, but they probably would be seen within maybe four weeks to 
eight weeks or even prolonged much more than the eight weeks…. they get seen at the lipid 
clinic, the specialist would probably start statins like atorvastatin or maybe ezetimibe and 
write a letter back to us telling us to continue with that medication and put the medication on 
repeat prescription.” (A11, GP) 
Secondary care clinicians provided similar accounts to the treatment journey 
described by clinicians in primary care. In the secondary care setting, however, 




“So, the referrals are in two different routes. The majority are through GPs but we also get 
referrals sent from secondary care so from the cardiologist. And particularly since PCSK9 
inhibitors have been introduced cause they are not prescribers of them, so patients who 
come in with myocardial infarction and they thought they may have FH and maybe a 
candidate for PCSK9 inhibitors.”(A5, consultant) 
“The typical patient can either come from primary or secondary care.  They start at primary 
care and the patient would see the GP and there would be an indication as to why their lipids 
are carried out.  This could be from the NICE Guidelines or from QOF… With secondary 
care, the referrals will usually be from either Cardiology or Stroke Medicine.”(A3, consultant) 
The treatment journey described by patient participants differed from the typical 
treatment journey explained by clinicians. Patient accounts involved the occurrence 
of a cardiac event, or cardiac event(s) in close family members, necessitating checks 
for familial hypercholesterolemia.  
“Okay, so back in December 2014, is when I had a heart attack and then had a stent fitted as 
a result. Now, at that point, although up until that point, although I had sort of, you know, I 
wasn’t aware my cholesterol levels were, they weren’t particularly high but they weren’t in the 
preferred range, they were in the region of five to six effectively, in that sort of area.”(A10, 
patient) 
“I’ve had the high cholesterol for a good few years now.  It’s hereditary obviously via me 
father.  He had angina and died of a heart attack at 62, and I think then after that we were 
told to go for a test. So me dad’s been dead probably 20 years so, 24 years, so probably 
about 20 years ago they started keeping a good eye on me.”(A12, patient) 
“It was probably through my brothers cause they’ve had it as well, my dad had angina and 
heart problems and died of a heart attack. So, the doctors really saying, we’ll get your tested 
out for your cholesterol and yeah, things like that.”(A6, patient) 
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Patient perceptions of the process of diagnosis and the provision of medication were 
mostly negative.  
“I think sometimes they try you on different, it’s a bit hard to tell ‘cause I was a bit different so, 
you know, try you on this tablet and try you on that. There were times I felt a little not guinea 
piggy but, you know…’” (A12, patient)   
“…it all feels a little bit reactive, you know, it all feels as though, you know, people didn’t 
really pick up on really on the high, you know, the five is high in terms of cholesterol levels or 
I’d had a heart attack, I think from there on in, its felt pretty, you know, obviously you’ve got a 
history there then all of a sudden, my local health authority, they suddenly became very 
active…”(A10, patient) 
Patient A9’s account also stated that they were attended to by various specialist 
consultants during the course of their treatment journey. They had an LDLC reading 
of 9 and a family history of cardiac events; however, HeFH was not considered until 
later in the treatment process. Other participants described similar experiences 
suggesting that the typical treatment journey was disorderly in some cases and was 
different from the system identified by clinicians.  
“…at the time I saw them(the GP), they might actually have some tests, you know, and it was 
never really identified as being a problem at all, you know, no one ever said, you should 
probably do something about it because it was just deemed to be, you know, because 
everything else was normal”(A10, patient)     
In one case (A6), the patient provided an account where he was happy with the 
treatment process. The patient’s case did not appear to be as severe as the other 
cases as he had not suffered a cardiac event. The patient was identified through 
cascade screening following cardiac events in family members. 
“I just think that everything that’s been done has been great. The treatment has been alright, 
you know, fine, tablets are working so yeah, I’m happy.”(A6, patient) 
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Participant views on the treatment process differed, especially between patients and 
clinicians. It appeared there was a consistent treatment journey for the patient with 
severe HeFH. This consisted of identification and management by GPs and nurses in 
primary care followed by referral to lipid consultants in secondary care.  
 
5.5.3.1.2 The efficacy of the HeFH patient identification pathway  
When questioned about the efficiency of the identification pathway, there was 
general congruence amongst clinicians that the system needed improvement. The 
reasons for, and the degree of acceptance to these inefficiencies varied amongst the 
stakeholders. These views are explored below. 
Secondary care clinicians identified low levels of knowledge in primary care, and the 
lack of genetic testing services as the main reasons for the limitations in the patient 
identification pathway. For example, participant A8 (consultant) described the 
identification of HeFH patients in primary care as “incidental” and in secondary care 
as “sporadic”. 
“I mean we know that a large number of patients with FH are not identified and unfortunately, 
we don’t have access routinely at the moment to genetic testing and so we’re not, we’re not 
being effective in introducing cascade testing as well in those patients that we’ve 
identified.”(A5, consultant)  
Consultants did not identify knowledge as a barrier to care provision amongst 
secondary care clinicians (research nurses, specialist consultants). However, 
participant A4 (a research nurse) indicated cases where the specialist pharmacist 
and cardiology specialist (secondary care clinicians) displayed a lack of knowledge or 
admitted insufficiencies in HeFH management. An excerpt from participant A4 is 
provided here, but the theme of knowledge is elaborated further under the section 
‘low awareness of HeFH amongst clinicians’.  
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“So, I think in primary care in GP practices it’s probably not as good as secondary care. I 
think we’re getting better in secondary care in that cardiology seems to know about PCSK9 
inhibitors but I think there probably is a lot more you know, education that needs to be done 
around FH in general, which will then obviously a lot of the time lead on to PCSK9 as well.” 
(A4, research nurse) 
This view supported patient accounts which suggested that the care pathway was 
inefficient in some cases, both in primary and secondary care. GPs were not 
confident that there was enough knowledge on HeFH in primary care. Additionally, 
GPs were not aware of what occurred in secondary care following a referral. GPs 
reported the use of QRISK scores and NICE guidelines to detect HeFH (further 
discussion provided under ‘the effect of clinical guidelines’).  
“…so then we refer to lipid clinic to go and find out really if it is familial and I guess they look 
into the genetic side of it. I don’t know if they do any special blood test or family tree tracing, I 
don’t know what they do, but it really is the specialist that takes over at that time.”(A11, GP) 
 “We don’t have a specific template for that but we do use the QRISK scores in general for 
any kind of primary or secondary prevention but apart from that, we don’t have any specific 
tools.”(A14, GP) 
In summary, it appeared that the HeFH patient identification and referral pathway 
may not be as organised as described in clinical pathways. All clinicians provided 
descriptions of methodical approaches to the management of HeFH as stipulated in 
clinical guidelines; this was contrary to patient accounts that cited delays in disease 
identification and referral to secondary care for effective medication provision. Both 
primary and secondary care clinicians identified inefficiencies in patient identification 
in primary care that appeared to support the patient participant accounts. The 
reasons provided for these inefficiencies revolved around  awareness of the disease. 
145 
 
5.5.3.2 Low levels of knowledge and awareness of HeFH  
This section presents the results of the stakeholder opinions on the level of 
knowledge on HeFH, and the disease treatment pathway. Participant accounts within 
this theme were obtained using direct enquiries about opinions on levels of 
knowledge. The excerpts also included cases where participants were not clear on 
certain issues during interviews; and accounts of other HCPs displaying low levels of 
knowledge.  
5.5.3.2.1 Low awareness of HeFH amongst clinicians 
The overall finding was that specialist lipid consultants had a better understanding of 
HeFH and its associated care than GPs and nurses in primary care. Two excerpts 
regarding the question of general HCP knowledge from secondary care clinicians are 
provided below.  
“I think especially in primary care in GP surgeries; they don’t have as much knowledge of FH 
and PCSK9. A lot of patients come to me and say, you know, I spoke to my GP about going 
on this medication and they… about the PCSK9 inhibitors and they don’t know what it was. 
So, I think in primary care in GP practices it’s probably not as good as secondary” (A4, 
research nurse) 
 “No, I don’t think there is enough knowledge there, I mean I can’t comment very much about 
pharmacists, but I think amongst GPs and nurses the knowledge is, you know, it’s not really 
high enough...” (A8, consultant) 
GPs and nurses did not object to the assertion that there were low levels of 
knowledge in primary care. Participant accounts were replete with cases of HCPs’ 
lack of awareness as regards HeFH and PCSK9 inhibitors, especially in primary 
care. An example of such a case involved an account of a nurse prescriber who 
provided statins without further referral for a patient with an LDLC of ‘about eight’ 
(Participant A11, GP).  
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“in terms of the knowledge I would probably think some people(GPs) might sort of confuse it 
with ordinary polygenic hyperlipidaemia and just ‘Oh it’s raised cholesterol, all I need to do is 
just do a QRISK and start statin and invite the patient to see the nurse and discuss about 
healthy lifestyle advice’. And I believe that’s a clinical error if that happens. If they mistake it 
for just normal hypercholesterolemia without ruling it out that it could be familial, I believe that 
will be a clinical error.” (A11, GP) 
Further cases involved GPs stopping medication inappropriately due to LDLC levels 
being lowered. 
“… some doctors sometimes see that the cholesterol’s gone quite low with the PCSK9 
inhibitors and on a couple of occasions, we’ve had them reduce the statin or take the statin 
off them or the fibrate or what have you and then we’ve seen them next, we’ve seen the 
cholesterol go up and then there’s questions as to why and they’ve said oh, well, my 
cardiologist for example, stopped my statin.” (A4, research nurse) 
Specialist consultants mostly considered knowledge of PCSK9 inhibitors and HeFH 
in secondary care to be sufficient. However, based on the accounts of nurses the 
perceived lack of knowledge was not limited to primary care. Participant A4 (a 
research nurse) noted a conversation she had with a cardiovascular surgeon that felt 
that some, potential, HeFH patients had missed clinical diagnosis because they were 
already being treated for other conditions in separate specialist clinics. Participant A4 
also recounted her experience dealing with a new specialist pharmacist that had to 
be educated on HeFH and PCSK9 inhibitors.  
“I know that initially when we got the pharmacist involved, he didn’t have, he may have had a 
little knowledge of familial hypercholesterolemia but generally that’s been the knowledge that 
he’s had to learn through you know starting these PCSK9 inhibitors… putting for example, 
possible or definite familial hypercholesterolemia, he was getting a bit confused what a 
possible and definite meant. Because he was saying, surely if they’re possible, they can’t go 
on the injections…” (A4, research nurse)    
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“I think we’re getting better in secondary care in that cardiology seems to know about PCSK9 
inhibitors but I think there probably is a lot more you know, education that needs to be done 
around FH in general, which will then obviously a lot of the time lead on to PCSK9 as 
well.”(A4, research nurse) 
Participant A5 corroborated this account and reported increased referral from other 
secondary care consultants. However, the participant attributed this increase to the 
fact that these consultants could not prescribe PCSK9 inhibitors.  
“I think the cardiologists are increasingly gaining knowledge, so we’re getting more referrals 
from our cardiology team as this patient may have FH and I think they might be eligible for 
PCSK9 inhibitors. So, we’re getting, you know, perhaps a referral every couple of months 
from our cardiology team which didn’t use to happen and that’s because this new treatment’s 
opened up which at the moment, they're not able to prescribe.” (A5, consultant) 
 
 
Participant views from both primary and secondary care suggested that knowledge 
on HeFH and PCSK9 inhibitors was low in primary care, and was improving in 
secondary care. The researcher also identified cases where primary care participants 
were not familiar with certain processes or terms commonly used in the management 
of HeFH. For instance, a GP (A11) was not aware of the term ‘cascade screening’, 
but went on to describe that the families of HeFH patients needed to be informed of 
the condition later in the interview. The participant also stated that they were not 
aware of what happened in secondary care.  
“So that’s really from my point of view the patient’s journey towards the lipid clinic. What 
happens in the lipid clinic I really don’t know.” (A11, GP) 
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The following participant (a GP), was not aware of the severity of HeFH and the need 
to identify the condition in primary care. 
“…when they talked about the lipid lecture, that I mentioned, they were not quite 
emphasising on the severity or the importance of this topic. Now having spoken to you it 
looks like it needs to be made aware more prominently to primary care, when to refer and 
what to do so this is quite a serious topic, I think more awareness needs to be created…” 
(A14, GP) 
A nurse prescriber (A13) in primary care had never heard of PCSK9 inhibitors; in 
response to the question the participant was quoted as saying, “Nobody’s mentioned 
any injection to me”. Whilst referring to PCSK9 inhibitors two GPs stated the 
following: 
“…(talking to patients) so it’s telling them about all the other options, your project about… the 
project you know about biological treatment, I’m not so sure if we have any of the patients 
taking these medications, I need to do a search to look into that.” (A15, GP) 
“I've been to one of the lipid lectures recently, so they did mention about this new medication 
which is still completely in research.” (A14, GP) 
Participant A14 (above) stated that PCSK9 inhibitors were completely in research 
when they had been approved for use in HeFH for the past 4 years.  
In summary, there was general agreement from both primary and secondary care 
clinicians that the knowledge of HeFH and PCSK9 inhibitors in both sectors. 
Secondary care clinicians believed that the level of knowledge on HeFH and PCSK9 
inhibitors was low in primary care. Primary care clinicians did not dispute this claim, 
and evidence of low levels of knowledge also emerged from interview responses. 
There was also an acknowledgement that the level of knowledge in secondary care 
was lacking in some aspects, but was improving.  
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Primary care participants also felt that some more education on HeFH and PCSK9 
inhibitors would benefit HCPs. Example of suggestions provided to rectify this was 
provided by GPs as shown below.  
“I think it would be a good idea that maybe a workshop is done for GPs and nurses on 
probably, I don’t know if the incidence is rising of FH, but I think a workshop will do the 
clinicians a world of good.” (A11, GP) 
“…with regards to improvements erm…I think more awareness needs to be created in terms 
of education meetings or even sending newsletters to all the GPs and nurses.” (A14, GP) 
5.5.3.2.2 Inadequate understanding of HeFH in patients 
Patient knowledge was perceived to affect the use of PCSK9 inhibitors as both a 
barrier and a facilitator. Lack of patient knowledge, of either HeFH or its associated 
medications, was thought to reduce patient compliance and engagement with 
treatment processes.  This therefore functioned as a barrier to the general use of 
medication. Conversely, an increase in patient knowledge, especially regarding 
disease severity, was generally found to improve acceptability of medication. These 
cases are discussed under section 5.5.4.2 below. 
HeFH patients in secondary care were generally aware of the disease; however, 
most patients did not fully understand the condition. The patients understood that the 
disease was hereditary, and they were aware of the need to inform family members 
about the condition. They also understood the heightened risk of CVD and the 
requirement to take a lifelong regimen of lipid lowering medication. Sample quotes 
from the data illustrated various levels of awareness. 
“Yeah, my condition is familial hypercholesterolemia; I think there's one that’s called hytro… 
with the one gene, so that’s the one that I have.” (A9, patient) 
“Interviewee: High cholesterol, I’ve had it for a few years now, yeah…  
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Interviewer: Do you know which particular type of high cholesterol you have? 
Interviewee: I haven’t got a clue, no, off the top of my head, I don’t know what it is.” (A6, 
patient) 
“I’ve had the high cholesterol for a good few years now.  It’s hereditary obviously via me 
father… Now I’m a little bit statin intolerant.  I was statin intolerant until me heart attack and 
then they, I didn’t have a choice.  I was getting the statins put in me mouth [laughs] in a nice 
way.”  (A12, patient) 
From the perspective of HCPs, there were differing views on patient knowledge 
between primary care and secondary care clinicians. This was largely because HeFH 
patients referred to secondary care had experienced some form of disease related 
complications; for example, cardiac events or statin intolerance. These patients 
engaged with the treatment process more, and understood the risks that they faced. 
The resultant effect was an increased willingness to use statins (despite experiencing 
side-effects), and general acceptance of PCSK9 inhibitors.  
“On the whole, a lot of the patients are fine; they understand why they need to take it and the 
risks of not taking cholesterol medication in terms of heart disease etc. And in terms of the 
injections, they are quite happy in taking an actual injection as well, not many of them are 
worried about injecting themselves.” (A4, research nurse) 
“Acceptability (of PCSK9 inhibitors) is excellent because most of the patients we have tried 
are patients who are statin intolerant.” (A3, consultant) 
“I think when you're explaining, educating the patient, say them to look, you know, this is 
really important for your cardiovascular health, we’re trying to stop you from getting heart 
attacks. I think if you explain the reasoning behind it, you know, most patients agree to use 
it.” (A8, consultant) 
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In contrast, primary care clinicians felt that HeFH patients in primary care were not 
sufficiently knowledgeable about the condition. This resulted in reduced engagement 
and non-compliance with treatments.  
“A lot of them don’t know and the funny thing is that when you’re explaining the condition to 
them, some of them might say ‘Yeah, but I’m not fat, I’m not obese.’” (A11, GP) 
“…I was talking in the pub and me mate’s said, he doesn’t take them anymore cause he gets 
this, this and this, so I thought I'm going to do that, so they listen a lot to the media and also 
what their friends think.” (A13, prescribing nurse) 
Patients felt that GPs and nurses in primary care did not inform them appropriately 
about the severity of the disease. Additionally, patients expressed concern about 
delays in diagnosis despite the existence of family history of cardiac disease.   
“I feel they did give me the medication but I think they didn’t make me aware of how 
important it was for me to take this? It was just, you know, they’ve done some bloods, come 
and pick your medication up or if I have made an appointment with the doctors, oh you know, 
you have cholesterol, you’ve got to take this, you know, the importance of it is not made, it’s 
not taken seriously at all with the cholesterol..” (A9, patient) 
“They could let people know, I don’t know how you do that, how you go about doing that. 
Maybe your GP, you know, but the chance that you’d got it and because you have to go for 
regular blood tests at the GP surgery, so if they suspect that you’ve got it, they could give 
you more information about it.” (A7, patient) 
“I’m thinking, now at this stage and I’m just turning forty-one but obviously three years ago, I 
was in my thirties, late thirties and I knew about this that you know, I just feel that if I knew 
about this a little bit earlier I could have, there's a lot of things that I could have helped 
myself...” (A9, patient) 
Finally, it was observed, in both primary and secondary care, that some patients took 
medication (statins) intermittently regardless of knowledge of the disease. In primary 
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care this was attributed to influence from peers and information in the media 
regarding statins by the nurses (as described in excerpt A13, above). In secondary 
care, side-effects were recognised as the cause of this non-adherence.  
“I think as well, if patients aren’t taking the statin as often as they should, and you explain to 
them, that you know, when you were taking your statin, your cholesterol came down to X and 
now you’ve, you know, only taken it every few days, or when you remember it, it’s now gone 
up to Y, and they tend to understand that you know…” (A4, Research nurse) 
These results suggested that more knowledge about HeFH was required in patients. 
In most cases, the disease was taken seriously only after a cardiac event was 
experienced. Patients felt that prescribers in primary care could improve the 
information they provided about the disease.  
5.5.3.3 Therapeutic gaps in clinical guidelines 
5.5.3.3.1 The use of clinical guidelines for lipid management in HeFH 
NICE guidelines were found to be the main reference resource for healthcare 
providers (HCPs), and were used by all clinicians in both primary and secondary 
care. 
5.5.3.3.1.1 Stakeholder level of knowledge on clinical guidelines 
In primary care, there was general awareness that markedly elevated LDLC levels, 
with or without a history/ family history of cardiac events, warranted secondary care 
referral. However, HCPs in primary care rarely mentioned specific details from NICE 
guidelines. In some cases, it was evident that the thresholds described differed from 
NICE recommendations (excerpt A14, below).   
“Depends on the levels of the cholesterol, so I've had lectures where they say it’s above 10, 
you need to start treatment straight away.” (A14, GP) 
“Well basically our target is, for diabetes, heart disease and cholesterol, below four, or 
certainly four or below and an LDL of two. For sort of people with just say for example, 
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hypertension without diabetes, without cardiovascular disease then erm, we target that to be 
less than five.”(A13, prescribing nurse) 
In contrast, HCPs in the secondary care management of familial 
hypercholesterolemia were more knowledgeable about guidelines, and also 
discussed specific thresholds regarding PCSK9 inhibitors.  
“At the moment, for FH without established cardiovascular disease, the LDL threshold (after 
maximum tolerated medication) is 5 mmol/L; whilst for the very high intensity that is more 
than one event or two bed event, it’s 3.5; whilst if it’s just one event or one single bed, it’s 4 
mmol/L.” (A3, consultant) 
“Okay, so generally speaking we aim for, a cholesterol of less than four LDL cholesterol, less 
than two. But if we can’t achieve that because there’re too ambitious lipids then we aim for 
an LDL reduction of 50% or more from the baseline figure.” (A8, consultant) 
Additionally, secondary care clinicians were found to use European guideline 
therapeutic LDLC targets for HeFH. This was mainly because NICE guidelines 
recommended a percentage LDLC reduction compared to concrete values presented 
in the European guidelines. 
“Obviously, for secondary prevention there are targets.  We use the European target of 1.8 
mmol/L. That’s the threshold.”(A3, consultant) 
“If patients have got FH and vascular disease, then we would aim for even lower LDL 
cholesterol so less than 1.5, even we would go down to less than 1.5, if we can.” (A8, 
consultant) 
5.5.3.3.1.2 The potential overuse of QRISK 
An emerging concern, raised by a consultant, was the use of QRISK in HeFH 
patients in primary care.  
“What really should happen is there should be a discussion with the patient as to what the 
risk is and what the pitfalls of the risk algorithm are which is very difficult in primary care but 
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also what the potential benefit would be. That never happens.  What really happens is that 
they go into the QRISK algorithm which is primary prevention and if they are above the 10% 
threshold, bang! They’re given statins.” (A3, consultant) 
QRISK scores are a guideline based tool used in the prevention of CVD. QRISK 
estimates the 10 year risk of CVD based on patient risk factor profile. NICE 
guidelines stipulate that a QRISK score of 10% or more indicates the need for a full 
assessment and potential treatment with statins. NICE also recommends that the 
QRISK assessment tool is NOT used in patients with HeFH (NICE CKS, 2019).  
Nevertheless, most clinicians from primary care mentioned the use of QRISK as the 
general practice for managing patients with elevated cholesterol. Nurses generally 
conducted NHS health checks, they were key to referring potential HeFH patients for 
further assessment y GPs. An account by participant A13 (prescribing nurse), 
confirmed participant A3’s (consultant) description of the process of treatment in 
primary care.  
“…we see patients for NHS health checks who are not on a register… the QRISK score and 
if that becomes over 10% for patients, irrespective of where the cholesterol sits then I ask to 
see them erm, with obviously sort of the guidelines… or if we’re over 10% with some of these 
patients dependent on obviously history and lifestyle, you know, recommend that they have 
statins.” (A13, prescribing nurse) 
A similarly important observation was that secondary care clinicians who were not 
specialised in lipid management also prioritised the use of QRISK. There was no 
acknowledgement that QRISK scores could potentially mask HeFH, as the score was 
based on several risk factors that were not all relevant to the HeFH. 
“I think we shouldn’t be too fixated about lipids because don’t forget that patient risk factor 
profile is not just about lipids it’s interaction between multiple risk factors so blood pressure 
smoking history lipids family history hmm you know weigh height so forth.  All this factors are 
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put in a risk calculator so QRISK in the UK or JBS3 which is currently recommended which is 
based on QRISK.” (A17, cardiology consultant) 
A prescribing nurse noted cases where patients with elevated cholesterol (potential 
HeFH according to NICE guidelines) did not score above 10% in QRISK. The 
participant was however not clear on the reasons behind this. As previously 
mentioned, NICE guidelines do not recommend the use of QRISK scores on HeFH 
patients because the risk score may be underestimated due to the asymptomatic 
nature of HeFH (NICE CKS, 2019). The prescribing nurse did not appear to be aware 
of this guideline. 
“Well you know, we have this QRISK, you know, about the QRISK now sometimes I can 
have somebody who can have a cholesterol of eight or nine, erm over the age of 40, weight 
might be okay, no family history, don’t smoke, blood pressure is okay and the risk comes 
less than 10… so I think sometimes you have to be careful, the computer can give you false 
reassurance.” (A13, prescribing nurse) 
Some clinicians in primary care, acknowledged the use of QRISK scores, but were 
aware of the inappropriateness of QRISK scores in HeFH patients. They also 
reported that clinicians possibly mistook HeFH for normal hypercholesterolemia and 
therefore treated it using QRISK scores.  
“And the reason why is because normally any blood result that comes back even with a 
raised total cholesterol, you look at the age, you look at other factors involved, do the 
patients … do they smoke an all that and then we do what we call a QRISK. But even in such 
patients you shouldn’t even be doing a QRISK too because the total cholesterol is really 
high…  
I would probably think some people (primary care clinicians) might sort of confuse it with 
ordinary polygenic hyperlipidaemia and just ‘Oh it’s raised cholesterol, all I need to do is just 
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do a QRISK and start statin and invite the patient to see the nurse and discuss about healthy 
lifestyle advice’.” (A11, GP) 
The resultant effect of these cases was that HeFH patients in general, were not 
signposted to appropriate medical services effectively. This, consequently, may have 
resulted in patients who required PCSK9 inhibitors not being identified in a timely 
manner.  
“…no one has really spotted anything really as being an issue to a certain degree. It wasn’t 
really regarded; no one mentioned that actually you should do something about that really 
(referring to high LDLC levels). I think it was, I mean one of the things that hadn’t been 
actively monitored, so I knew it was around five, you know, it was never much more than that 
but you know, therefore I was aware, even at the point when I had my MI, I think they 
mentioned it then, it was about 5.5 at the point.” (A10, patient) 
In summary, clinicians in the secondary care of HeFH (consultants in lipid clinics, 
research nurses) were more knowledgeable about HeFH specific guidelines than 
clinicians in primary care. Clinicians in primary care (GPs, nurses) and secondary 
care specialist in fields other than lipidology were knowledgeable about general CVD 
prevention guidelines but not HeFH specific guidelines. In such cases, it was 
reported that some clinicians would incorrectly use QRISK scores to assess and 
manage patients, even those that could potentially have HeFH. This theme focussed 
in the use of HeFH guidelines. The further theme of ‘knowledge’ emerged from this 
discussion. This theme is discussed under the section ‘low awareness of HeFH 
amongst clinicians’.  
5.5.3.3.2 Strict clinical guidelines on PCSK9 inhibitor provision 
Of the participating stakeholders, clinicians in primary care did not comment on 
matters concerning guidelines in PCSK9 inhibitors. Only lipid specialist consultants 
discussed this issue, this was likely because only these consultants were allowed to 
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prescribe this new class of medication as indicated by participant A2 (cardiology 
consultant).  
Amongst the lipid specialist consultants, there was general consensus that PCSK9 
inhibitor prescription was strictly based on NICE guidelines. In fact, the main issue 
identified was a perceived defect of clinical guidelines; strict LDLC targets. 
Participants thought that this had the potential to deny PCSK9 inhibitors from patients 
who were deemed to require them. 
“In terms of introducing PCSK9 inhibitors, we have to abide by the NICE guidance so we 
follow the NICE guidance.” (A8, consultant) 
“…so we can only use PCSK9 inhibitors in line with the guidance, you know, the TA 
guidance from Nice.” (A5, consultant) 
 “And I think you know there are sort of very strict criteria in terms of which patients benefit 
from PCSK9 inhibitors and which don’t benefit, because even then it’s a very small pool of 
patients with PCSK9 inhibitors that are allowed to use it.”(A2, consultant) 
The strict criteria referred to are NICE (National Institute of Health and Care 
Excellence) technology appraisals (TA -393 and 394) and NICE clinical guidelines 
(CG71) on HeFH. These guidelines stipulate when PCSK9 inhibitors should be 
initiated in an effort to ensure appropriate and cost-effective use of the medication. 
The guidelines recommend the use of PCSK9 inhibitors when LDLC levels are 
consistently above 3.5mmol/l and 5mmol/l in secondary and primary prevention 
treatment respectively despite maximum and ineffective use of conventional lipid 
lowering therapies such as statins. This theme was extensively elaborated in the 
excerpt below.  
“There is no way round this but the big issue is that certain patients try very hard and their 
LDL may come down to 3.8 and they’re not eligible for PCSK9s.  You may find another 
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patient with the same clinical pattern who doesn’t try very hard.  They take the tablet and 
maybe their compliance isn’t brilliant and the patient denies it but with the diet, you know 
there is a little bit of cholesterol but perhaps not that much.  They don’t try very hard and their 
LDL is 4.2. The person, who doesn’t try very hard, with poorer compliance which we know 
nothing about, is eligible for PCSK9; whilst the patient who plays by the book and tries very 
hard is not eligible. There is unfairness but I don’t know how the system can get round that. 
That is a major unfairness.”(A3, consultant) 
“…it may be that they’ve got less than 50% reduction but the LDL, they’ve not got 
cardiovascular disease and the LDL is less than five, then we’ve got no other option…” (A5, 
consultant) 
To clarify this comment, HeFH patients are required to meet the recommended LDLC 
thresholds in order to qualify for PCSK9 inhibitors. In some cases, the LDLC levels of 
patients deemed to require PCSK9 inhibitors by lipid consultants are below these 
targets, and therefore these patients are not eligible for the medication.  
In summary, lipid specialist consultants were in agreement that strict NICE guidelines 
were directing the use of PCSK9 inhibitors. These guidelines could potentially restrict 
the provision of PCSK9 inhibitors to patients who were deemed to require them. This 
section is concluded with an excerpt describing a consultant’s view of clinical 
guideline. This participant (A3) was a member of the area prescribing committee and 
was therefore involved in the inclusion of medication to organisational formulary. This 
allowed insight that the other consultants did not have as they were not part of this 
process. 
“My main point is that I have a major problem with a lot of the guidelines that come out.  My 
biggest issue is that they are practical and pragmatic but they do not look at the disease…  
There isn’t enough information about the differences between the drugs.  It’s all about the 
pathway.  With pathways, you do not talk about what the underlying risk factors are.  What is 
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the best drug?  What is the most appropriate drug for this patient?  For instance, fibrates are 
not covered.” (A3) 
The excerpt discussed matters that revolved around ‘mechanical prescribing’ of 
statins as discussed in section 5.5.3.3.1 (The use of clinical guidelines for lipid 
management in HeFH). However, it also discussed a potential lack of specification in 
guidelines as regards medications. This introduced an element of flexibility with 
respect to the interpretation of guidelines into organisational policy. The effect of this 
flexibility was observed in the development of organisational policies as discussed in 
the section 5.5.3.4 (Inhibitory organisational practices). 
5.5.3.4 Inhibitory organisational practices 
This theme explored the organisational factors that had the potential to influence 
PCSK9 inhibitor use. Organisational policies for the management of HeFH, and multi-
disciplinary cooperation in the care for the disease were identified as key sub-
themes. The theme was mainly discussed by HCPs in various capacities. 
5.5.3.4.1 Inhibitory prescription policies for PCSK9 inhibitors 
Organisational practices varied between the primary and secondary care treatment 
setting for HeFH. These differences were based on NICE guidelines and revolved 
around the roles served in each setting.   
At the primary care level, patient care was focused on disease detection as 
discussed under section 5.5.3.3.1 (The use of clinical guidelines for lipid 
management in HeFH). There were no specific organisational procedures set up for 
the identification of potential HeFH patients in primary care. Instead, general 
practices in CVD detection and prevention were presumed to cover HeFH patients. 




“I don’t think they have a structure in place but… they do have a national health screen for… 
diabetes and familial hypercholesterolemia. So I think the 40’s the Government does have a 
screening and anyway all people that have health conditions like diabetes, they do have their 
annual or six-monthly check anyway. So I do think there are systems in place for people to 
be picked up with familial hypercholesterolemia but if it’s very strong history of, you know, in 
their early 20’s then we don’t have a check or a screen for them…” (A14, GP) 
Similarly, the nurses who were in charge of conducting heath checks felt that the 
system for identifying HeFH was adequate. In response to the question on the role of 
primary care in HeFH management, a nurse prescriber provided the following 
response. 
“…when we identify the patients, that cascading about getting the siblings you know, or 
children checked etc. particularly if you’ve got, you know, sudden death and a lot of 
cardiovascular problems within in a family, you know, at a young age to about 86, often we 
look at them. I think otherwise, other than what we’re doing erm, you know, sort of screening 
patients over 40 and obviously that’s just picking out the ones that erm, they’ve got 
significant family history that makes you think like that.” (A13, prescribing nurse) 
The responses suggested NHS checks for patients over 40, and annual reviews for 
patients with chronic illnesses were used to opportunistically identify HeFH patients. 
However, this system had the potential of disregarding patients with HeFH under the 
age of 40. 
The secondary care setting involved the treatment of complicated cases of HeFH, 
and therefore, the use of PCSK9 inhibitors. The main influential factor was found to 
be organisational policies; these policies dictated the prescribing practices. Lipid 
specialist consultants are the only HCPs permitted to prescribe PCSK9 inhibitors; this 
section therefore included limited contribution from the other stakeholders in the 
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study. The following excerpts are provided to describe the process through which 
PCSK9 inhibitors are made available in the formulary of NHS trusts.  
“…each hospital has a committee that looks at a particular drug, the benefits the costs 
associated with it and then they would make the clinical decision as to whether it would go 
onto hospital formulary or not. And they’ll be different service users that’ll be on that 
committee there would be hospital pharmacists they’ll be doctors with an interest in that area. 
So you know, it may be lipidologists it may be cardiologists I’m not involved in that process.” 
(A17, consultant) 
“Each of the CCGs still has an Area Prescribing Committee.  I actually sit on the APC in xxx.  
If the NICE Guidelines come up (and a lot of doctors are not aware of this), it is up to the 
APC to make absolutely certain that it’s in the formulary within a three month period.  Lots of 
doctors aren’t aware of this.  It is up to the APC to go and find the appropriate clinician to fill 
in an abbreviation form and then it has to be stamped by the CCGs, come what may.” (A3, 
consultant) 
Once PCSK9 inhibitors were approved by NICE, the Area Prescribing Committees 
(APC) included the medication in organisational formulary of their member hospital 
trusts. This recommendation is presented to the Clinical Commissioning Group 
(CCG) which then sets prescribing policies for the medication. There was general 
agreement amongst the consultants that prescription of PCSK9 inhibitors strictly 
adhered to these organisational policies.  
“…so although we prescribe it (PCSK9 inhibitors), it then has to go on a database and goes 
to the CCG for approval… we put it onto a blueteq form… they go to the commissioning 
groups and it’s the commissioning groups who then agree whether they can, the prescription 
can be renewed when they come up to a year. And sometimes they're actually turning them 
down although we think that they meet the criteria.” (A5, consultant) 
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“So, we have to complete the blueteq forms and then once the blueteq form is completed, we 
can write a prescription, and that is, it is dispensed by the hospital pharmacy and then, they 
either continue to get the drug from the hospital pharmacy or we use the home delivery 
services and that works reasonably well.” (A8, consultant) 
The blueteq forms had variations amongst CCGs but they were based on NICE 
guidelines. As described by participant A5, the forms in their CCG required that other 
lipid lowering agents be used before trying PCSK9 inhibitors.   
“Yeah, I think the criteria, they're not, they use a NICE criteria but it’s a criteria really about, 
whether the patients have got LDL cholesterol, say take someone without CVD, has got an 
LDL above five, but it’s a criteria about whether every possible lipid lowering therapy other 
than PCSK9s has been tried. So, I might say, well they’ve tried all the statins they’ve tried 
pravastatin, they’ve tried atorvastatin then they might say well have you tried fluvastatin.”(A5, 
consultant) 
Similar points were raised by other consultants. However, further comments revealed 
that some blueteq forms required multiple LDLC readings above the NICE threshold 
in order to ascertain the fulfilment of this requirement. 
“It is available (PCSK9 inhibitors) and there is a bit of a postcode lottery at the moment. It is 
available but the process is deferring from CCG to CCG. In xxx, for the CCG, there’s a 
blueteq that has to be filled. They require two LDLs above the threshold which is not in the 
NICE Guidelines. There are certain other CCGs which want three and again, isn’t in the 
NICE Guidelines. In xxx, at the moment, they’re not doing them. They’re following the NICE 
Guidelines.” (A3, consultant) 
Although consultants were in agreement that PCSK9 inhibitors should be provided 
after the use of other lipid lowering agents; there was concern that the 
unstandardized blueteq system had the potential to cause delays in medication 
provision. This, in turn, would cause frustration in HeFH patients. 
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“…it will probably delay everything by six months for them to have two or three blood tests to 
prove it. It also makes the patients quite irritable because these are very high risk patients 
and they would rather get on to it than having to come back in two or four months for the next 
step. Of course, what actually happens if, for instance, an LDL in a secondary prevention 
patient – high risk but not extreme risk which is one event – is, say, 4.1 and the next time 
they come at 3.9 and the following time, it’s 4. These patients do get quite frustrated.” (A3, 
consultant) 
This section is concluded with excerpts from patient participants who experienced 
these delays.  
“They need to know which one is which and it just takes such a long journey, the 
appointments come every three months or every four months, by the time they’ve taken the 
bloods after four months when they're going to call you back again, so then they will do your 
bloods again, then it’s another four months, by the time, they’ve written to your doctors…” 
(A9, patient) 
“…actually the recommendation was get off statins cause its causing all these other issues, 
but there was nothing quickly, you know, it was nine months before I actually I got onto the 
new drug, you know, cause there's lots of tests and procedures to go through to get to that 
point…” (A10, patient) 
5.5.3.4.2 Lack of consensus on stakeholder roles in the care for HeFH 
This sub-theme set out to assess the role of multi-disciplinary cooperation in the 
management of HeFH. Divergent views regarding collaboration were elicited from 
stakeholders. The data so far suggests that nurses (in primary care) were involved in 
the identification of potential HeFH patients. In secondary care, nurses were involved 
in patient education and training as regards the use of PCSK9 inhibitor injections. 
GPs were involved in the management and monitoring of HeFH patients, however, 
they were also tasked with referral of patients to secondary care. Specialists in 
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secondary care manged complicated cases of HeFH (statin intolerance, markedly 
elevated LDLC etc.) 
Some consultants felt that the use of PCSK9 inhibitors was a clinical decision that 
had to be left to the specialists. Participant A3 (excerpt below) also felt that the 
involvement of other HCPs in the prescription of other medication was not always 
advantageous.  
“No, I don’t think they actually have a role here because this is actually a clinical decision.  
It’s based on NICE.  It’s an expensive drug.  It’s a new drug and even the primary care are 
not allowed to use it.  The PCSK9 is specifically secondary care and that’s the way it should 
be. When it comes to other treatments, yes and no.  I’ve seen places where statins are used 
by pharmacists.  By and large, it’s okay but a lot of what I hear is a load of rubbish.” (A3, 
consultant) 
Similar accounts regarded pharmacists, nurses and GPs as providing support rather 
than being involved in the direct management of patients.  
“We haven’t used them in that way, we’ve mainly used them to discuss particularly when we 
started to prescribe PCSK9s and helped us with making sure that we have identified the 
correct patients and the system for prescribing which is obviously because we can’t, normally 
if we prescribe, if I prescribe a statin, it’s the GP that does the prescribing.” (A5, consultant) 
Conversely, some consultants suggested that trained specialist nurses and 
pharmacists could be involved in either prescription or support services in order to 
help with workload. Examples were provided of research nurses and pharmacists 
running clinics under the consultant during clinic trials for PCSK9 inhibitors. 
“…it doesn’t need to be the cardiologist or the lipidologist, lots of this can be managed by 
specialist pharmacists and specialist nurses.” (A16, consultant)  
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“And then I think more resources in terms of specialist nurses and lipid specialist nurses, I 
think to help us in clinics, I think that would be very welcome.” (A8, consultant) 
Nurses felt that they could be more involved in the treatment journey of HeFH 
patients. Suggestions provided included increased involvement in education of both 
patients and HCPs. In some cases, nurses (participant A4) were also aware of 
services for HeFH blood testing within organisations that clinicians were largely not 
familiar.  
“…a lot of it would need to come from us to initiate it or with the help from some of the drug 
companies as well to set up meetings for various people. But I think its about us, you know 
doing the education and educating other people in the hospital. And to know where they can 
refer to, it’s not always easy knowing who to refer to or where to refer.” (A4, research nurse) 
On the other hand, GPs felt that the current roles were sufficient; with pharmacists 
verifying prescriptions and nurses running screening services. However, they noted 
that improvement could be made to the roles of the pharmacists and nurses.  
“…with the nurses, they could be given more erm, kind of update and learning knowledge 
about picking up familial hypercholesterolemia and how they can do it, certainly, you know, 
the nurses can be educated more…” (A14, GP) 
In summary, the opinions on multi-disciplinary collaboration were mixed. 
Recommendations largely involved the increase of knowledge in certain roles, and 
suggestions of services that were not being used effectively. Overall, it seemed that 
there was a need to re-organise the treatment process for HeFH management as 
regards multi-disciplinary collaboration. This suggestion was mentioned by a consult 




“I think, reorganise the workforce in such a way that it would be more effective, I think 
definitely, yes, you can utilise them in a slightly different way to provide a more efficient 
service.” (A8, consultant) 
5.5.4 Facilitators of PCSK9 inhibitor adoption 
Fewer facilitators were identified compared to barriers to the use of PCSK9 inhibitors. 
The sub-themes of ‘patient awareness of disease severity’ and ‘views on medication 
use’ were generally considered to facilitate PCSK9 inhibitor use amongst different 
stakeholders. However, the sub-theme on ‘influence from pharmaceutical companies’ 
was discussed by three consultants that had previously worked in clinical trials of 
medication. The sub-themes are only discussed briefly. 
5.5.4.1 PCSK9 inhibitor use support from pharmaceutical companies 
Pharmaceutical companies were found to deal mainly with consultants in the care for 
HeFH. Other stakeholders did not directly work with pharmaceutical companies. 
However, a research nurse believed that working with companies increased scope to 
educate HeFH patients about PCSK9 inhibitors.  
“I mean obviously I think a lot of it would need to come from us to initiate it or with the help 
from some of the drug companies as well to set up meetings for various people.” (A4, 
research nurse) 
This was echoed by a consultant that had worked with a pharmaceutical company.  
“The pharmaceutical companies have put money forward for education. They haven’t had 
any say about policy and that; I can categorically say…The reason is because Sanofi offered 
us free patient access to the Nursing Service.  We didn’t have the capacity in the clinic to 
teach patients how to use it.  Amgen was slow off the mark.  They’ve got a policy in now and 
now, the prescribing will be around even, so 50% for each.” (A3, consultant) 
The provision of a nursing service helped to improve HCPs knowledge on PCSK9 
inhibitors; and therefore increase the turnover of patients who required PCSK9 
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inhibitors. Sponsorship was also associated with the use of the company’s 
medication as is evident from the quote below: 
“They probably do get a little bit upset because if you look at my practice, about 80% plus are 
on the Sanofi drug and so Amgen would be quite upset.”(A3, consultant)   
5.5.4.2 Patient awareness of disease severity 
Patient awareness of disease severity was identified as a facilitator to the use of 
PCSK9 inhibitors, and statins among other lipid lowering agents. Patients agreed to 
take statins despite experiencing side-effects once knowledge of the disease was 
improved. PCSK9 injections were also found to be well accepted.  
“..I think so and I think after having a heart and a bypass you seem to make it a bit more 
tolerant, don’t you, you know, like [laughs].  Prevention is better than cure they say but after 
that really I just go along with it and, to be fair, sometimes if I think they’re a bit much I’ll miss 
the odd day out of the statin and then take them where last time I just thought I can’t, that I 
can’t handle this, and then I was back to the doctors trying to sort things out.” (A12, patient) 
“On the whole, a lot of the patients are fine; they understand why they need to take it and the 
risks of not taking cholesterol medication in terms of heart disease etc. And in terms of the 
injections, they are quite happy in taking an actual injection as well, not many of them are 
worried about injecting themselves.” (A4, research nurse) 
Intolerance remained problematic even though patients agreed to stay on statins. 
Despite knowledge of disease severity, intolerance reduced patient adherence as 
seen in excerpt <A12> above. This served to further increase acceptance of PCSK9 
inhibitors in such cases. 
5.5.4.3 Negative views on the use of statins 
In patients, negative perceptions of statins due the reports in the media were 
perceived as a barrier to the use of statins, but a facilitator to the use of PCSK9 
inhibitors. It is also worth noting that patients who were referred for PCSK9 inhibitor 
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use (therefore, all patients in this study), had either experienced side-effects or 
insufficiency with statins. It is therefore unsurprising that their views on statins may 
largely not be positive.  
A nurse in primary care, for example, noted that the link made between statins and 
diabetes in media reports was a common concern for patients. 
“I think some of the reasons are obviously there's been quite a lot of erm, press erm, 
awareness about statins being linked with diabetes… there's been quite a lot of awareness 
about statins that it raises the blood sugar, that’s one.” (A13, prescribing nurse) 
“…you know for some people there is quite a big resistance and they, you know, they sort of 
and you know in the media they are starting sort of looking at treatment options so it’s 
demonised so we tend to have some issues with that, you know, patients stop taking and 
obviously the risk is high… 
…” (A15, GP) 
“I was talking in the pub and me mate’s said, he doesn’t take them anymore cause he gets 
this, this and this, so I thought I'm going to do that. So they listen a lot to the media and also 
what their friends think and say so there's definitely an element sometimes can be around 
compliance.”(A13, prescribing nurse) 
Similar views were observed in the secondary care management of the disease.  
“There are a handful of patients, because they are on statins and they’ve got a lot of bad 
press, you know, in the newspapers and things like that, they’re a bit cautious, you know, to 
take them. But generally, on the whole, people are okay” (A4, research nurse) 
In some cases, patients requested to be taken off statins once they were using 
PCSK9 inhibitors.  
“A lot of people, when they go on the PCSK9 inhibitors, ask if they can then reduce or come 
off the statin. So, we just have to explain to them, that you know, the studies show that taking 
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them both together is of greater benefit than just taking one or the other. And so, they tend to 
understand that and continue on the statin as well.” (A4, research nurse) 
Some patients also showed the willingness to use PCSK9 inhibitors because of 
negative perceptions towards statins.  
“And there are a few patients who surprisingly seem to be happier to take you know, an 
injection of a new largely, you know, we’ve not got years of evidence base about 
effectiveness and safety, but they're happy to do that than take statins because there's a lot 
of adverse publicity in the national press about statins.” (A5, consultant) 
On the contrary, views on PCSK9 inhibitors were generally positive amongst both 
HCPs and patients.  
“On the whole, a lot of the patients are fine; they understand why they need to take it and the 
risks of not taking cholesterol medication in terms of heart disease etc. And in terms of the 
injections, they quite happy in taking an actual injection as well, not many of them are 
worried about injecting themselves.” (A4, research nurse) 
“No, no, I’ve been taking the tablets and the injections as well. So, the injection seems to 
have fetched it right down, my cholesterol.” (A6, patent) 
“Acceptability is excellent because most of the patients we have tried are patients who are 
statin intolerant.  Altogether, I probably have close to 70 patients across both sites…” (A3, 
consultant) 
“I’m fine with it.  I just think this, the injection thing that is working.  It works.  I think statins 
just seem to have a bit of a bad press, don’t they, so, and people talk about them, there’s so 
many on them and that, but maybe I wouldn’t have had them either.” (A12, patient) 
Some patients were hesitant to use injections but acclimatised to the use of PCSK9 
inhibitors due to increased LDLC reduction and insufficiency of statin treatment. 
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These patients retained negative thoughts on PCSK9 inhibitors despite their 
acceptance to use the medication.  
“Well at first I wasn’t too keen on the injection, I really wanted the tablets to work and it just 
wasn’t happening. They were pushing me to take these tablets and really told me to take the 
injection and I was just a bit optimistic about taking the injection, I just really hoping that it 
come down with the tablets but it just didn’t, for me. It would not come down with the tablets 
alone, and when they put me on the eighty, that was affecting the liver so I didn’t want that 
either. So, my only other option was to try this injection so, when I did go and get the 
injection, and it has brought it down dramatically, which, you know, I’m really pleased. But, 
you know, my only other thing I’m thinking, will I have to be on this for life?” (A9, patient) 
Finally, polypharmacy was identified as a concern by some patients. This was often 
associated with reduced levels of LDLC following the initiation of PCSK9 inhibitors. 
Patients suggested a reduction to the amount of medication taken, or objected to the 
addition of medication to their treatment regimen. In these cases, an 
acknowledgement of the effect of PCSK9 inhibitors was reported. This suggested 
that the patients would not want to PCSK9 inhibitors to be removed from their 
treatment regimen, but questioned the need for other medication.  
“I found the tablets alone didn’t bring my cholesterol down, they wanted it to come down. And 
with the injection and taking the tablet, it’s come down to four. Yes, this is just recent and the 
LDL is 2.1 and now they want to put me on ezetimibe just to bring the LDL one down but I’m 
not sure if I want to go on because I already take enough medications…” (A9, patient) 
“I think it’s difficult, cause for me one, what's interesting for me now is, with statins I 
understand and obviously with the evolocumab because obviously it’s doing a positive thing 
it’s keeping your cholesterol below a certain level… I queried why, you know, even though 




5.6 Discussion of qualitative analysis results 
This chapter identified potential barriers and facilitators to the adoption of PCSK9 
inhibitors using thematic analysis of interviews with stakeholders. Five key themes 
emerged from the analysis.   
The theme on ‘Low referral rates to secondary care’ described the patient 
identification pathway and the process of receiving lipid lowering medication. The 
overall implication was that a small number of HeFH patients were being identified 
and referred to secondary care. Specialist consultants felt that the identification and 
referral of patients to secondary care was ‘incidental’. By contrast, clinicians in 
primary care felt that the use of NHS health checks and patient medical reviews were 
sufficient to identify HeFH. However, there were no specific systems set up to detect 
HeFH. Patient accounts supported the consultants’ viewpoint; these suggested that 
HeFH was mainly considered when a cardiac event occurred in a patient. Following a 
cardiac event, cascade screening provided an avenue for the patient’s family to be 
identified.  
‘Therapeutic gaps in clinical guidelines’ assessed specific processes in the 
management of HeFH and the provision of PCSK9 inhibitors. Two key results were 
extracted from this theme. Firstly, GPs and consultants felt that there was a 
possibility that clinicians in primary care treated HeFH as the non-familial versions of 
the disease. Some participants (GPs) reported that some clinicians possibly 
calculated a QRISK score and prescribed statins without realising other signs for 
HeFH, such as family history of elevated cholesterol or heart disease. The accounts 
of other primary care clinicians appeared to support this claim. GPs and nurses 
reported the use of QRISK and general CVD prevention guidelines for patients. 
HeFH was identified by markedly elevated LDLC levels combined with a history or 
family history of CVD. However, some GPs noted that the recording of cardiac event 
172 
 
history was ‘random’, and suggested that all healthcare providers pro-actively seek to 
establish accurate medical histories. Secondly, the use of NICE guidelines for the 
prescription of PCSK9 inhibitors was described as ‘strict’ by specialist consultants. 
Consultants found that some patients, who were deemed to require PCSK9 
inhibitors, were denied the medication because they did not meet the set LDLC 
thresholds.     
Healthcare practitioners in secondary care acknowledged that the level of knowledge 
of HeFH was increasing in secondary care. However, there was general congruence 
that the level of knowledge in primary care was significantly lower. The interviewer 
encountered participants in primary care (GPs and a prescribing nurse) who were not 
aware of PCSK9 inhibitors. These corroborated accounts from secondary care that 
reported failed attempts by patients to discuss PCSK9 inhibitors with some primary 
are clinicians. Furthermore, a GP admitted to not knowing how serious HeFH was, 
and the fact that more was expected from primary care with regard to the 
identification of patients. Patients asserted that the severity of the disease was not 
expressed to them in a timely manner. GPs and nurses felt that patients did not take 
the disease seriously and were influenced by negative media reports on statin use. 
Patients felt that they were not informed about the disease severity; they also felt that 
HeFH was considered by primary care clinicians when it was too late. This had the 
dual effect of delaying HeFH diagnosis, reducing patient engagement with treatment.  
Organisational factors affected the prescription of PCSK9 inhibitors by increasing the 
time required to receive the medication. In primary care, the lack of a structured 
system of HeFH identification delayed referral times for patients that would end up 
using PCSK9 inhibitors. Once in secondary care, the prescription of PCSK9 inhibitors 
was defined by organisational policy. Consultants were required to fill in the Blueteq 
form for each patient that required PCSK9 inhibitors. The Blueteq form was mainly 
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used to ensure that the patient had used other available lipid lowering agents before 
PCSK9 inhibitors were indicated. The form also ensured that that the patient met the 
LDLC thresholds stipulated by NICE guidelines for PCSK9 inhibitor use. However, 
additional requirements were included in the Blueteq forms of some organisations. 
For example, consultants reported that some organisations required two or three 
LDLC readings above the recommended threshold in order for the patient to qualify 
for the treatment. Patients found the system frustrating as it further delayed 
treatment, and in some cases, they had to attend LDLC profile tests over several 
months.         
The final theme constituted the factors that were perceived as facilitators to the use 
of PCSK9 inhibitors. One factor that was independent of the stakeholders was the 
influence of pharmaceutical companies. Secondary care clinicians reported that 
assistance from pharmaceutical companies helped to improve patient education on 
the use of safety syringes. Participant A3 (section 5.5.4.1) indicated that the 
pharmaceutical company’s support allowed for the setup of a nursing service that 
allowed for the training of patients on PCSK9 inhibitor injection/ pen use. A research 
nurse (A4) also indicated that provision of training helped to facilitate the process of 
prescribing PCSK9 inhibitors. Negative views on statins were also found to be 
potential facilitator for the use of PCSK9 inhibitors. Clinicians reported patients 
asking to be taken off statins once their LDLC levels were reduced by PCSK9 
inhibitors. One patient noted that they would have preferred to have statins removed 
from their treatment regimen but were informed that they had to take both 
medications. Finally, opposite to the theme on lack of awareness, it was found that 
an understanding of disease severity improved both clinician and patient 




The current chapter presented the views and opinions of stakeholders in the care for 
HeFH patients who use PCSK9 inhibitors. 5 themes emerged from interview data 
following thematic analysis. In primary care, barriers associated with HeFH 
management were found to indirectly affect eventual PCSK9 inhibitor use. For 
example, low awareness of both HeFH and PCSK9 inhibitors led to low rates of 
referral to secondary care where PCSK9 inhibitors were considered. In secondary 
care, prescription of PCSK9 inhibitors was found to be reliant on LDLC 
measurements. Barriers to medication use were related to inhibitory prescription 
policies for PCSK9 inhibitors using the Blueteq system, and clinical guidelines that 
were perceived to be restrictive. Comments on facilitators to PCSK9 inhibitor use 
were minimal, however, patient understanding of the disease, negative views on 
statin use and the influence of pharmaceutical companies in improving PCSK9 




Chapter 6 Discussion 
The aim of this thesis was to identify the potential facilitators of, and barriers to the 
adoption of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors. This 
resulted in two research questions as outlined below:  
1) To study the barriers and facilitators to the usage of PCSK9 inhibitors by 
exploring the views and opinions of key stakeholders (patients, specialist 
consultants/GPs and nurses) in the care of heterozygous familial 
hypercholesterolemia (HeFH) in the UK.  
2) To assess the feasibility of using the Clinical Practice Research Datalink 
(CPRD) database to develop a predictive model that can identify HeFH 
patients who meet the LDLC eligibility targets for PCSK9 inhibitors. 
A multimethod approach was adopted; with quantitative methods being used to 
address question 2 (chapter 4), while qualitative methods were used to address 
question 1 (chapter 5).  
This chapter consolidates the thesis chapters by discussing and integrating the 
results of chapter 4 and 5 in relation to the overall research aim. The chapter also 
conceptualises the results and outlines their importance to current medical practice.   
6.1 Summary of thesis chapters 
Chapter One: A background to the thesis. The chapter introduces HeFH, PCSK9 
inhibitors and provides a rationale for studying the barriers and facilitators to the 
adoption of PCSK9 inhibitors. 
Chapter Two: A systematic search and narrative synthesis of studies specifically 
focusing on PCSK9 inhibitor use in clinical practice and the associated barriers and 
facilitators to their use. The chapter identifies the gaps in literature and outlines the 
two research questions addressed in the thesis. 
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Chapter Three: A discussion of the multimethod approach adopted to address the 
two research questions.  
Chapter Four: Presents and discusses the results and analyses of the quantitative 
phase of the project using both descriptive and inferential statistics. 
Chapter Five: Presents and discusses the results and analyses of the qualitative 
phase of the project illustrating the themes identified as potential barriers or 
facilitators to PCSK9 inhibitor use by HeFH stakeholders. 
Chapter Six: A discussion of the results obtained from chapter four and five. The 
chapter outlines the significance of these results to current practice and identifies the 
potential impact of the work. 
 
6.2 Structure of the discussion section 
The current section begins with a discussion of the quantitative results (chapter 4) in 
relation to the overall aim of the thesis. This was followed by a summary of the 
themes emerging from the qualitative phase of the study (chapter 5). The results 
from the two phases of the study were then integrated as shown in section 6.2.3. A 
joint display approach was used to highlight corresponding and contrasting results 
from the qualitative and quantitative data. The subsequent section (6.3 - Discussion 
of emerging themes) then discusses the themes developed from both phases of the 
study.  
6.2.1 Quantitative results summary 
The quantitative phase of the study addressed research question two and was 
presented in chapter 4.  
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The main study aim was to assess the feasibility of predicting HeFH patients who 
could potentially require PCSK9 inhibitors using CPRD data. With regard to this aim, 
the following conclusion was drawn: 
Despite the potential for identifying HeFH patients who could benefit from PCSK9 
inhibitors, the overall model prediction was inadequate to sustain clinically significant 
results. We therefore conclude that the clinical attributes currently available in CPRD 
may be insufficient to predict PCSK9 inhibitor requirement among HeFH patients. 
The predictive model developed retained three patient clinical attributes (age at 
diagnosis, maximum LDLC on record and the use of lipid lowering medication) and 
produced a predictive ability that was greater than chance. These variables were 
statistically significant to overall LDLC reduction; however the derived predictive 
model could not distinguish between positive and negative cases sufficiently. 
Nevertheless, the existence of clinical attributes that are associated with LDLC 
reduction suggested potential for further research for PCSK9 inhibitor use modelling; 
these may involve the use of different health databases with clinical attributes outside 
the scope of CPRD.  
With regard to the overall research aim of identifying potential barriers and facilitators 
to PCSK9 inhibitor use, the study found the following relevant statistics – 
63.9% of HeFH patients who did not achieve guideline recommended treatment 
targets did not meet the LDLC threshold for PCSK9 inhibitor eligibility. 
Patient records for clinical attributes relevant to PCSK9 inhibitor use were sparsely 
recorded e.g. just over half of HeFH patients in the database had at least one record 
of LDLC. 
About 80% of HeFH patients did not meet guideline recommended LDLC treatment 
targets and could potentially require referral to secondary care. 
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 A summary of the data used for analyses is provided herein. All HeFH patients 
considered for secondary prevention treatment were eligible for PCSK9 inhibitors (i.e. 
LDLC > 3.5 mmol/l). This was expected because HeFH patients typically present with 
markedly elevated LDLC values, a large number of these patients would therefore 
have LDLC values above 3.5mmo/l. 
 
Figure 6.1 Summary of PCSK9 eligibility within the study data set 
In the primary prevention cohort 532 patients were found to be eligible for the new 
class of medication. In total, 582 (19.7%) patients in the study sample would meet 
the PCSK9 inhibitor eligibility threshold. These results were similar to eligibility 
studies from past literature; Glueck et al. (2016), Jetty et al. (2017). However, 63.9% 
(1885) of HeFH patients did not achieve the 50% LDLC reduction target but did not 
qualify for PCSK9 inhibitors based on the 5mmol/l threshold. This suggested that a 
proportion of inadequately treated HeFH patients in the UK may not be eligible for 
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PCSK9 inhibitors based on current NICE guidelines. This potential concern has not 
been addressed in current literature. 
6.2.2 Qualitative results summary 
The qualitative phase of the study addressed research question one above and was 
presented in chapter 5.  
The main study objective was to explore the views and opinions of stakeholders in 
the care of HeFH on the potential barriers and facilitators to PCSK9 inhibitor use. The 
results were presented as themes emerging from the of participant responses as 
follows.  
Barriers to PCSK9 inhibitor adoption included:  
Low referral rates to secondary care 
Therapeutic gaps in clinical guidelines 
Low levels of knowledge and awareness of HeFH  
Inhibitory organisational prescribing policies 
Facilitators of PCSK9 inhibitor adoption included:  
PCSK9 inhibitor use support from pharmaceutical companies 
Patient awareness of disease severity 
Negative views on the use of statins 
6.2.3 Integration of quantitative and qualitative results 
In this section, the quantitative and qualitative data are integrated and explored. The 
integration of data was primarily conducted at the data analysis and interpretation 
stages as discussed by Fetters, Curry and Creswell (2013). This section presents a 
summary of four key complementary results from the qualitative and quantitative 
phases of the study using a joint display as described by Guetterman, Fetters and 
Creswell (2015) – table 6.1.  
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The themes that emerged from the quantitative and qualitative phases of the study 
were interrelated at numerous levels as shown in figure 6.2 below. For example, the 
quantitative finding that a majority (~80%) of HeFH patients did not meet guideline 
recommended treatment targets in primary care and would therefore require referral 
supported the qualitative theme of low referral rates to secondary care.   
 
Figure 6.2 Relationships between emerging themes from qualitative and quantitative results 




Table 6.1 Joint display of corresponding qualitative and quantitative data 
Quantitative finding Qualitative finding Implication Effect of 
integration 
The recording of patient clinical 
attributes was found to be varied. For 
example, 64.2% (3297) of the total 
sample size (n=5134) had more than 
one LDLC measurement on record. Of 
the total data, 3018 (58.8%) patients 
had LDLC data that were at least a 
year apart.  
“…there’s a blueteq (prescription system section 6.3.1) that has 
to be filled.  They require two LDLs above the threshold which is 
not in the NICE Guidelines.  There are certain other CCGs which 
want three… The biggest issue with this is that these patients 
are going to have a high level and so they will be started on it 
(PCSK9 inhibitors); but it will probably delay everything by six 
months for them to have two or three blood tests to prove it. ” 
(A3, consultant) 
There was agreement that the records for 
patient attributes were not always 
sufficient for PCSK9 inhibitor prescription. 
This suggested that the records of patient 
clinical attributes may be influencing 
PCSK9 inhibitor usage in the UK in a 
manner that is similar to the effect of 
documentation in the US.       
Corroboration 
Of 892 HeFH patients that did not 
register LDLC reduction, 59.2% (528) 
did not meet the LDLC threshold for 
PCSK9 inhibitor treatment in the 
cohort (5mmol/l). 
“…it may be that they’ve got less than 50% reduction but the 
LDL, they’ve not got cardiovascular disease and the LDL is less 
than five, then we’ve got no other option…” (A5, consultant) 
A therapeutic gap may exist in the 
management of inadequately treated 
HeFH patients that do not meet LDLC 





A proportion of HeFH patients (30.8%) 
did not register any reduction in LDLC 
levels. 484 (16.7%) of HeFH patients 
were found to achieve a 50% LDLC 
reduction. A further 1523 (52.5%) 
registered LDLC reduction but not 
more than 50%.(Although literature on 
effectiveness of conventional lipid 
lowering therapy varies, the common 
result is that a majority of patients do 
not meet LDLC targets stipulated by 
guidelines (Pijlman et al. (2011), 
Versmissen et al. (2008)).    
“…so it’s probably about 30% of patients achieved target with 
high intensity statins so a significant number who don’t with high 
intensity statins and those are the kinds of patients who probably 
benefit from going on to sort of alternative treatment.  Some of 
it’s due to compliance, some of it’s due to intolerance, some of 
it’s due to you know, I think people’s sort of perceptions of FH 
and things it’s not the fatalistic sort of doesn’t affect me kind of 
attitude.  But a significant number will not achieve target you 
know…” (A2, consultant) 
Due to low rates in achievement of LDLC 
targets set by guidelines, more HeFH 
patients could potentially require referral 
from primary care; and therefore, 
consideration for PCSK9 inhibitor use. 
Expansion/ 
Corroboration 
In the final study cohort, 10.3% of 
patients had a record of family history 
of HeFH; while 5.2% had a family 
history of high cholesterol on record. 
“…particularly the LDLC and maybe their non-HDL, I think if it’s 
greater than 5 or there about and if we get a family history of 
premature heart attacks or coronary heart disease then we 
refer.” (A11, general practitioner) 
“…sort of screening patients over 40 and obviously that’s just 
picking out the ones that erm, they’ve got significant family 
history that makes you think like that.” (A13, prescribing nurse) 
Healthcare providers indicated that they 
relied on the recording of patient history 
to identify HeFH. However, quantitative 
results suggest that these patient 
attributes are not frequently recorded. 
The potential implication is that under-
diagnosis of HeFH in primary care could 








6.2.4 Answering the research questions 
In the context of the current management of HeFH, the qualitative findings 
highlighted insufficiencies in the identification and referral of HeFH patients to 
secondary care. They also indicated potential negative effects of strict guidelines and 
organisational prescription policies in delaying or preventing PCSK9 inhibitor 
prescription.  
The quantitative results suggested low rates of recording of HeFH patient attributes. 
This finding was supported by qualitative accounts which associated inadequate 
recording of patient information to delayed identification of HeFH patients in primary 
are and delayed prescription of PCKS9 inhibitors in secondary care. 
The overall result of the integration was a set of themes that depicted barriers to 
PCSK9 inhibitor use at various points of the HeFH patient treatment journey.  Figure 
6.3 below shows an illustration of this journey with the emerging barriers highlighted 




Figure 6.3 HeFH patient journey towards PCSK9 inhibitor use highlighting the current study's emerging themes 
 
6.3 Discussion of emerging themes 
This section discusses the themes emerging from both the quantitative and 
qualitative analyses as shown in figure 6.3 above.  
6.3.1 Insufficient recording of HeFH patient clinical attributes 
The main finding was that inadequate recording of patient clinical attributes was an 
influencing factor to the prescription of PCSK9 inhibitors. Stakeholder (lipid 
consultants and general practitioners) accounts revealed that the unavailability of 
LDLC records delayed the prescription of PCSK9 inhibitors. Similarly, quantitative 
analysis showed that patient data was seldom recorded with slightly more than half of 
the study cohort having at least 1 record of LDLC. The result suggested that a large 
proportion of HeFH patients could potentially experience delays during the initiation 
of PCSK9 inhibitors.  
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The effect of the unavailability of patient clinical records on PCSK9 inhibitor 
prescription emerged from organisational policies for prescription in the current study. 
In order to monitor usage of costly medication (such as PCSK9 inhibitors), the 
Blueteq prescription system is used to regulate the prescription process. Based on 
interviewee accounts, the Blueteq form for PCSK9 inhibitors includes as part of its 
requirements, evidence of LDLC records above 5 mmol/l (in primary prevention 
treatment) and 3.5mmol/l(in secondary prevention treatment), a record of the use of 
other lipid lowering agents, reasons for unsuccessful treatment. These requirements 
are always in adherence to NICE LDLC targets and recommendations. However, 
some CCGs, for example, require two or three LDLC readings above the stipulated 
thresholds. Although this requirement technically adhered to NICE guidelines, 
clinicians felt that the additional conditions only served to lengthen the approval 
process. The addition of these steps to the prescription process appears to act as a 
barrier to medication provision. This may suggest a potential need for a re-evaluation 
of how CCGs interpret and implement NICE guidelines on PCSK9 inhibitors as this is 
not a standard process across NHS trusts.   
The reasons for the inadequate documentation of HeFH patient clinical attributes are 
not addressed in literature; two key reasons for this emerged from the interviewee 
accounts. Firstly, primary care physicians (GPs and nurses) reported that patients did 
not actively engage with the treatment process in cases where a cardiovascular 
disease (CVD) event had not been observed. This meant that patient records and 
tests were conducted unsystematically as they were dependent on a limited number 
of patient visits. Secondly, healthcare providers (GPs, nurses, consultants) reported 
that the identification of HeFH patients was opportunistic rather than through cascade 
screening. This resulted in cases of HeFH patients being identified with minimal 
relevant medical histories prior to the prescription of PCSK9 inhibitors.  
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6.3.2 Therapeutic gap in the provision of PCSK9 inhibitors 
Corroborating results between quantitative and qualitative analyses suggested that a 
therapeutic gap existed in the management of HeFH patients using PCSK9 inhibitors. 
This was attributed to the absolute targets of LDLC that were stipulated by NICE 
technology appraisals (TA) 393 and 394 (for alirocumab and evolocumab 
respectively) for the initiation of PCSK9 inhibitors. Specialist consultants reported that 
some HeFH patients who were not adequately treated did not meet the LDLC 
thresholds set by guidelines.  
The evidence base for PCSK9 inhibitors does not appear to address these potential 
gaps in the management of PCSK9 inhibitors extensively. Orringer (2019) discussed 
the extent to which lipid management guidelines were useful to clinicians. They found 
that updated guidelines offered an effective evidence base for the management of 
HeFH. The paper reported the existence of therapeutic gaps in guidelines and 
recommended the use of literature to support decision making in such instances. The 
current study identified such a gap in the guidelines in the use of PCSK9 inhibitors.  
Specialist consultants reported that some patients had to be managed on less 
effective lipid lowering agents due to the high LDLC cut-off for PCSK9 inhibitor 
initiation in guidelines. The specialists in these cases deemed the patient to require 
PCSK9 inhibitors based on clinical judgement of their treatment history but felt 
inhibited by the need to comply with NICE guidance. One specialist consultant in this 
study described the process as a ‘post-code lottery’ for patients in these cases, as 
patients had to ‘earn’ the right to PCSK9 inhibitor use by waiting until their LDLC level 
rose to the required levels. These patients expressed frustration as some of them 
had to wait for a year or more before they could receive the medication.  
Suggestions to rectify the matter from clinicians revolved around the lowering of 
LDLC thresholds, and the general consensus was that the LDLC cut-off points were 
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high. The explanation for this was that NICE guidelines, though evidence based, also 
account for cost-effectiveness of medication. This could lead to initial high thresholds 
for medication eligibility while it the medications are costly. The clinicians in this study 
understood this; however, they expressed frustration at the lack of options for 
patients they deemed to require PCSK9 inhibitors. If medication costs are lowered in 
the future, the requirements for the use of PCSK9 inhibitors may be less restrictive.  
6.3.3 Inadequate level of knowledge amongst stakeholders 
Both primary care and secondary care health professionals felt that the level of 
knowledge of HeFH was low, especially in primary care. Consultants and nurses in 
secondary care admitted that although knowledge levels in secondary care were not 
ideal, they felt that it was improving. Interviewee accounts included cases of primary 
care practitioners (GPs and nurses) not being aware of the existence of PCSK9 
inhibitors. Such cases were also witnessed by the primary researcher during the 
conduct of the interviews. Furthermore, a GP admitted to not knowing how serious 
HeFH was, and the fact that more was expected from primary care with regard to the 
identification of patients.  
“…when they talked about the lipid lecture, that I mentioned, they were not quite 
emphasising on the severity or the importance of this topic. Now having spoken to you it 
looks like it needs to be made aware more prominently to primary care, when to refer and 
what to do so this is quite a serious topic, I think more awareness needs to be created…” 
(A14, GP) 
Cardiologists appeared to be aware of PCSK9 inhibitors and indicated that they 
would refer patients whose LDLC levels were uncontrolled so that they are 
considered for the medication. The opinion of consultants in lipid clinics suggested 
that cardiologist referral rates for HeFH were historically low, but had started to 
increase. Lipid specialists attributed this increase to the introduction of PCSK9 
inhibitors, and the fact that it could only be prescribed at the lipid clinic. This view was 
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verified by a one cardiologist who stated that they referred HeFH or potential HeFH 
patients to the lipid clinics only when they felt that they required PCSK9 inhibitors.  
GPs and nurses relied on QRISK and general CVD in their encounters with HeFH or 
potential HeFH patients, some GPs indicated that they would suspect HeFH if LDLC 
levels were above 7.5mmol/l. Physicians in primary care have the role of identifying 
HeFH patients from the general public. The use of these tools without HeFH specific 
guidelines could potentially mask the existence of HeFH. In such cases, HeFH would 
be managed as normal hypercholesterolemia. Interviews with primary clinicians 
identified that some physicians mistook HeFH for normal hypercholesterolemia. This 
result suggested that clinicians required more knowledge on HeFH and PCSK9 
inhibitors, particularly clinicians in primary care.   
In this study, most HeFH patients on PCSK9 inhibitors were found to be aware of the 
condition and kept up to date with their LDLC management. Primary care clinicians 
reported that some patients did not take the disease seriously and were influenced 
by negative media reports on statin use.  
“…I was talking in the pub and me mate’s said, he doesn’t take them anymore cause he gets 
this, this and this, so I thought I'm going to do that, so they listen a lot to the media and also 
what their friends think.” (A13, prescribing nurse) 
This finding was in agreement with past studies on HeFH patients that found varying 
levels of engagement in HeFH patients. Watts et al. (2016) suggested that the 
opinions of HeFH patients on the controllability of the disease and the efficacy of 
pharmacological therapies were a potential influencing factor of engagement. The 
current study agrees to some degree with Watts et al. (2016); however, it was found 
that patients were serious about the disease if they had experienced a CVD event. 
Some patients felt that they were not informed about the disease severity; they also 
felt that HeFH was diagnosed by primary care clinicians when it was too late. The 
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patients’ perceptions echo the finding on the level of knowledge of clinicians. The 
overall results on level of knowledge amongst stakeholders in the care of HeFH 
suggested that both clinician (in primary care) and patients needed to be educated 
about the condition and its management. 
6.3.4 Low levels of referral of HeFH for secondary care treatment  
HeFH patients are under diagnosed and undertreated (Nordestgaard et al., 2013). 
The current study added to this by identifying that once identified in primary care only 
a relatively small number of HeFH patients were referred for secondary care 
treatment and potentially PCSK9 inhibitor initiation. Quantitative data revealed that a 
majority of HeFH patients in primary care did not meet therapeutic LDLC targets 
following statin therapy and were potential candidates for referral for specialist 
management. Through the qualitative interviews, clinicians in secondary care 
confirmed this finding; the overall feeling was that referral rates for HeFH patients 
were low. Secondary care clinicians felt that the potential reason for this was the 
possible management of HeFH as normal hypercholesterolemia; primary care 
clinicians did not oppose the viewpoint. 
 “in terms of the knowledge I would probably think some people(GPs) might sort of confuse it 
with ordinary polygenic hyperlipidaemia and just ‘Oh it’s raised cholesterol, all I need to do is 
just do a QRISK and start statin and invite the patient to see the nurse and discuss about 
healthy lifestyle advice.” (A11, GP) 
The management of HeFH as normal hypercholesterolemia meant that HeFH 
patients were treated with lipid lowering agents (mainly statins) as stipulated in CVD 
prevention treatment guidelines. No further measures were taken to ensure that the 
disease was not genetic (HeFH). This finding is consistent with studies such as 
O’Brien et al. (2014) and O’Brien et al (2015) which found that only 42% of 1295 
adult familial hypercholesterolemia patients were receiving the guideline 
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recommended high intensity lipid lowering therapy. Similarly, De Backer et al. (2015), 
a study of 24 European countries, found that 45% of FH patients with a recorded 
cardiac event were not receiving high intensity statin treatment. The quantitative 
phase of the current study found that 36% (1492) of 4116 HeFH patients were not 
receiving any form of lipid lowering. These results suggested that HeFH patients 
were not effectively treated despite a formal diagnosis of the condition. 
Subsequently, lower levels of referral were observed.   
Low rates of referral could be attributed to several reasons; a lack of awareness of 
the disease as discussed in section 6.3.3 above, poor identification of potential HeFH 
patients, and non-adherence to clinical guidelines among other reasons. For 
example, a contradiction was found between the qualitative accounts of clinicians 
and CPRD quantitative data that could negatively affect the identification of HeFH 
patients. GPs and nurses in primary care relied on patient clinical histories for the 
identification of HeFH patients; however, quantitative data revealed that these 
records were limited. This suggested that lack of prior patients records could be a 
potential hindrance to the identification of HeFH. Without the records of family history 
CVD or HeFH, a physician who was aware of HeFH identification criteria had a 
limited chance of suspecting HeFH in cases with elevated but borderline values of 
LDLC. These cases would therefore be treated as normal hypercholesterolemia. 
These findings implied that low referral rates to secondary were caused by varying 
reasons  
A GP suggested that nurses could improve the recording of family histories for HeFH 
patients because they conducted NHS health checks. However, they felt that all 
clinicians in primary care had a role in recording of medical histories to facilitate 
identification of HeFH.   
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 “I think where the diagnosis of FH comes from if there’s that family history and raised 
cholesterol… I think because there’s this scheme that is called NHS Health checks between 
the age of 40 and 45, when they come to see the nurse it actually is documented. So I think 
nurses should be a bit more proactive and find out if truly there’s that family history under the 
age of 60, document it…” (A11, GP) 
6.3.5 Facilitators to the use of PCSK9 inhibitors 
The final theme constituted the factors that were perceived as facilitators to the use 
of PCSK9 inhibitors. One factor that was independent of the stakeholders was the 
influence of pharmaceutical companies. Secondary care clinicians reported that 
assistance from pharmaceutical companies provided access to HeFH patients. This 
translated into increased prescription of PCSK9 inhibitors as eligible patients were 
identified. A research nurse also indicated that provision of training helped to 
facilitate the process of prescribing PCSK9 inhibitors. Negative views on statins were 
also found to be a potential facilitator for the use of PCSK9 inhibitors. Clinicians 
reported patients asking to be taken off statins once their LDLC levels were reduced 
by PCSK9 inhibitors.  
“A lot of people, when they go on the PCSK9 inhibitors, ask if they can then reduce or come 
off the statin. So, we just have to explain to them, that you know, the studies show that taking 
them both together is of greater benefit than just taking one or the other…” (A4, research 
nurse)  
One patient noted that they would have preferred to have statins removed from their 
treatment regimen but had to take them as their condition deteriorated.  
“…I think after having a heart and a bypass you seem to make it a bit more tolerant, don’t 
you, you know, like [laughs].  Prevention is better than cure they say but after that really I just 
go along with it and, to be fair, sometimes if I think they’re a bit much I’ll miss the odd day out 
of the statin and then take them where last time I just thought I can’t, that I can’t handle this, 
and then I was back to the doctors trying to sort things out.” (A12, patient) 
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Finally, opposite to the theme on lack of awareness, when patients understood the 
potential severity of the disease in causing cardiac events, their level of engagement 
with the HeFH treatment pathway was improved. Such patients expressed frustration 
when PCSK9 inhibitor prescription was delayed while their LDLC levels were still 
uncontrolled.  
6.3.6 Summary of discussion 
The Blueteq prescription system was perceived to be a barrier to prescription in 
cases where multiple records of LDLC measurements that met guideline stipulated 
targets for PCSK9 inhibitor eligibility were required. Prescribers also stated that 
current NICE guidelines for the provision of PCSK9 inhibitors were restrictive in some 
cases. Some patients who were deemed to require PCSK9 inhibitors by lipid 
consultants based on clinical judgement and history of treatment did not meet the 
LDLC thresholds for eligibility. Other themes included ‘inadequate level of knowledge 
amongst stakeholders’ and ‘insufficient patient clinical records’. Both primary care 
and secondary care practitioners felt that knowledge on HeFH could be improved, 
especially among primary care clinicians.  
“I think especially in primary care in GP surgeries; they don’t have as much knowledge of FH 
and PCSK9…” (A4, research nurse) 
“in terms of the knowledge I would probably think some people(GPs) might sort of confuse it 
with ordinary polygenic hyperlipidaemia and just ‘Oh it’s raised cholesterol, all I need to do is 
just do a QRISK and start…” (A11, GP) 
Inadequate levels of knowledge and insufficient patient clinical records led to low 
levels of referral of HeFH patients’ to secondary care; preventing consideration for 
PCSK9 inhibitor use in patients who were not sufficiently treated. Insufficient patient 
clinical records were found to slow down the pace of PCSK9 inhibitor prescription as 
these patient data were required prior to prescription approval. The rate of HeFH 
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patient identification was also reduced by insufficient patient records because clinical 
attributes such as family history of CVD and HeFH were required to make a 
diagnosis of HeFH. 
6.4 Significance and limitations of the study 
6.4.1 Significance of the study 
The main significance of this study exists in the identification and delineation of the 
treatment journey for the ‘difficult-to-treat’ group of HeFH patients that would require 
PCSK9 inhibitors. The study also identified specific factors that acted as barriers or 
facilitators to PCSK9 inhibitor use. In particular, LDLC measurements and records 
were found to be an important determining factor in the prescription of PCSK9 
inhibitors. This provides knowledge on the under-researched area of barriers and 
facilitators to PCSK9 inhibitor use in the UK and could serve to guide further 
research.  
New findings included the barriers associated with the Blueteq prescription system, 
and the potential restrictiveness of NICE guidelines.  The themes related to low 
referral rates of HeFH patients to secondary (low level of awareness of HeFH and 
PCSK9 inhibitors, and inadequate recording of clinical attributes) have been shown 
to affect HeFH management in past literature. This study confirmed that these factors 
remain relevant to the provision of PCSK9 inhibitors and described how they affected 
PCSK9 inhibitor use. The facilitators of PCSK9 inhibitor use also provide insight on 
the improvement of patient awareness and knowledge of HeFH and PCSK9 
inhibitors. 
The current study presents a potential contribution to methodological advancements 
in the study of PCSK9 inhibitor use as no other studies were found to use both 
quantitative and qualitative methods on the topic. The availability of (or lack of) 
patient clinical records had been identified as a potential hindrance to the prescription 
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of PCSK9 inhibitors elsewhere (Cohen et al., 2017). This did not appear to be 
relevant in the use of PCSK9 inhibitors in the United Kingdom prior to the study. This 
study showed that value can be drawn from using multiple methods approaches to 
study barriers to the use of PCSK9 inhibitors. The assessment of the views of 
multiple stakeholders involved in the use of PCSK9 inhibitors contributed to the 
development of a treatment path for HeFH patients by corroborating participant 
accounts. Other studies have previously evaluated the interaction of stakeholders in 
order to assess the factors influencing healthcare provision (e.g. Raaijmakers et al., 
2013); however, no body of work has focused on identifying specific barriers and 
facilitators to PCSK9 inhibitor use in the UK using this method.  
Finally, the current study also provided insight into predictive modelling for a rare 
disease. In cases where the management of such diseases is difficult the collection 
of patient data can be lacking. This could possibly be because most patients with 
rare diseases are treated on a case by case basis in secondary care, and there are 
usually limited clinical guidelines about disease management. However, the present 
study showed the potential of continuous feasibility assessments on rare disease 
data in order to determine whether useful insights can be developed. Similar to the 
development of diagnostic predictive models in HeFH such as Weng et al. (2015), it 
may be possible to gradually extend these analyses to other rare diseases and their 
associated databases.    
 
6.4.2 Limitations of the study 
The quantitative sample had a sample size that produced enough power for multiple 
logistic regression analysis. However, the recording of patient clinical attributes was 
found to be minimal (~48 of patients did not have an LDLC measurement recorded); 
this had the potential of limiting the functionality of the developed predictive models. 
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Admittedly, this finding was relevant to the overall research question; and echoed 
studies in other countries that identified similarly low levels of patient records (Weng 
et al. 2015, Cohen et al. 2017). Nevertheless, this showed that CPRD data may not 
be appropriate for modelling PCSK9 eligibility. 
A potential limitation was that the views of pharmacists were not captured in the 
present study. Lipid consultants reported that the pharmacist did not have a clear role 
in the management of HeFH patients that were referred to secondary for PCSK9 
inhibitor provision. Once PCSK9 inhibitors were prescribed, secondary care nurses 
provided training on the use of injections and further prescriptions were placed on 
repeat delivery systems with the exception being when the patient was required to 
attend the clinic. In the patient journey of receiving statin treatment from the GP 
practice to referral to secondary care for PCSK9 inhibitor use; it was unclear where 
the pharmacist was involved in a manner that would have an effect on PCSK9 
inhibitor prescription. When asked about pharmacists, consultants strongly 
expressed that PCSK9 inhibitor use needed to be left to experts. It was indicated that 
pharmacists were not used in the provision of PCSK9 inhibitors but had been 
involved in ensuring that prescription had no ill effect (Discussion – chapter 5, section 
5.5.3.4.2).   
“No, I don’t think they actually have a role here because this is actually a clinical decision.  
It’s based on NICE.  It’s an expensive drug.  It’s a new drug and even the primary care are 
not allowed to use it.  The PCSK9 is specifically secondary care and that’s the way it should 
be. When it comes to other treatments, yes and no.  I’ve seen places where statins are used 
by pharmacists.  By and large, it’s okay but a lot of what I hear is a load of rubbish.” (A3, 
consultant) 
“We haven’t used them in that way, we’ve mainly used them to discuss particularly when we 
started to prescribe PCSK9s and helped us with making sure that we have identified the 
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correct patients and the system for prescribing which is obviously because we can’t, normally 
if we prescribe, if I prescribe a statin, it’s the GP that does the prescribing.” (A5, consultant) 
The typical lipid clinic was small and consisted of a lipid consultant that ran the clinic 
a number of times a week. The consultant was assisted by nurses who worked 
across a few departments. In larger trusts, lipid specialist nurses assisted in the clinic 
and also run research activity. This could indicate why pharmacists were not part of 
the clinics. Nevertheless, the inclusion of pharmacists may have served to add their 
opinions on how they could contribute to the use of PCSK9 inhibitors.   
6.5 Implications for the provision of PCSK9 inhibitors 
It was found that lack of awareness of PCSK9 inhibitors produced varying effects 
alongside the reduced knowledge on HeFH. Clinicians in primary care appeared to 
focus on cardiovascular disease CVD management (using QRISK) when 
hypercholesterolemia was encountered. This increased the likelihood of HeFH being 
ignored. The condition was suspected when a CVD event was experienced or due to 
markedly elevated LDLC levels. The resultant effect was delayed referral to lipid 
specialists for PCSK9 inhibitor consideration. The general implication outlined by 
GPs was that it was necessary to improve stakeholder knowledge through the use of 
healthcare campaigns or educational training programs.  
Due to the low prevalence rate of the disease however, awareness campaigns alone 
may not be sufficient to increase patient referral. The use of a case identification tool 
implemented into the management system for general hypercholesterolemia or CVD 
management could help to identify patients who potentially require referral. Similarly, 
a computer program that could highlight potential HeFH cases could act as an 
automatic system of disease identification. For instance, Weng et al. (2015) 
developed a successful detection tool for HeFH based on presenting patient clinical 
characteristic and suggested integration into a computer system. The finding in the 
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quantitative phase of this study showed that further research on modelling for PCSK9 
inhibitor eligibility may be possible.   
Another key finding was that the Blueteq system thresholds for the indication of 
PCSK9 inhibitors proved difficult to achieve for some patients. These thresholds were 
determined by NICE guidelines and based on cost-effectiveness estimations. 
However, some CCGs asked for 2 or 3 LDLC readings above the threshold for 
PCSK9 inhibitor indication while other only required 1. When patients had not 
achieved these multiple readings, they were deemed ineligible for PCSK9 inhibitor 
use. The process of repeatedly taking LDLC measurements to meet these criteria 
took up to 9 months according to some patients. Although CCG requirements are 
subject to change, it may be necessary to review these requirements for PCSK9 
inhibitor use and the possible effect they could have in delaying treatment.   
Low recording rates of HeFH clinical attributes were found to affect the provision of 
PCSK9 inhibitors in two main ways. The identification of HeFH patients in primary 
care was hindered by a lack of recording of family histories of the disease or of 
elevated cholesterol. While in secondary care, prescription requirements demanded 
evidence of patient data prior to prescription of PCSK9 inhibitors. The overall 
recommendation was, of course, to increase the rate of recording. However, the root 
cause of the low levels of HeFH patient data reverts back to the discussion on 
knowledge and awareness. 
6.6 Recommendations for future research  
Blueteq prescription systems were found to vary between hospitals. Clinical 
commissioning groups (CCG) set different policies for the prescription of PCSK9 
inhibitors as long as these policies were within NICE guidelines. A recommendation 
for further research would be a study on the variations in Blueteq requirements for 
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PCSK9 inhibitors use in different NHS trusts, and how the requirements affected the 
use of the medication.  
Secondly, lipid specialists felt that the current NICE LDLC threshold for PCSK9 
inhibitor prescription was too high and acted as a barrier to medication use in some 
cases. Some patients who were deemed to be inadequately treated could not meet 
these targets and were therefore not eligible for the medication. An assessment of 
the effect of these hard targets could prove to reduce the number of cases where 
patients in need of this new class of medication do not meet the necessary 
requirements.  
In assessing the level of impact that HeFH patient clinical attributes had on the 
prescription of PCSK9 inhibitors, prediction models were developed. Although the 
results indicated that the model functionality could not be considered successful 
using CPRD data, the model showed some potential. This is especially so because 
the recording of LDLC was found to be low, while clinical attributes such as 
lipoprotein A (LpA) that have been found to have a link to heart disease and LDLC 
were not routinely monitored. Further research using other datasets (such as the 
SAFEHEART study’s longitudinal data) may therefore be possible on the modelling 
for PCSK9 inhibitor eligibility.    
6.7 Conclusion 
This study focused on exploring the potential factors that could influence the 
prescription of PCSK9 inhibitors. These were presented as themes that reflected 
potential barriers and facilitators to the use of PCSK9 inhibitors.  
The main finding was that LDLC records were important in the prescription of PCSK9 
inhibitors. Both the quantitative data and qualitative accounts found that the recording 
of HeFH patient clinical attributes was inadequate. In the CPRD dataset, only 52% of 
HeFH patients had at least 1 LDLC measurement on record. From the qualitative 
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interviews, it was found that the Blueteq system was used in the approval process for 
PCSK9 inhibitors. Requirements for PCSK9 inhibitor prescription within Blueteq 
varied between different organisations with some CCGs requiring 2 or 3 LDLC 
readings above the recommended threshold for PCSK9 inhibitor indication, while 
others requested 1. The resultant effect was that some patients who were deemed to 
require PCSK9 inhibitors by lipid consultants would have to attain multiple readings 
of LDLC above the required threshold before the medication was approved. Patient 
accounts indicated that the process of taking repeated LDLC measurements took up 
to 9 months before PCSK9 inhibitors were approved. 
Similarly, evidence from both the quantitative data and qualitative accounts showed 
that a number of patients who did not achieve 50% LDLC reduction did not meet the 
5mmol/l LDLC threshold for PCSK9 inhibitor eligibility. The quantitative data found 
that ~18% of patients who recorded no LDLC reduction following the usage of lipid 
lowering medication for a year were not eligible for PCSK9 inhibitor eligibility. Lipid 
consultants expressed similar concerns and maintained that the LDLC threshold for 
primary prevention treatment in particular was high and strict.  
In primary care, low levels of knowledge on HeFH and PCSK9 inhibitors among 
clinicians were associated with low referral rates of HeFH patients to secondary care. 
HCPs in both primary and secondary care agreed that primary care clinicians were 
less knowledgeable about HeFH than secondary care clinicians. In particular, there 
was concern that HeFH was potentially treated as hypercholesterolemia or some 
other forms of polygenic hyperlipidaemia by primary care clinicians. This was 
expressed as a reliance on the use of the QRISK tool. As the QRISK tool did not 
account for all risk factors associated with HeFH such as family history of HeFH, the 
scores could potentially mask HeFH and the elevated levels of cholesterol would be 
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treated with statins. This had the effect of delaying case identification and referral to 
secondary care for patients who would eventually require PCSK9 inhibitors.  
Finally, the factors that facilitated PCSK9 inhibitor use revolved around the provision 
of support from pharmaceutical companies, the understanding of disease severity by 
patients and the negative views on the use of statins by patients. In one case, a lipid 
consultant confirmed that the use of a specific PCSK9 inhibitor agent was based on 
interactions with the pharmaceutical companies. In this case, the pharmaceutical 
company was providing training to nurses on the use of injectable devices in order to 
improve their capacity for educating patients. Negative views on statins (based on 
information from the media and peers) and the understanding of disease severity 
improved the patient’s acceptance of the injection formulation of PCSK9 inhibitors. 
Achievement of LDLC reduction was also indicated as a reason that patients 
accepted the use of PCSK9 inhibitors.  
Overall, the study was able to identify specific barriers and facilitators to the use of 
PCSK9 inhibitors. The study also highlighted the complexity of the treatment pathway 
for the difficult-to-treat HeFH patient, who would end up requiring PCSK9 inhibitors. 
This information has the potential to guide improvements in the care of the disease, 
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Appendix 10 Search words 
 
Population Intervention Comparison Outcome
familial hypercholesterolaemia PCSK9 inhibitors perception* high cholesterol
FH proprotein convertase subtilisin kexin detect* low density lipoprotein cholesterol
heterozygous familial hypercholesterolemia alirocumab opinion* LDL*
heFH evolocumab determin* high density lipoprotein  cholesterol
familial hypercholesterolemia kexin 9 inhibitors screen* HDL*







S1 S2 S3 S4
62,313 4,832 19,281,778 1,341,421
S1 AND S2 1,118
S2 AND S3 2,824
S2 AND S4 4,145
S1 AND S2 AND S3 749
S1 AND S2 AND S3 AND S4 742
241 
 




Barriers to PCSK9 inhibitor adoption 0 0
Experiences and opinions on medication 0 0
Medication 0 0
Patient in denial of HeFH 2 2
Patient journey of receving medication 13 51
Knowledge of stakeholders 0 0
Clinicians 0 0
Ignorance of ldlc above 5 due to lack of other symptoms 2 4
Knowledge of clinicians on FH 8 42
Knowledge of FH identification pathway 6 11
Specialists' approach to FH patients 3 6
Patients 0 0
Opinions on patient diet and effect on FH 3 4
Patient knowledge on HeFH 7 17
Organisational factors 0 0
Organisational factors that may affect PCSK9 use 5 8
Other healthcare providers involvement in FH treatment 9 33
Patient perceptions on secondary care 2 5
Why implementation of new services is slow 4 9
The effect of clinical guidelines 0 0
Effect of hard LDLC targets set by guidelines 0 0
Determination of LDLC targets 5 6
Patient clinician acceptance of higher ldlc target 2 3
Which ldlc targets are used in practice 5 6
Lack of clear guidance on treating children 2 6
The use of clinical guidelines for lipid managment 7 27
Facilitators to PCSK9 inhibitor adoption 0 0
Influence from pharmaceutical companies 3 7
Patient awareness of disease severity 0 0
Severity of disease 3 5
Precriber engagement with the medication provision pathway 0 0
Views on medication use 0 0
Negative perceptions on statin use 0 0
Efficacy of statins in FH 7 12
Patient perceptions on statins 6 14
Patients refusing statin treatment 5 9
Statin intolerance 7 27
Opinions on polypharmacy 3 5
Positive views on PCSK9 inhibitors 0 0
General perceptions on PCSK9 inhibitors 3 5
HCP views on PCSK9 inhibitors 3 12
Patients perceptions on PCSK9 inhibitors 8 18
242 
 




















Appendix 13 Readcodes for familial hypercholesterolemia and pure 

























Appendix 14 How guidelines potentially hinder the use of PSK9 inhibitors 
An application of the >50% LDLC reduction guideline to the primary treatment cohort 
(n=2899) results in 484 (16.7%) of the cases achieving a 50% LDLC reduction, 1523 
(52.5%) registering LDLC reduction but not more than 50%, and 892 (30.8%) cases 
did not register a reduction of LDLC levels.  
PCSK9 inhibitors are initiated at different LDLC levels for primary and secondary 
prevention treatment. In the secondary treatment cohort all patients met the LDLC 
target of 3.5mmol/l and therefore qualified for PCSK9 inhibitor initiation (n=50). In the 
primary prevention treatment group, 18.4% of patients (n=532) met the 5mmo/l 
threshold for PCSK9 inhibitor requirement. Therefore, the total number of patients 
who were eligible for PCSK9 inhibitors was 582 (19.7% of the total study cohort 
n=2949). These values are similar to Lee et al. (2017) and Glueck et al. (2016), who 
studied the eligibility for PCSK9 in the US; US guidelines are based on patients 
having HeFH or CVD and an LDLC above approximately 3.5mmo/l (190mg/dl). 
A cross tabulation of these two sets of results suggests that there potentially exists a 
gap in the therapeutic management of HeFH patients under the current guidelines.  
A cross tabulation between final LDLC value attained and therapeutic effect 
achieved 
  Therapeutic effect group  Total 
  1 Reduction in 





3 No change 
in LDLC or 
increase 
 




1357 482 528 2367 




Total  1523 484 892 2899 
 
It is worth noting that 528 (18.2%) patients registered no change in LDLC lowering 
but did not meet the requirements for PCSK9 inhibitor initiation. This was because 
their LDLC levels remained below 5mmol/l. However, in practice this could indicate 
failure to respond to treatment as guidelines suggest, at least, a 50% LDLC 
reduction. 
The acceptance of a high LDLC value could potentially be explained by past studies 
which found that patient-physician agreement sometimes meant that guideline 
stipulated targets were not achieved (Pijlman et al., 2010). This practice is 
acceptable because CVD specific guidelines (Cohen et al., 2017; NICE CG71) 
stipulate that in cases where therapeutic LDLC targets cannot be reached, alternative 
treatment targets can be set by discussion between the clinician and the patients. 
Nevertheless, there remains a potential therapeutic gap in the management of HeFH 




Appendix 15 Tests for normality 
 
FirstOfAgeatdiagnosis 
  Mean 52.00138074 
Standard Error 0.248623336 
Median 53 
Mode 57 
Standard Deviation 13.38184939 














  Mean 5.4197378 
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Standard Error 0.0283863 
Median 5.4 
Mode 5.5 
Standard Deviation 1.5283855 













  Mean 3.69715764 
Standard Error 0.0286025 
Median 3.4 
Mode 3.3 
Standard Deviation 1.54002617 















  Mean 2.67845411 
Standard Error 0.03131254 
Median 2.22 
Mode 2 
Standard Deviation 1.68565051 
















  FirstOfAgeatdiagnosis Ldlcmax LastOfdata2 Triglyceridemax 
FirstOfAgeatdiagnosis 179.0120796 
   Ldlcmax -2.791745214 2.335157 
  LastOfdata2 -3.790587374 1.091798 2.370862497 










Appendix 16 Logistic regression analysis 
Case Processing Summary 
Unweighted Cases
a
 N Percent 
Selected Cases Included in Analysis 1907 100.0 
Missing Cases 0 .0 
Total 1907 100.0 
Unselected Cases 0 .0 
Total 1907 100.0 
a. If weight is in effect, see classification table for the total number of cases. 
 
 
Dependent Variable Encoding 









MedicineUse Whether the 
patient took medication or not 
1.00 1656 1.000 
2.00 251 .000 
FamHistFH 1.00 204 1.000 
2.00 1703 .000 
FamHistMI 1.00 102 1.000 
2.00 1805 .000 
FamHistHC 1.00 92 1.000 
2.00 1815 .000 
Hypothyroidism 1.00 106 1.000 
2.00 1801 .000 
KidneyDisease 1.00 1 1.000 
2.00 1906 .000 
DiabetesMellitus 1.00 27 1.000 
2.00 1880 .000 
LDLCmaximumvalue 1=0-5 1.00 749 1.000 
2.00 1158 .000 
Triglyceride 1.00 615 1.000 
2.00 1292 .000 
AgeAtDiagnosis 1.00 348 1.000 
2.00 1559 .000 
gender 1 762 1.000 














Step 0 FinalLDLCvalue 1=0-4.9 1.00 1555 0 100.0 
2.00 352 0 .0 
Overall Percentage   81.5 
a. Constant is included in the model. 
b. The cut value is .500 
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant -1.486 .059 633.470 1 .000 .226 
 
 
Variables not in the Equation 
 Score df Sig. 
Step 0 Variables gender(1) 4.525 1 .033 
FamHistFH(1) 6.495 1 .011 
FamHistMI(1) 1.008 1 .315 
FamHistHC(1) 3.738 1 .053 
Hypothyroidism(1) .021 1 .884 
KidneyDisease(1) 4.420 1 .036 
DiabetesMellitus(1) 3.961 1 .047 
AgeAtDiagnosis(1) 16.730 1 .000 
Triglyceride(1) .901 1 .342 
1=0-5(1) 255.504 1 .000 
Whether the patient took 
medication or not(1) 
1.222 1 .269 
Overall Statistics 279.604 11 .000 
 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 341.874 1 .000 
Block 341.874 1 .000 
Model 341.874 1 .000 
Step 2 Step 16.667 1 .000 
Block 358.541 2 .000 
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Model 358.541 2 .000 
Step 3 Step 9.210 1 .002 
Block 367.750 3 .000 




Step -2 Log likelihood 






 .164 .267 
2 1465.590
b
 .171 .278 
3 1456.380
b
 .175 .285 
a. Estimation terminated at iteration number 7 because parameter 
estimates changed by less than .001. 
b. Estimation terminated at iteration number 8 because parameter 
estimates changed by less than .001. 
 
 
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 .000 0 . 
2 .323 1 .570 
3 1.097 3 .778 
 
 
Contingency Table for Hosmer and Lemeshow Test 
 
FinalLDLCvalue 1=0-4.9 = 1.00 FinalLDLCvalue 1=0-4.9 = 2.00 
Total Observed Expected Observed Expected 
Step 1 1 743 743.000 6 6.000 749 
2 812 812.000 346 346.000 1158 
Step 2 1 567 567.689 4 3.311 571 
2 176 175.311 2 2.689 178 
3 812 812.000 346 346.000 1158 
Step 3 1 480 480.442 3 2.558 483 
2 242 242.030 3 2.970 245 
3 21 20.528 0 .472 21 
4 637 631.802 221 226.198 858 












Step 1 FinalLDLCvalue 1=0-4.9 1.00 1555 0 100.0 
2.00 352 0 .0 
Overall Percentage   81.5 
Step 2 FinalLDLCvalue 1=0-4.9 1.00 1520 35 97.7 
2.00 314 38 10.8 
Overall Percentage   81.7 
Step 3 FinalLDLCvalue 1=0-4.9 1.00 1546 9 99.4 
2.00 349 3 .9 
Overall Percentage   81.2 
a. The cut value is .500 
 
 
Variables in the Equation 






 1=0-5(1) -3.966 .415 91.372 1 .000 .019 .008 .043 
Constant -.853 .064 176.557 1 .000 .426   
Step 2
b
 1=0-5(1) -4.222 .424 99.040 1 .000 .015 .006 .034 
Whether the patient 
took medication or 
not(1) 
-.967 .234 17.117 1 .000 .380 .241 .601 
Constant .044 .225 .039 1 .844 1.045   
Step 3
c
 AgeAtDiagnosis(1) .467 .152 9.431 1 .002 1.595 1.184 2.148 
1=0-5(1) -4.208 .425 98.276 1 .000 .015 .006 .034 
Whether the patient 
took medication or 
not(1) 
-.995 .235 17.977 1 .000 .370 .233 .586 
Constant -.032 .227 .020 1 .889 .969   
a. Variable(s) entered on step 1: 1=0-5. 
b. Variable(s) entered on step 2: Whether the patient took medication or not. 











Step 1 Constant 1.000 -.155    
1=0-5(1) -.155 1.000    
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Step 2 Constant 1.000  -.239 -.958  
1=0-5(1) -.239  1.000 .204  
Whether the patient took 





Step 3 Constant 1.000  -.239 -.946 -.107 
AgeAtDiagnosis(1) -.107  .001 -.051 1.000 
1=0-5(1) -.239  1.000 .205 .001 
Whether the patient took 
medication or not(1) 
-.946 
 
.205 1.000 -.051 
 
 




Change in -2 Log 
Likelihood df 
Sig. of the 
Change 
Step 1 1=0-5 -912.065 341.874 1 .000 
Step 2 1=0-5 -911.435 357.280 1 .000 
Whether the patient took 
medication or not 
-741.128 16.667 1 .000 
Step 3 AgeAtDiagnosis -732.795 9.210 1 .002 
1=0-5 -903.843 351.305 1 .000 
Whether the patient took 
medication or not 
-736.939 17.497 1 .000 
 
 
Variables not in the Equation 
 Score df Sig. 
Step 1 Variables gender(1) .213 1 .645 
FamHistFH(1) .742 1 .389 
FamHistMI(1) 1.695 1 .193 
FamHistHC(1) .379 1 .538 
Hypothyroidism(1) .081 1 .776 
KidneyDisease(1) 2.349 1 .125 
DiabetesMellitus(1) .972 1 .324 
AgeAtDiagnosis(1) 8.653 1 .003 
Triglyceride(1) .221 1 .638 
Whether the patient took 
medication or not(1) 
18.235 1 .000 
Overall Statistics 33.993 10 .000 
Step 2 Variables gender(1) .052 1 .819 
FamHistFH(1) .998 1 .318 
FamHistMI(1) 2.230 1 .135 
FamHistHC(1) .712 1 .399 
Hypothyroidism(1) .106 1 .745 
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KidneyDisease(1) 2.517 1 .113 
DiabetesMellitus(1) 1.140 1 .286 
AgeAtDiagnosis(1) 9.523 1 .002 
Triglyceride(1) .092 1 .761 
Overall Statistics 16.021 9 .066 
Step 3 Variables gender(1) .527 1 .468 
FamHistFH(1) .179 1 .673 
FamHistMI(1) 2.141 1 .143 
FamHistHC(1) .242 1 .622 
Hypothyroidism(1) .028 1 .868 
KidneyDisease(1) 2.796 1 .094 
DiabetesMellitus(1) .936 1 .333 
Triglyceride(1) .014 1 .906 








             Step number: 1 
 
             Observed Groups and Predicted Probabilities 
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             Step number: 2 
 
             Observed Groups and Predicted Probabilities 
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Area Under the Curve 






Asymptotic 95% Confidence Interval 
Lower Bound Upper Bound 
.772 .017 .000 .739 .805 
The test result variable(s): predicted_logit has at least one tie between the positive 
actual state group and the negative actual state group. Statistics may be biased. 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
 
 
Coordinates of the Curve 
Test Result Variable(s):   predicted_logit   
Positive if Greater 
Than or Equal 
To
a
 Sensitivity 1 - Specificity 
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-10.971000 1.000 1.000 
-9.737500 .996 .917 
-9.240000 .978 .833 
-8.742500 .889 .611 
-7.136000 .447 .033 
-5.529500 .438 .022 
-5.032000 .351 .011 
-4.534500 .293 .000 
-3.301000 .000 .000 
The test result variable(s): predicted_logit has at 
least one tie between the positive actual state 
group and the negative actual state group. 
a. The smallest cutoff value is the minimum 
observed test value minus 1, and the largest 
cutoff value is the maximum observed test value 
plus 1. All the other cutoff values are the averages 







Appendix 18 Derivation and validation dataset analyses 
 
Study variables In-dataset variable 
name 
Variable categories 
Treatment effect (outcome 
variable) 
effect2 1: did not work 2: did work 
Age at diagnosis agediag2 1: 0-40 2: more than 40 
Gender gender 1: male 2: female  
Maximum low density lipoprotein 
cholesterol (ldlc) measurement 
ldl2 1: 0-5 mmol/L 2: more than 5 mmol/L 
Maximum triglyceride 
measurement 
tri3 1: 0-1.7mmol/L 2: more than 1.7 mmol/L 
Family history of familial 
hypercholesterolemia  
famfh1 1: yes 2: no 
Family history of myocardial 
infarction  
fammi1 1: yes 2: no 
Family history of high cholesterol  famhc1 1: yes 2: no 
Diagnosis of hypothyroidism hpy1 1: yes 2: no 
Diagnosis of kidney disease kd1 1: yes 2: no 
Diagnosis of diabetes diab1 1: yes 2: no 
Prescribed drug groups  druggroups 1: Took medication 2: Did not take medication  
 
Dataset randomly split by 66% to 34%, derivation and validation cohorts, using SPSS.   
 
 Derivation cohort (number & 
percentage)  
1941(65.8%) 
Validation cohort (number and 
percentage) 
1008(34.2%) 
Treatment outcome   
1:medication worked 307(15.8%) 181(18%) 
2:medication did not work 1634(84.2%) 827(82%) 
Age at diagnosis    
1:0-40 338(17.4%) 204(20.2%) 
2:more than 40 1601(82.5%) 804(79.8%) 
Gender   
1:male 789(40.6%) 404(40.1%) 
2:female 1152(59.4%) 604(59.9%) 
Maximum LDLC measurement   
1:0-5mmol/L 709(36.5%) 359(35.6%) 




1: 0-1.7mmol/L 572(29.5%) 312(31%) 
2: more than 1.7 mmol/L 1368(70.5%) 696(69%) 
Family history of familial 
hypercholesterolemia 
  
1:yes 209(10.8%) 96(9.5%) 
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2:no 1732(89.2%) 912(90.5%) 
Family history of myocardial 
infarction 
  
1:yes 107(5.5%) 45(4.5%) 
2:no 1834(94.5%) 963(95.5%) 
Family history of high 
cholesterol 
  
1:yes 104(5.4%) 50(5%) 
2:no 1837(94.6%) 958(95%) 
Diagnosis of hypothyroidism   
1:yes 116(6%) 63(6.3%) 
2:no 1825(94%) 945(93.8%) 
Diagnosis of kidney disease   
1:yes 1(0.1%) 0(0%) 
2:no 1940(99.9%) 1008(100%) 
Diagnosis of diabetes   
1:yes 30(1.5%) 18(1.8%) 
2:no 1911(98.5%) 990(98.2%) 
Prescribed drug groups   
1: statins 1164(60%) 598(59.3%) 
2: statins + ezetimibe 267(13.8%) 156(15.5%) 
3: statins + ezetimibe+ fibrates 73(3.8%) 49(4.9%) 
4: medication not recorded 262(13.5%) 119(11.8%) 




Significance level 0.05 
Two tailed hypothesis 
 





df1 = N - 1 = 27 - 1 = 26 
M1: 862.56 
SS1: 13617512.67 






df2 = N - 1 = 27 - 1 = 26 
M2: 448 
SS2: 3635586 







s2p = ((df1/(df1 + df2)) * s
2
1) + ((df2/(df2 + df2)) * s
2





p/N1 = 331790.36/27 = 12288.53 
s2M2 = s
2
p/N2 = 331790.36/27 = 12288.53 
 




M2) = 414.56/√24577.06 = 2.64 
The t-value is 2.64434. The p-value is .010796. The result is significant at p < .05. 
 
 
F-Test Two-Sample for Variances 
 
     Variable 1 Variable 2 
Mean 448 862.5555556 
Variance 139830.231 523750.4872 
Observations 27 27 
df 26 26 
F 0.26697871 
 P(F<=f) one-tail 0.00062949 
 F Critical one-tail 0.51834617   
 
F is smaller than critical so the samples are the same.  
Alpha 0.05 
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